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Abstract 
 
Lanthanide-based complexes play a significant role in biological applications, 
spanning MRI contrast agents to molecular luminescent tags. Regardless of their 
application, these complexes should conform to general requirements, such as high 
stability against decomplexation at physiologically relevant conditions and sufficient 
solubility in water. Other more specific requirements may also apply, demanding a 
customised design of the ligand for a specific application. 
 
Emissive bio-responsive lanthanide complexes comprise a large and dynamically 
developing area, which possesses several intrinsic advantages over non-lanthanide 
analogues. Large Stokes’ shifts, long-lived excited states, ratiometric bands in the 
emission spectrum, strong cirularly-polarised signals are but a few to be named. 
These beneficial properties can be employed for efficient measurement of pH or 
determination of bioactive molecules both in vitro and in cellulo. For instance, 
europium complexes bearing sulphonamide arms showed reversible pH-response, 
producing noticeable changes in both the total emission and CPL spectra (Chapter 2). 
Other europium complexes possessing polarity-sensitive emission intensity were 
successfully used for detection of human serum albumin and α1-AGP – two the most 
abundant serum proteins – by following both total emission and CPL spectra, and 
these results are discussed in Chapter 3.  
 
Selective detection of biologically relevant anions needs specific probe design 
requirements. Even subtle changes in the structure of the ligand may lead to 
considerable changes in selectivity and affinity towards selected species. Such a 
correlation between structure and binding properties was exemplified in a series of 
europium complexes for the detection of nucleotides and zinc and led to the creation 
of probes spanning 5 orders of affinity constants. Furthermore, a nucleotide-specific 
induced CPL signal allowed monitoring the ratio between ADP and ATP – a 
parameter that characterises metabolic rates in mitochondria. These observations are 
thoroughly analysed in Chapter 4. 
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I.1. Theoretical background of the Eu(III) luminescence 
 
I.1.1. Historical milestones 		
The very first luminescence spectrum of Eu3+ was recorded[1] in 1885 by Sir William 
Crookes (Fig.I.1), sixteen years before the element europium was isolated[2] by 
Eugène-Anatole Demarçay (Fig. I.1), analysing yttria and samarium-containing ores. 
The transition band, which is now known as a hypersensitive 𝐷! →! 𝐹!!  transition 
was described by him as having ‘great brilliancy of a fine orange-red colour, as sharp 
as a gasline’. This band could not be ascribed to either samarium or yttrium, which 
had been already isolated and whose emission spectra had been analysed, and 
therefore this band corresponded to another unknown element, present as an impurity 
in samaria. This fact encouraged Demarçay to proceed further with multiple 
extractions of samaria until the penultimate lanthanide element was obtained; the last 
stable rare earth element, lutetium, was isolated in 1907.  
 
 
 
              Fig. I.1 Portraits of Eugène-Anatole Demarçay (left) and Sir William Crookes (right). 
 
The luminescence properties of Eu(III) compounds were scarcely studied until the 
late 1930s, when Van Vleck made a first attempt[3] to investigate the influence of 
chemical structure on the emission spectrum. Van Vleck deduced that the 
luminescence observed was due to f-f intraconfigurational transitions of the Eu(III) 
ion, mainly of magnetic-dipole nature, and suggested that the excitation is 
vibronically induced. Within the next decade a considerable breakthrough was 
achieved on both chemical and physical fronts. In 1942, Weissman published his 
thorough study[4] of several europium complexes with different organic ligands, 
possessing much brighter luminescence than inorganic phosphors. Trying to explain 
	 14	
this difference, a so-called ‘antenna effect’ was suggested, i.e. an indirect excitation 
of Eu(III) via the organic ligand bound to it – a conception solely based on Van 
Vleck’s assumption of the intraconfigurational  nature of observed emission lines in 
the spectrum, for which direct excitation is Laporte forbidden.  
 
The development of new emission detectors resulted in a series of works[5] produced 
by a group of spectroscopists from the Zeeman Laboratories (University of 
Amsterdam), which published the first high-resolution spectra of lanthanide ions in 
aqueous solution. As a result, they managed to calculate oscillator strengths of 
several transitions. Moreover, it was shown that transitions of magnetic-dipole origin 
were substantially less probable than induced electric dipole ones and were only 
possible for those transitions that cannot borrow intensity by an induced electric 
dipole mechanism. They also concluded that static and vibrational perturbations are 
comparable in terms of the probability to induce an electric dipole transition. 
 
The last step towards the creation of a consistent theory of electron transitions in 
lanthanides was made simultaneously by Judd[6] and Ofelt[7] in 1962. They derived 
an expression to calculate the oscillator strength of the transition at given positions of 
coordinated atoms around the lanthanide ion, along with polarizabilities of these 
ligated atoms. The main assumption underlying the proposed theory is an admixture 
of 4fn-15d states of opposite parity to 4fn, induced by odd-parity terms of crystal-field 
components.  
 
Judd-Ofelt theory is unable to provide ab initio predictions of spectroscopic data 
based on crystal structure data. Fundamental computational obstacles (e.g. the 
precision of calculation of radial integrals and crystal field parameters) need to be 
overcome to make this theory more widely used. Judd-Ofelt parameters can be used 
for approximate spectroscopic analysis as phenomenological parameters, especially 
in the case of the complexes of europium, for which a mathematical description 
substantially simplifies. 
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I.1.2. Electronic structure of lanthanides 		
Extensive attempts to determine energy structure of lanthanides in various crystal 
matrices were carried out in 1950s and 1960s by Dieke and co-workers[8], which 
were finally summarised in his book published in 1968[9]. The so-called ‘Dieke 
diagram’ has since been extended to a theoretically calculated energy diagram – the 
‘extended Dieke diagram’[10], which is shown in Fig. I.2.  
 
                      
Fig. I.2 Energy level diagram for Ln3+ ions (referred to as ‘Dieke diagram’) with the energy levels up 
to 40,000 cm-1 accessible within a typical optical experiment[11]. The most common resonance levels 
are marked red. 
 
Due to the fact that the conventional electronic configuration [Xe]4fn corresponds to 
the single electron model, it neglects electron repulsion and the impact of spin-orbital 
coupling. These factors should be considered differently for lighter and heavier 
elements, as the value of spin-orbital coupling is proportional to the atomic number. 
Two schemes have been put forward: the so-called Russell-Saunders coupling for 
lighter elements and ‘jj-coupling’ for heavier ones. In the case of lanthanides, the 
spin-orbit coupling constant is comparable to the electrostatic interaction energy 
between electrons. This implies that the ‘intermediate coupling’ scheme (in this case 
the electronic configuration is considered as the linear combination of L-S 
configurations) instead of pure L-S (Russell-Saunders) coupling or ‘jj-coupling’, is 
valid for light and heavy elements respectively. Nevertheless, the assignment is 
undertaken in accordance with the L-S scheme[12]. This assumption sometimes 
causes controversies in the interpretation of emission and absorption spectra, because 
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J, frankly speaking, is no longer a good quantum number. For example, a splitting of 
the 𝐷! →! 𝐹!!  transition in complexes with only one type of coordination 
environment is usually considered as breaking the L-S scheme. However, it should 
be always kept in mind that energy levels in Dieke diagram are not pure, and certain 
level of admixing of adjacent energy levels is expected (‘J-mixing’).  
 
The number of possible microstates (𝑁!"#"$! ) for a lanthanide ion with a 
configuration of [Xe]4fN is given by 𝑁!"#"$! = !"!!! !"!! !, and in the case of Eu3+ 
([Xe]4f6) 3003 microstates exist. It is often forgotten that for a lanthanide (III) ion 
with 3 ≤ 𝑁 ≤ 11, an additional seniority quantum number (𝜏) should be used, since 
several 𝐿!!!!!  terms with the same S, L and J numbers, but with different energies 
may exist[13]. For example in the case of Eu3+, three 𝐷!!  states are present with 
energies of 17200 cm-1, ca. 42000 cm-1 and ca. 75000 cm-1, which can be designated 
as 𝐷(3)!! , 𝐷(2)!!  and 𝐷(1)!! , respectively[14]. Both 𝐷(3)!!  and 𝐷(1)!!  are 
believed to contribute to the 𝐹!!  state: 93.4% 𝐹!! + 3.5% 𝐷(1)!! + 2.8% 𝐷(3)!! + 0.12% 𝑃(6)!! .[14] 
 
I.1.3. Lanthanide complexes for bio-imaging applications 		
Two major advantageous optical features of lanthanide complexes are that bands in 
emission are narrow, with energies only slightly affected by the nature of the ligand, 
and there is a large separation (a “pseudo-Stokes’ shift”) between the absorbing 
(ligand-antenna) and emitting (lanthanide ion) photon energies.  These favourable 
properties create a myriad of opportunities to devise responsive systems by judicious 
ligand design. Europium(III) complexes have particular advantages over other 
lanthanide complexes in biologically relevant applications:  the higher transparency 
of biological tissue towards the red region of the visible spectrum; their high inherent 
brightness and low sensitivity to quenching by oxygen;  the presence of three excited 
states (5D2, 5D1 and 5D0) spanning the range 17500-21000 cm-1 that are lower in 
energy than  the triplet levels of many different types of ligands; the presence of an 
environmentally insensitive magnetic-dipole transition 5D0 to 7F1 in the luminescence 
spectrum, that can be used as an internal reference to the hypersensitive transition 
bands around 620 (5D0→7F2)  and 700 nm (5D0→7F4); the high emission anisotropy 
factors, gem, in circularly polarised luminescence  (CPL) spectra.   
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A simplified photophysical schematic pathway, involving energy transfer from an 
absorbing antenna with appropriate singlet (S) and triplet (T) energies in the 
sequence, S→T→Eu3+, has been shown to be valid for the majority of complexes 
studied. There are a few cases in which the pathway involves competitive direct 
energy transfer from the singlet excited state to the lanthanide ion, but these are 
generally considered to be rare[15],[16]. The photophysical phenomena observed in 
certain special cases requires further consideration. For example, a significant 
dependence of emission and excitation spectra on solvent polarity can be observed 
sometimes, and a very low efficiency of Eu3+ sensitisation has been reported in 
certain systems, notwithstanding an optimal value of the energy gap between triplet 
level and a resonance energy level of Eu3+. The presence of donor and acceptor 
groups within the same molecule, separated by a conjugated system, gives rise to 
charge-transfer states. The term can be used in a broad definition to embrace all 
energy states that involve at least partial separation of charge in an excited state. 
Accordingly, the energy of these transitions can be highly dependent on the polarity 
of the solvent, and therefore the observation of solvatochromism provides evidence 
in support of the assignment of these bands as charge-transfer (CT) transitions. 
 
The question of the participation of these bands in the sensitisation pathway of Eu3+ 
emission has been often raised. It has been suggested that the intervention of an 
intra-ligand charge-transfer (ILCT) state can efficiently compete with a pathway 
involving the ligand triplet, for sensitisation of Eu3+ luminescence, provided that it 
has a suitable energy to match the resonance levels of Eu3+. Evidence in favour of the 
predominant singlet character of these bands is given by observation of direct 
excitation into the ILCT band, with a decay rate of the order of nanoseconds and the 
absence of triplet oxygen quenching of metal emission. 
 
Besides ligand-centred ILCT states, ligand-to-metal charge-transfer (LMCT) states, 
involving intermediate reduction of Eu3+ to Eu2+ can be observed in the 
absorption/excitation spectra of europium(III) complexes. The reduction potential for 
Eu3+/Eu2+ is the lowest in the lanthanide(III) series, for example −0.35 V for the aqua 
ion, and approximately −1.1 V for Eu(III) complexes with many strongly 
coordinating octadentate ligands that stabilise Eu(III) with respect to Eu(II)[17],[18]. 
The energy of these broad LMCT bands, with widths in the range 5,000–15,000 
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cm−1, varies considerably depending on the electron-donating ability of the ligand[19]. 
The states have mainly singlet character. If an LMCT state is located close to the 
resonant excited state levels of Eu3+, it serves as an efficient quenching pathway, 
permitting non-radiative depopulation of an excited state of Eu3+. Since the energy of 
the LMCT state is proportional to the reduction potential of the triply charged 
lanthanide ion, isostructural complexes with lanthanide ions other than Eu3+ should 
shift this band hypsochromically in their absorption spectra, by a fixed value that is 
independent of the nature of the ligand. 
 
             
Fig. I.3 Schematic representation of the major energy transfer processes occurring in responsive 
europium(III) complexes, including interactions with quenching species (Q), dioxygen, proximate 
vibrational oscillators (X-H; X = C, N, O) and transition metal ions (Mn+). 
 
A variety of excited state pathways characterises the sensitisation of Eu3+ emission 
(Fig. I.3). External perturbation of these energy-transfer processes allows different 
types of luminescent responsive probes to be devised. These probes can be divided 
into three major groups: those involving a change in the overall intensity of Eu3+-
centred emission; those involving changes of the spectral profile without major 
change of total emission intensity; those that involve changes in both the overall 
intensity and the emission spectral signature. The first group can be subdivided into 
three sections, depending on the multiplicity of the excited state involved or a 
charge-transfer character. 
 
Perturbation of the singlet excited state.   In this case, efficient energy transfer may 
occur between the singlet state of the antenna and the singlet state of another 
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molecule (or moiety within the same molecule), either by a long-range (Förster 
mechanism) or by a close contact interaction (e.g., π–π stacking). Alternatively, the 
coupling to a charge transfer state (ILCT or LMCT) can lead to deactivation of the 
antenna S1 state. In the limit, this process may involve complete electron transfer, 
and is often simply termed as photoinduced electron transfer.   
 
Perturbation of the triplet excited state.   Deactivation of the triplet level can occur 
either by back energy transfer from resonant levels of Eu3+, if the energy gap is less 
than 1800 cm−1, or by ligand phosphorescence or non-radiative vibrational 
quenching, if the energy gap is too large and the rate of energy transfer is relatively 
slow. Such back-energy transfer processes are much more common in analogous 
terbium complexes, owing to the higher lying 5D4 excited state. Alternatively, 
coupling with a charge-transfer state (ILCT or MLCT) can also quench a triplet state. 
An efficient deactivation by energy transfer to triplet oxygen in solution is 
occasionally observed, leading to formation of singlet oxygen.  
 
Perturbation of the excited states of Eu3+. Non-radiative deactivation of the excited 
state of the europium ion can occur by energy transfer to electronic energy levels of 
transition metal ions (e.g. Cu(II), Mn(II) or Co(II)) or by a FRET-mechanism to 
different acceptor molecules/ions. These probes can be ratiometric in nature and may 
be addressed using excitation spectroscopy, if the induced response to an external 
stimulus is accompanied by an absorption spectral shift.   
 
The second group involve changes in the coordination environment of the Eu3+ ion. 
They are usually ratiometric probes and typically involve observation of the 
‘hypersensitive’ electric-dipole transitions whose intensities can be referenced to the 
emission intensity of the magnetic-dipole transition, 5D0→ 7F1 that is usually 
insensitive to change in the primary coordination sphere. Typically, perturbation of 
the coordination environment is accompanied by variation in the number of 
quenching oscillators X-H (X = O, N, C). Such a change will alter the overall 
intensity as well, if the conditions for favourable Franck-Condon overlap are met.  
 
The third group includes probes that combine both sensing mechanisms, i.e. 
involving perturbation of the coordination environment and energy levels of the 
chromophore. 
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I.2 pH-Sensitive luminescence probes 
 
Many physiologically relevant processes in living organisms are accompanied by 
changes in the pH of the medium. Inside the living eukaryotic cell, pH values inside 
the organelle may vary from 4.7 inside the lysosome, which digests all unwanted 
species by multiple hydrolytic enzymes called hydrolases, up to 8.0 in mitochondria 
– the ‘power plant’ of the cell (Fig. I.4). The live monitoring of pH values of specific 
organelles can provide deeper insight into processes occurring on a cellular level and 
can be accomplished by utilising organelle-selective luminescent probes. 	
																												 		
Fig. I.4 The pH distribution of individual cellular organelles in a prototypical mammalian cell.[20] 
 
 
Several classifications of pH-sensitive molecular probes are possible, e.g. by 
chemical structure (e.g. small molecules, metal complexes, fluorescent peptides), 
type of the response (turn-on/turn-off, ratiometric/non-ratiometric) or signal type 
detected (e.g. absorption/emission maximum, emission intensity, lifetime of an 
excited state). In the present work structure-based classification was selected.  
 
I.2.1. Commercially available fluorescent pH-probes 	
The necessity to monitor pH values on a cellular level has stimulated considerable 
research activity and led to the appearance of dozens of luminescent pH-responsive 
probes on the market, spanning the whole range of physiologically relevant pH 
values (Fig. I.5).[21]  
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Fig. I.5 Molecular structures of the most widely used molecular dyes and corresponding pH-sensitive 
ranges[21] 
 
Oregon Green 488, carboxyfluorescein, BCECF and C.SNARF-2 share the same 
conjugated core and belong to a large group of fluorescein dyes. Upon reversible 
protonation, a shift of the emission or excitation band is observed, and by following 
the ratio between the intensities of protonated and non-protonated forms a pH value 
can be determined. By extending the conjugation (C.SNARF-2) or by introducing 
electron-withdrawing groups (Oregon Green 488 and BCECF), the pKa of the 
corresponding probes was varied. The common drawback of fluorescein-based 
probes is their fast leakage from cytosol through cell membrane, potentially giving 
rise to erroneous readings[21].  
 
The highly water-soluble dye HPTS has a pKa of 7.3, making it a suitable probe for 
measuring pH in cytoplasm, by following the shift in its excitation spectrum[22]. 
However, the lack of cell permeability necessitates direct microinjection, 
electroporation or scrape loading of this dye into a cell. To monitor changes at the 
other end of the pH range, a lysosome-specific pyridyl oxasol probe, Lysosensor LD-
160, is normally used by monitoring the ratio between the emission bands of 
protonated and non-protonated forms. High photostability and cell-permeability, 
along with high quantum yield for both protonated and non-protonated forms makes 
this probe near-ideal for lysosomal studies[23]. 
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I.2.2. Recent advances in small-molecules probes 		
Fluorescein and its derivatives are widely used as platforms to create pH-sensitive 
probes, owing to the change in the emission wavelength following protonation. 
However, it is impossible to use probes with only a fluorescein-based emission 
centre, as an additional emission band is required to serve as internal reference, 
making the responsive probe amenable to ratiometric analysis within a certain pH 
range. A typical strategy is to graft fluorescein to another emissive pH-insensitive 
moiety or to an acceptor, such as a BODIPY moiety[24] (Fig. I.6). In the latter case, 
the energy of the emissive charge transfer state will depend strongly on the pH value. 
Under neutral and basic conditions, the compound emits in the green (ca. 520 nm) 
from the fluorescein sub-unit; at acidic pH, charge-transfer state emerges due to the 
donor-acceptor interaction between fluorescein in its phenolic form and the BODIPY 
group. Emission in the red then dominates (ca. 600 nm).  
 
           
Fig. I.6 Variation of pH leads to change of the maximum in the emission spectrum (left); ex vivo 
calibration curves with values observed in endosomes at 37 °C and cytosol at 4 °C (right).[24]  
 
In vitro studies show that by varying the temperature, the probe-protein-peptide 
adduct with bovine serum albumin and ‘Pep-1’ non-covalently bound peptide 
predominantly is located in either the endosomes (at 37 °C) or in the cytosol (4 °C). 
However, this selectivity is driven by peptide Pep-1, rather than by the behaviour of 
the probe itself, as it was previously demonstrated that protein-dye conjugates 
containing Pep-1 specifically localize in endosomes.  
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Another well-known dye, rhodamine, is also used as a building block in pH-
responsive systems, being sensitive to pH over a broad pH range. One of the most 
recent examples is a dual-excitation ratiometric probe based on coumarin-rhodamine 
FRET dyads[25] (Fig. I.7), where Förster energy transfer between the coumarin and 
rhodamine moieties is strongly pH-dependent. The main requirement for dual-
excitation ratiometric probes is a large separation between maxima of excitation 
spectra of each component comprising the probe. Such a separation is observed in 
this pair (350 nm and 560 nm for the coumarin and rhodamine units, respectively). 
Upon increasing pH, population of the coumarin phenolate increases, giving rise to a 
new excitation band at 400 nm. The band is ascribed to an ICT transition 
(intramolecular charge transfer); emission intensity corresponding to the phenolic 
form correspondingly decreases. At the same time, the intensity of the rhodamine-
based excitation band remains relatively constant over the whole pH range, and 
hence can be used as an internal reference in ratiometric analysis.  
 
 
Fig. I.7 Coumarin-rhodamine FRET dyads (left); calibration curve for 1a (right).[25] 
 
However, efficient pH-sensitive probes can also be obtained without introduction of 
energy transfer states and two pH-sensitive dyes can be simply connected with a 
spacer. In this way, a dual-emissive probe was designed including both fluorescein 
and rhodamine moieties[26] (Fig. I.8). It operates over a broad range of pH values, 
since the pKa values of fluorescein and rhodamine are substantially different (3.1 and 
9.2 for rhodamine and fluorescein, respectively). By plotting the ratio between the 
emission band maxima of each moiety (512 nm and 580 nm), a quasi-linear 
dependence was observed.  
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Fig. I.8 Proposed structural changes upon changing pH (left) and pH titration curve (right).[26] 
 
The aforementioned examples lack any selectivity towards a specific organelle. 
Therefore, each cellular study that was performed can be considered only as a ‘proof 
of concept’ study, to confirm the absence of toxicity. These examples serve to 
identify the starting platform in probe design, to which different groups promoting 
selective recognition can be attached. One of the simplest, but nonetheless most 
efficient strategies is utilization of weakly basic side chains, making the whole probe 
acidotropic, thereby promoting its accumulation within acidic organelles, such as 
lysosomes and endosomes. The pKa of this type of weak base, typically a secondary 
amine, should correspond to the expected pH value inside the organelle. For 
example, this principle is employed in commercially available Lysotracker 
GreenTM (Fig. I.9). This molecule comprises of an amine containing side chain, 
which quenches the luminescence of an adjacent emitting core by intramolecular 
photo-induced electron transfer (PET) upon deprotonation at alkaline pH.  
 
                            
Fig. I.9 Protonation of Lysotracker GreenTM leads to enhanced fluorescence.[27] 
 
Another interesting example of a lysosomal probe R6G-EDA – a rhodamine 
containing a lactam group[27] (Fig. I.10), which is non-luminescent at neutral and 
basic pH due to formation of the rigid lactam ring, making it stable against photo-
induced degradation. On lowering the pH, ring opening can occur resulting in the 
formation of highly luminescent product. Apart from the aforementioned example, a 
side chain does not serve as a ‘quencher’ and is only used to promote the probe 
inside the lysosome. In fact, the proposed pH probe has a substantial drawback – the 
lack of an internal reference; it therefore cannot be considered as a useful probe.  
	 25	
  
Fig. I.10 Structural rearrangement of R6G-EDA upon varying pH (left) and the pH titration curve 
(right).[27] 
 
In theory, by knowing the exact concentration of the probe used for in vitro 
measurements, an estimate of the pH value can be obtained. However, in cellulo 
studies require an internal reference as the concentration of the probe can vary 
substantially and does not correspond to that of prepared solutions. 
 
The same intrinsic flaw can be found in another example of a rhodamine-based 
lysosomal probe (RML), with a highly pH-sensitive spirocyclic structure[28] (Fig. 
I.11). An aminoethylmorpholine group (pKa ca. 7.4) was introduced to replace the 
aminoethyl group in order to promote lysosome targeting, in accordance with 
previous empirical reports. In the present case, the pH response is not solely 
rhodamine-based and is partially mediated by the side-chain via formation of an 
intramolecular hydrogen bond with the amide moiety of a rhodamine unit. Formation 
of this hydrogen bond enhances the pH-sensitivity, as shown by comparison with the 
probe, where a dehydro-2H-pyran group replaces the aminoethylmorpholine moiety. 
The pyran probe exhibited significantly less intense luminescence upon lowering the 
pH.  
 
  
Fig. I.11 Structural rearrangement in RML on varying pH  (left) and pH titration curve (right).[28] 
 
A guiding theme in cellular studies is the adoption of experimental conditions that 
minimise the energy needed to study the system. Thus there is a strong desire to use 
probes that can be excited at longer wavelengths. Moreover, detection of emission in 
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the near-IR region has the advantage that cellular autofluorescence can be excluded. 
One of the few examples in the literature is the class of cyanine-based probes, since 
cyanine derivatives typically emit in the near-IR region.  
 
In a recent paper, Ma employed a commercially available heptamethine dye (IR780) 
to synthesize a new pH-sensitive lysosome-targeted probe Lyso-pH[29] (Fig. I.12) by 
attaching a morpholine moiety to act as the lysome-targeting group. Heptamethine is 
a decomposition product of cyanines, and has substantially higher photostability 
compared to the initial compound. It also emits in the near-IR region, and hence has 
advantages for practical applications. Upon changing the pH, a red shift of the 
emission band was observed, giving a quasi-linear dependence over the region 
4<pH<6. Furthermore, variable temperature fluorescence imaging was performed in 
order to mimic the processes that occur during heat shock, a side effect of many 
diseases, and evaluate its impact on lysosomes. It was revealed that a temperature 
increase causes an irreversible rise of pH in lysosomes, presumably caused by partial 
neutralisation between the cytosol and lysosome. 
 
  
Fig. I.12 Structure of cyanine-based pH-sensitive probe Lyso-pH (left), a titration curve (middle) and 
temperature dependence of pH in lysosomes (right).[29] 
 
Various attempts to use cyanines as pH-ratiometric probes have been reported, 
particularly with systems employing protonated monoamine groups to promote a pH-
dependent response of the system. Unfortunately, in spite of their wide operational 
pH range, these probes undergo irreversible tranformations. However, introduction 
of a diamine moiety that is able to form a bifurcated hydrogen bond, improved the 
stability and reversibility of the pH dependent behaviour of the system[30] (Fig. I.13), 
resulting in the creation of an effective pH-ratiometric probe. The pKa of the system 
can be tuned by choosing a diamine moiety with an appropriate pKa value.   
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Fig. I.13 Structural rearrangement upon pH change (left) and pH-titration curve (right).[30] 
 
A specific aspect of the chemical structure of cyanines gave rise to another pH-
dependent response – aggregation induced emission (AIE). Cyanine dyes normally 
consist of large aromatic 𝜋-conjugated cores with sparsely distributed electrically 
charged head groups. Therefore, 𝜋-interactions and hydrophobic effects promote 
aggregation of cyanines in aqueous media. Typically, AIE-active molecules are 
twisted and strained. The fluorescence is effectively quenched due to the low-
frequency motions. Upon aggregation, those motions are physically restricted, and 
therefore the excited state can be radiatively depopulated. Pursuing an opportunity to 
combine both effects – aggregation and AIE – in a single molecule, Tsang reported a 
new hybrid pH-responsive probe TPE-Cy[31] (Fig. I.14). The mechanism 
underpinning the pH-dependent response is the protonation of a sulfonate group at 
low pH (pKa = 6.42), combined with nucleophilic attack by OH- at the double bond, 
with a subsequent disruption of conjugation. In each case, the hydrophobicity of the 
whole system decreases due to neutralization of the sulfonate group in an acidic 
medium and the presence of an overall negative charge in more basic media.   
 
                                      
                                      
Fig. I.14 Structural rearrangements (top) and change in aggregation (bottom), accompanying 
pH variation in TPE-Cy probes.[31] 
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Another prominent class of pH-responsive probes is based on naphthalimide 
derivatives.  The ease of structural modification, along with the bright fluorescence 
of these compounds has attracted much interest. It is difficult to suggest any 
plausible classification for the numerous derivatives of naphthalimide. Therefore 
only a few examples are discussed.  
 
One of the most recent examples is a lysosome-targeted probe with a N,N-
dimethylaminoethyl group appended in order to promote the specific penetration of 
lysosomes and to provide a pH-sensitive PET quenching of the naphthalimide 
core[32] (Fig. I.15). Despite the high Stokes’ shift, high fluorescence quantum yield 
and almost linear pH response in the range 4<pH<7, allowing detection in both 
lysosomes and cytoplasm, the proposed system lacks any internal reference. This 
limits the use of this probe in obtaining reliable pH values.  
 
 
Fig. I.15 Structural rearrangement upon changing pH (left) and pH-titration curve (right).[32] 
 
There are many examples of ICT-based ratiometric fluorophores, bearing a 
naphthalimide core. They are typically coupled with other conjugated groups, for 
instance, with a triazole moiety at the 9-position (Fig. I.16)[33], without significantly 
affecting the  photophysical properties of the naphthalimide core. The pH response is 
attributed to reversible deprotonation of the N-H group in the heterocycle-fused 
naphthalimide structure, while a long-chain substituent attached to nitrogen of 
naphthalimide makes it cell membrane permeable. It is worth noting that a sample 
with a (CH2)15CH3 substituent was localised both on the cell surface and inside the 
cell. This behaviour enables measurement of the pH values in intra- and extracellular 
regions, which could be useful in analysing tumour cell pH, as they may exhibit 
lower extracellular pH values compared to healthy cells. 
 
	 29	
   
Fig. I.16 Structural rearrangement on changing pH (left), pH-titration curve based on absorption 
(centre) and luminescence (right) spectra, corresponding to R = CH2CH2OH.[33] 
 
Naphthalene derivatives have also been examined as active units in pH-responsive 
luminescent probes due to similar advantageous properties; high photostability, high 
quantum yields of fluorescence and diverse opportunities for structural modification. 
One of the prominent examples, is a probe termed NP1, which is a 2-methoxy-6-(5-
oxazolyl)naphthalene with an attached pyridine  group[34] (Fig. I.17). It has been used 
to investigate living cells by two-photon microscopy (TPM). This technique has 
certain advantages in comparison with conventional one-photon microscopy (OPM), 
such as increased penetration depth, localised excitation and enhanced observation 
time. Protonation of the pyridine group in a slightly acidic medium (pKa ≈ 5.0) 
enhanced ICT between two parts of the molecule, effectively quenching the 
naphthalene-centred fluorescence. The pyridine moiety enhanced the acidotropic 
character of the whole molecule and was believed to lead to an increased 
accumulation of the probe within lysosomes and the cytoplasm. The authors 
emphasised that the emission maximum strongly depends on the polarity of the 
medium, and speculated about its possible utilisation to estimate the polarity of 
intercellular fluids. Such behaviour is typical for ICT-based probes, making the 
generation of a pH calibration curve difficult due to concomitant medium polarity 
dependence, limiting the wider implementation of this probe.  
 
  
Fig. I.17 Structural rearrangement upon changing pH (left) and pH-titration curve (right) in probe 
NP1.[34] 
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Notwithstanding the useful information gained with the NP1 probe with regard to the 
pH values of esophagus tissues obtained from patients with esophagitis, the low 
quantum yield (less than 0.1) and fairly narrow operational pH range restricts the 
scope of possible applications. Therefore, in attempting to address these problems, 
this research group substituted the pyridine moiety with a benzimidazole group[35] 
(Fig. I.18). The operational pH range only shifted slightly, but improved 
luminescence efficiency was found. The introduction of the protonated 
dimethylaminoethyl side chain (BH1L) can be tentatively linked to its lysosomal 
uptake, enabling real time monitoring of fluctuations as small as 0.1 pH units.  
 
                   
Fig. 18 Structural rearrangement upon changing pH ; chemical structure of a lysosome-targeted 
BH1L dye (left) and in cellulo pH-titration curve (right).[35] 
 
As the last example of the latest developments in the area of pH-sensing based on 
small molecules, an unusual example of a pH-responsive fluorescent false 
neurotransmitter (FFN) will be discussed. Monoamine neurotransmitters are 
accumulated in synaptic vesicles by vesicular monoamine transporter 2 (VMAT2), 
which translocates the monoamines (e.g., dopamine) from the cytosol to the lumen of 
synaptic vesicles. A pH gradient is the driving force, promoting the transport of 
neurotransmitters into vesicles. Since there are not any examples of pH-dependent 
probes specifically targeting synaptic vesicles. FFN (FFN511), a commercially 
available vesicle stain, used to stain vesicles, was used as a starting point to create a 
pH-responsive probe[36] (Fig. I.19). The structure was modified to resemble that of 7-
hydroxycoumarin (umbelliferone) to give the probe Mini101, which demonstrates 
pH-dependent luminescent properties, while an additional alkyl chain was attached 
to investigate the influence of lipophilicity on penetration of synaptic vesicles. The 
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probe specifically targeted synaptic vesicles without penetration of other acidic 
organelles, demonstrating the exceptional recognition of the coumarin core structure 
by synaptic vesicles. 
 
                
Fig. I.19 Structures of commercially available FFN511, pH-responsive umbelliferone, Mini101 and 
the final synaptic vesicle targeting pH-responsive probe (left); in cellulo pH-titration curve (right).[36] 
 
 
 
I.2.3 pH-sensitive luminescent europium-based probes 		
	  
Fig. I.20 Structural rearrangement upon changing pH (left) and pH-dependent change of luminescent 
intensity of MD transition (right).[37] 	
One of the early examples of a lanthanide-based pH-sensitive probe was given by 
Parker and was based on the reversible linkage of a hydroxide anion, leading to the 
formation of a pseudo-base[37] (Fig. I.20). Such transformation resulted in efficient 
quenching of Eu(III) luminescence upon increasing pH, thought to be due to the 
considerable hypsochromic shift of the triplet level, resulting in inefficient energy 
transfer between the ligand and Eu3+.  
 
Another class of lanthanide-based pH-sensitive luminescent probes is based on the 
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principle of quenching of the luminescence of the lanthanide ion by reversible 
replacement of a coordinated anionic group in the coordination sphere with one or 
more water molecules[38] (Fig. I.21). 
 
 
                                                  
 
                     
Fig. I.21 Replacement of water molecules in the coordination sphere of the lanthanide with an 
intermolecular anionic analyte gives rise to enhanced luminescence intensity.[38] 
 
The most widely used ligand platforms are 1,4,7-triazacyclononane and 1,4,7,10-
tetraazacyclododecane (cyclen), which have being thoroughly studied by Parker. 
These platforms provide several opportunities for chemical modification along with 
low toxicity, whilst the macrocyclic structure enhances the kinetic stability of the 
complex with respect to metal dissociation.  For example, using a cyclen platform a 
lysosome-targeting pH-responsive probe was synthesised, that exhibited a dual 
ratiometric luminescence and CPL response[39] (Fig. I.22). The substituted 
sulphonamide nitrogen reversibly binds to the Eu3+ centre creating the pH-dependent 
response. The CPL response was related to complex rigidification in the N-bound 
form at higher pH, resulting in a larger emission dissymmetry factor. The integral 
azaxanthone chromophore serves both as an efficient antenna to harvest incident 
light in near UV-region, and as an efficient recognition moiety, promoting cell 
uptake by macropinocytosis, followed by accumulation of the complex in the 
lysosomes.   
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Fig. I.22 Structural rearrangement upon changing pH (top) and pH-dependent variation of 
dissymmetry factor gem (bottom).[39] 
 
Another example is based on 1,4,7-triazacyclononane[40], where a substituted 
sulphonamide is again the key motif governing the pH response, whilst two 
pyridylalkynylaryl-based chromophores provide efficient energy harvesting in the 
near-UV region,  along with rigid coordination around Eu3+. This probe localised 
selectively to the endoplasmic reticulum. In this case, both the relative intensity of 
the hypersensitive transition and the lifetime of the 𝐷!!  excited state were 
monitored as a function of pH (Fig. I.23). The influence of several bioactive species 
that can compete with sulphonamide ligation was also studied, revealing that only 
the hydrogencarbonate ion can bind to the Eu3+ causing changes in emission spectral 
form. The reasons behind selective accumulation of the complex in the endoplasmic 
reticulum remained uncertain, since analogous complexes with three 
pyridylalkynylaryl-based chromophores had previously shown selective 
accumulation in mitochondria[41].  
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Fig. I.23 Structural rearrangement upon changing pH (left) and pH-dependent variation of relative 
intensity of the hypersensitive transition (black squares) and lifetime of the 𝐷!!  excited state (red 
squares) (right).[40] 
 
An alternative strategy was employed in recent work by Faulkner, where pH-
sensitivity was triggered by reversible changes in the conjugation of the 
chromophore[42] (Fig. I.24). Upon increasing pH, deprotonation of the CH2CO group 
occurs, giving rise to a putative low-lying LMCT state, effectively quenching the 
𝐷!!  excited state. In the analogous ytterbium complexes lacking this quenching 
pathway, such behaviour was not observed. It was also demonstrated that subtle 
variations in the chemical structure of the chromophore led to considerable changes 
in the pKa value of the resulting complex. For this example the pKa value lies outside 
the key range and the simple on/off switching mechanism does not allow internal 
calibration, limiting the scope for any practical application.  
 
 
Fig. I.24 Structural rearrangement upon changing pH (left) and the pH-dependent change in 
luminescence intensity, plotted also in the inset (right).[42] 
 
A bimetallic probe with two DO3A fragments with 4-nitrophenol as both a bridging 
and pH-sensitive moiety has also been reported[43]. Depending on pH of the medium 
reversible binding of the hydroxyl group of nitrophenolic moiety with one or two of 
the DO3A fragments occurs, modulating the change in the emission and absorption 
spectra (Fig. I.25). At low pH values the nitrophenolic moiety is protonated and is 
not coordinated by either of the metal centres, leading to low emission intensity as a 
result of quenching Eu3+ ions by outer-sphere water molecules. At elevated pH 
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levels, deprotonation of nitrophenolic occurs leading to its binding first to one DO3A 
fragment, and then to both of them, giving rise to a significant increase of the total 
emission intensity as a result of removing outer-sphere water molecules from 
coordination spheres of Eu3+ ions. Thus, two distinct pH-dependent transitions 
between three states occur in this system, even though the second transition is 
somewhat less pronounced.   
 
	 	  
Fig. I.25 Putative mechanism of reversible binding of nitrophenolic moiety as a function of pH (left) 
and concomitant changes in the absorption (middle) and emission (right) spectra.[43] 
 
In a related system developed by Allen, the 2-hydroxypropyl group was used in a 
pH-sensitive moiety bridging two DO3A fragments, which was also reversibly 
protonated/deprotonated as a function of pH (Fig. I.26)[44]. However, in the present 
case a bridging hydroxyl group was much closer to both europium centres and 
therefore renders a more significant perturbation on both metals following pH 
variation. This resulted in a considerable change of crystal field splittings in the 
emission spectrum, as well as in the lifetime of an excited state.  
                      	  
Fig. I.26 Proposed mechanism of reversible ratiometric pH sensitivity (left) and corresponding 
changes of the lifetime (top right) and the total emission intensity (bottom right).[44] 
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A pH-dependent reversible tautomerism can be also employed for modulating a 
change in the photophysical properties of europium centre, as shown by Lowe in 
example of a DO3A derivative with a phosphinamide arm (Fig. I.27)[45]. Once 
protonated, a phosphinamide arm was displaced by coordinated water molecule, 
increasing the q value from 1 to 2 and leading to the decrease of the emission 
intensity. 
 
      										  
Fig. I.27 Proposed mechanism of reversible ratiometric pH sensitivity (left), pH-titration curve of 
Eu.1 (middle) and corresponding changes of the total emission intensity (right).[45] 
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I.3 Sensing of plasma proteins 
 
 
Human serum is a complex mixture of different proteins, electrolytes, antibodies, 
antigens, hormones along with compounds of exogenous origin (e.g., drugs and 
viruses) that can be used for monitoring the health status of a patient. An 
approximate composition of human plasma is given in Fig. I.28, where all human 
plasma proteins are subdivided into three groups: classical plasma proteins, tissue 
leakage proteins and cytokines, spanning a concentration range of at least 10 orders 
of magnitude. The deviation from a standard concentration of certain proteins may 
indicate the malfunctioning of certain body systems. In particular, those proteins, 
which are designated as acute phase proteins, show a large enhancement or decrease 
of their concentration in response to inflammation processes occurring in the body 
(e.g. a1-AGP, a1-AAT, etc.).     
 
 
Fig. I.28 Concentration ranges of major proteins in human plasma. An arrowhead indicates that only 
the upper limit is indicated.[46] 
 
The nomenclature of serum proteins (a, b, c, etc.) derives from the order of 
fractions during electrophoresis of a serum sample (Fig. I.29).  
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Fig. I.29 Typical pattern for serum electrophoresis in a healthy human.[47] 
 
I.3.1 Binding human serum albumin 
 
The most abundant protein (55% of total amount of serum proteins) in human serum 
– serum albumin – plays a significant role as a carrier, delivering fatty acids, 
hormones and drugs, maintaining the oncotic pressure and pH of the blood. Even 
though its physiological role is not completely understood, several studies suggest 
that it can be used as a biomarker to predict the survival rate of patients with terminal 
conditions[48],[49]. Since serum albumin is biosynthesised in the liver and excreted 
through the kidneys, its concentration may be indicative of chronic liver (under-
expression) or kidney (over-expression) failure.   
 
Multiple studies on binding essential drugs were carried out over the past decades, 
which revealed two primary binding sites in HSA, which are according to Sudlow’s 
nomenclature, are called site I and site II and sometimes are referred to as warfarin 
and ibuprofen binding sites, respectively, named after two drugs that bind to these 
two pockets (Fig. I.30). In general, it has been demonstrated that bulky heterocyclic 
anionic drugs preferentially bind to FA-1 (FA-1 to FA-7 are seven fatty acid binding 
pockets), whilst extended aromatic carboxylates are more likely to bind to FA-2[50]. 
However, secondary binding sites are sometimes observed for those drugs, which 
had been previously considered to bind selectively at just one site. For example, 
although the thyroid hormone thyroxine preferentially binds to site I, it also binds to 
site II and FA5 as secondary sites with different binding constants. The binding 
constant values given for the drugs in the literature are usually averaged values over 
all binding sites. They are usually determined by an equilibrium dialysis of the 
HSA/drug complex from any excess of added drug or by competitive binding studies 
with a drug with a known binding constant by following changes in the absorption 
and emission spectrum. The primary binding site of a drug can be determined from 
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the crystal structure of HSA co-crystallised with this drug, or by competitive 
bindings studies with drugs having a well-established primary binding pocket. 
 
      
Fig. I.30 Primary drug-binding sites in human serum albumin and corresponding site-selective drugs. 
Drug-site selectivity is provided from crystallographic data.[51] 
 
The advent of new bright and selective probes for HSA might help to follow the 
subtle changes in its concentration and can also help to establish the binding pattern 
of novel drugs. From a practical point of view, only the probes showing a turn-on 
response upon binding to HSA possess a real interest and therefore only those probes 
will be considered henceforth. Also, it seems that in many cases no discrimination 
between human and bovine serum albumins is made and the latter is usually used as 
a more affordable alternative, although it was shown that the response in both cases 
can be dramatically different. 
 
One of the basic principles behind the enhancement of the emission intensity once 
the probe is bound to the protein is the change of the local medium surrounding the 
probe going from water molecules to amino acid residues of the protein with little or 
no access of water molecules, giving rise to changes of physical parameters, such as 
dielectric constants, viscosity, spacious confinement, lack of OH-oscillators as 
potential quenchers of the emission, etc.  
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Solvent dependent aggregation is a well-known phenomenon, which is highly 
dependent on the nature of the solvent used, but usually it is considered detrimental 
for practical applications, as formation of excimers and exciplexes may serve as 
efficient quenching pathways. However, a few examples of exactly the opposite 
behaviour have been reported, for instance the sodium 1,2-bis[4-(3-
sulfonatopropoxyl)phenyl]-1,2-diphenylethene (BSPOTPE), which showed a turn-
on of the total emission intensity on going from aqueous solution to acetonitrile due 
to formation of emissive aggregates, which restrict molecular rotation in the 
molecule causing very low emission efficiency. The same principle was employed 
for sensing HSA, since binding of BSPOTPE to the protein causes the restriction of 
molecular motion inside the binding pocket, giving rise to an enhancement of the 
emission intensity (Fig. I.31)[52]. 
 
	 	 	
Fig. I.31 Molecular structure of BSPOTPE (left) and the emission intensity response as a function of 
added HSA (right).[52] 
 
On the other hand, a more classical approach was demonstrated with 3,30-di(3-
sulfopropyl)-4,5,40,50-dibenzo-9-methylthiacarbocyanine triethylammonium salt 
(MTS), where an initial aggregate in aqueous solution dissociates upon binding to 
the protein, giving rise to the appearance of new absorption and emission bands 
corresponding to the monomer, with a concomitant decrease of the bands 
corresponding to the aggregate (Fig. I.32)[53]. Since in each case (a monomer and an 
aggregate) the absorption band is in the visible part of the spectrum, an easy 
evaluation of colour can be undertaken.  
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Fig. I.32 Molecular structure of MTC (left), sensing mechanism upon binding to HSA (middle) and 
change in the emission spectrum upon addition of HSA for H2-aggregates (right).[53] 
 
The high hydrophobicity of HSA was also invoked to account for the high selectivity 
of 2,4-dihydroxyl-3-iodo salicylaldehyde azine (DISA) towards HSA, where a ten-
fold increase of the emission intensity was observed upon binding to HSA (Fig. 
I.33)[54]. It was shown that an increase in emission intensity follows the 
hydrophobicity trend for selected proteins, being large for HSA and lowest for 
ovalbumin. 
 
     
Fig. I.33 Molecular structure of DISA (left), enhancement of the emission intensity upon addition of 
HSA (middle) and change of the emission intensity following the change in polarity (right).[54] 
 
Even though very limited attention has been dedicated to the probes that can detect 
human serum albumin selectively over serum albumins of other species, a study on 
the binding of rosamine G13 with different serum albumins has been carried out 
(Fig. I.34). The HSA showed the most significant rise (36-fold) in the emission 
intensity over rabbit serum albumin (15-fold), bovine, sheep, porcine (all less than 5-
7-fold)[55]. The response behind the proposed probe is based on a restricted rotation 
of the 9-phenyl ring in the protein, leading to an increased quantum yield of the 
emission. The observed variation in quenching efficiency reflects subtle changes in 
the structure of the binding pockets, despite at least 75% homologenity in their 
structures. 
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Fig. I.34 Molecular structure of G13 and its selectivity towards selected proteins (left) and 
photographs of solutions containing G13 and different serum albumins (right).[55] 
 
Another example of a different response towards HSA over other species’ serum 
albumin is the ‘push-pull’ system DH1, where the aromatic amine served as an 
electron donor and malononitrile as an electron acceptor, giving rise to a strong ICT 
state that is very sensitive to the local environment. Bearing in mind that the 
hydrophobicity of HSA and BSA binding pockets is different, the intensity increase 
upon binding to HSA (70-fold) and BSA (9-fold) is very different. The ICT state 
which quenches the fluorescence is highly dependent on the medium polarity, and 
consequently on the hydrophobicity of the binding pocket (Fig. I.35)[56].  
 
 
      
Fig. I.35 Molecular structure of DH1 (left), enhancement of luminescence intensity of DH1 as a 
function of HSA added (middle) and selectivity of DH1 over other selected proteins, in particular 
BSA (right).[56] 
 
Evidence in favour of these hypotheses was provided by polarity-dependent studies 
of the emission intensity in water/1,4-dioxane mixtures, showing a steady increase in 
the emission intensity upon reducing solution polarity. In a related study, another 
‘push-pull’ probe PQX was thoroughly investigated to probe the polarity of the 
binding site of BSA (Fig. I.36)[56]. To calibrate the polarity probe, a series of organic 
solvents with different polarities (expressed in terms of Reichardt’s coefficients ENT) 
was used to plot the dependence between the emission maximum and ENT. Upon 
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binding to BSA, the fluorescence maximum of PQX was blue-shifted from 608 nm 
for the unbound probe to 530 nm, approximately corresponding to the band 
maximum of PQX in acetone. 
 
        
Fig. I.36 Molecular structure of PQX (left), emission spectra of PQX in different solvents (middle) 
and change of the emission spectrum upon addition of BSA (right).[56] 
 
As an example of the rational design of these ‘push-pull’ systems, the nature of the 
substituent was varied to alter the magnitude of the dipole moment and hence the 
energy of the ICT state. It was demonstrated (Fig. I.37) that on going from dimethyl- 
to diethyl- and diphenylamine the polarity-sensitivity reduced, as well as selectivity 
towards HSA. The significant decrease from diethyl- to diphenylamine could be 
partially explained by an increased steric demand and lower solubility[56]. In the case 
of diphenylamine, no selectivity was observed towards HSA over other abundant 
proteins.  
 
      
Fig. I.37 Molecular structure of a studied series of probes with a dipole moment depicted (left), 
change of the emission intensity of probe 1 (middle) and probe 3 (right) as a function of polarity of 
the solvent used.[56]  
 
The development of two-photon probes has been gaining momentum over the last 
decade and therefore it is not surprising that a two-photon probe Ant-PIm for HSA 
sensing was reported[57]. A ‘push-pull’ system with anthracene as an electron 
acceptor and two substituted alkynylaniline moieties as electron donors provided 
both a relatively high TPA cross-sections for the unbound (σ2Ant‑PIm = 813GM at 820 
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nm) and bound dye (σ2Ant‑PIm−HSA = 469 GM and σ2Ant‑PIm−BSA = 443 GM at 820 nm), 
along with high polarity dependence of the emission intensity. The latter effect was 
manifested in the rise of the emission intensity with a concomitant hypsochromic 
shift of the emission band upon binding HSA (Fig. I.38).  
 
 
Fig. I.38 Molecular structure of Ant-PIm and change of the fluorescence intensity upon addition of 
HSA.[57] 
 
A combination of the two aforementioned sensing principles – polarity-sensitive ICT 
state and TICT state – was devised in a single probe AL-1, which showed both high 
selectivity towards HSA over BSA due to the presence of an ICT state and a ‘turn-
on’ response upon binding of the protein, as a result of unrestricted torsional motion 
in aqueous media (Fig. I.39)[58]. In a very similar study, an additional functionality – 
pH-sensitive emission response – was introduced to the polar probe 
benzo[e]indolium, whilst the electron-donating moiety and the length of the spacer 
was altered (Fig. I.39)[59]. Similarly to the previous example, both the TICT and ICT 
states are responsible for quenching of the total emission intensity in aqueous 
solution. 
 
  	  
Fig. I.39 Restricted rotation of AL-1 bound to HSA leads to an increase of the emission intensity 
(left)[58] and benzo[e]indolium derivatives L1-L4 (right).[59]  
 
Apart from reversible probes, which have been considered so far and which can be 
easily displaced by addition of a more strongly binding drug, irreversibly binding 
probes have also been created. It was shown that HSA hydrolyses drugs possessing 
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ester groups and this finding was employed in the irreversible tagging of HSA by a 
series of probes (Fig. I.40)[60]. In the absence of HSA the emission from these probes 
was quenched by PET, but was recovered once the probe bound to HSA.   
 
																																			 										
Fig. I.40 Mechanism of irreversible binding of luminescent tags as a result of pseudo-esterase activity 
of HSA.[60] 
 
The analysis of HSA content is often performed in complex mixtures, as blood 
plasma and urine, which gives significant residual emission bands in the total 
emission spectrum, hampering the read-out of data. One possible solution to 
overcome this obstacle is the use of time-gating instrumentation using probes 
emitting on a millisecond timescale. Transition metal and lanthanide complexes are 
among those probes, which are worthy of mention, even though just a few examples 
of these systems have been reported so far. The cyclometalated iridium(III) complex 
with a ‘push-pull’ ligand, showed a 5-fold increase in the emission intensity along 
with a 25-nm hypsochromic shift (Fig. I.41)[61]. The response towards BSA was only 
4 times lower, what can be again ascribed to the differences in hydrophobicity of 
drug-binding pockets between HSA and BSA. Competitive binding studies suggest 
Sudlow’s site I as the binding site. Binding to both of the Sudlow’s sites has been 
observed for an iridium(III) complex with two different N,S-chelating ligands[62]. 
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Fig. I.41 Molecular structure of cyclometalated iridium complex (left), change of the phosphorescence 
intensity upon binding to HSA (middle) and selectivity over other selected proteins (right).[61] 
 
The only reported example of a lanthanide complex as an HSA probe was a terbium 
complex with a polydentate ligand bearing two 2-methyl-5-nitroimidazole moieties, 
known for their binding to HSA (Fig. I.42)[63]. The complex had one water molecule 
bound in the absence of the protein and this water molecule is likely retained upon 
binding to the protein, although no q values were provided for the complex with 
HSA bound. The apparent mechanism behind an enhancement of the total emission 
intensity upon HSA binding is reduction of -NO2 groups in 1,3-diazole moieties, 
which were probably responsible for quenching of the emission in the absence of the 
protein. On the other hand, as the complex was excited at λ = 265 nm, it was 
probably primarily sensitised through conjugated amino-acids on a side chain of 
HSA, which was the major cause of the observed increase of the total emission 
intensity. 
 
															  
Fig. I.42 Molecular structure of terbium complex and change of its emission intensity upon binding to 
HSA.[63] 
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I.3.2 Binding human acidic glycoprotein (a1-AGP) 
 
 
Acidic glycoprotein is the second most abundant protein in the blood plasma and 
belongs to the group of acute phase proteins, meaning that their concentration is 
highly susceptible to the occurrence of inflammation processes in the body. In 
comparison with HSA, there are fewer reports of the sensing of a1-AGP in vitro and 
in biological samples, primarily due to the 30 times lower concentration of a1-AGP 
compared to HSA. Since a1-AGP also plays a significant role in drug delivery, 
multiple studies have been dedicated to unraveling binding motifs of common drugs. 
It was revealed that only one primary binding site is present in a1-AGP. However, 
the analysis is considerably hampered by the presence of different human a1-AGP 
polymorphs (F1 and/or S and A) with different amino acid sequences, which are 
usually not separated before performing binding studies. F1 and S polymorphs, 
which make up 70% of commercially available a1-AGP, differ in only one amino 
acid only at position 20 (Gln/Arg substitution). Therefore, they are often considered 
together as the F1*S polymorph (ORM 1)[64].  
 
At the same time, polymorph A (ORM 2) has 22 amino acids replaced and in several 
cases showed different drug-binding properties. Apart from the co-existence of three 
polymorphs with variable ratio between them, the glycosylation pattern of a1-AGP 
varies as well. However, it was shown that these changes do not have a pronounced 
effect on drug-binding properties and therefore are usually ignored.  
 
The only example of the selective binding of luminescent tag to human a1-AGP is 
the Eu(III) achiral DO2A-derived complex [EuLx1] bearing two azaxanthone 
chromophores, which showed both the increase of the total emission intensity, as 
well as the appearance of the strong induced CPL signal (Fig. I.43)[65]. It was 
hypothesized that upon protein binding, the nitrogen of one of the chromophores is 
replaced by the oxygen of Glu-64 in the coordination sphere of Eu(III). In addition 
one of the chromophores dissociates and is bound to the α1-AGP drug-binding site. 
Indeed, CD studies revealed the presence of two different azaxanthone 
chromophores in the protein adduct. Even though the overall emission intensity 
changed in the presence other plasma proteins, the induced CPL signal was 
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considerably less intense and its spectral form was easily distinguishable from the 
one caused by a1-AGP. Furthermore, competitive drug-binding studies were carried 
out by following the change of the dissymmetry factor gem[66].  
 
	 	 	
Fig. I.43 Molecular structure of europium complex [EuLx1] (left), decrease of the total emission 
intensity (middle) and CPL signal (right) upon addition of racemic bupivacaine to a complex 
[EuLx1]*a1-AGP.[65],[66] 
 
I.3.3   Other plasma proteins 
 
Other plasma proteins can potentially be used as targets for molecular probes. a1-
Antitrypsin – an endogenous and exogenous protease inhibitor – is also an acute 
phase protein, whose concentration in blood changes in response to inflammatory 
processes. Unlike a1-AGP, very few attempts of drug-binding studies have been 
reported[65] and therefore very limited data is available on its drug-binding site 
behaviour.  
 
A series of publications was dedicated to the binding of lanthanide ions to apo-
transferrins (Tf) – an iron-binding glycoprotein, which controls the level of free iron 
in plasma by reversible binding of two Fe(III) ions – one binding site per lobe (Fig. 
I.44). The lanthanide ions occupy the same coordination sites as Fe(III) with the only 
difference that two additional water molecules are bound to the lanthanide, 
increasing the coordination number from 6 – typical for Fe(III) – to 8[67]. The total 
emission and CPL spectral studies of EuTf and TbTf complexes revealed the 
equivalence of both binding sites in a transferrin, by comparing spectral signature 
after addition of one equivalent of Tb3+ to monoferric N- and T-terminal transferrins 
(Fig. I.44)[68]. Despite the fact that the binding constant for lanthanides (pKb = 13) 
was much lower than for iron (pKb = 20), addition of Tb3+ to a human body-fluid 
sample facilitated detection and subsequent separation of TbTf complex using 
HPLC, without interference from residual signals[69].  
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Fig. I.44 Two coordination sites for binding Fe(III) in human serum transferrin (left).[70] CPL 
(top right) and total emission spectra (bottom right) of Tb3+ bound to monoferric N-terminal 
(a) and C-terminal (b) transferrins.[68] 
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I.4   Sensing of biologically relevant anions with 
europium(III) complexes 		
The design of anion-selective probes is governed by the physicochemical properties 
of the analyte. Key properties to consider include the nature of anion binding to the 
metal centre, the potential to engage in stabilising hydrogen bonding or π–π-stacking 
with the probe, the anion charge density and pKa. Such considerations have been 
taken into account in the series of ratiometric Eu(III) probes that have been devised 
for citrate, lactate, urate and bicarbonate, used successfully in complex media and 
applied in biological studies both in vitro and in cellulo[71],[72],[73]. 
 
Europium complexes with high selectivity towards specific anions are still relatively 
scarce. Here, the discussion is restricted to two limiting cases–examining fluoride 
and nucleotide sensors. In the first case, the small fluoride ion can replace a water 
molecule in the coordination sphere of Eu3+ at sub-millimolar concentrations, if 
additional stabilisation through formation of hydrogen bonds with F− is provided. In 
the second case, the bulky nucleotide molecules possess both a nitrogenous base 
capable of π–π-interactions with a probe and a phosphate group, which can 
coordinate to Eu3+. 
 
In the majority of cases discussed in this section the binding molecule/ion replaces a 
coordinated water molecule(s), so that the photophysical response accompanying the 
binding event is an increase of total luminescence intensity, upon removal of the 
O−H quenching oscillators. In parallel, alterations to the Eu3+ spectral profile occur, 
caused by changes in the nature and polarisability of the coordinated donors that 
define the ligand field. 
 
The fluoride ion plays an essential role in many physiological processes, such as 
bone and enamel mineralisation. However, if fluoride is present in excessive 
amounts, it can lead to disturbances of bone homeostasis (skeletal fluorosis) and 
enamel development (dental fluorosis)[74]. Therefore, its concentration in drinking 
water and biological tissues needs to be monitored. The fluoride anion is comparable 
in size with OH− (1.29 Å for F− and 1.32 Å for OH−), and their competitive binding 
can present a challenge. However, within the physiologically relevant pH range, the 
concentration of OH− in aqueous solutions is very low and does not usually hamper 
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F− binding. As a hard Lewis base, fluoride has a relatively high affinity towards hard 
Lewis acids, such as lanthanide ions. Therefore, the use of lanthanide complexes as 
fluoride probes is sensible. However, the usually observed binding constants of 
fluoride ions for lanthanide complexes in water are relatively low (logKa=1.5–3), due 
to the high free energy of hydration of the fluoride ion (−ΔG°hydr=465 kJ mol−1). 
Efficient binding has been observed only with cationic complexes, where a water 
molecule in the ninth coordination site of europium can be replaced by the fluoride 
ion, stabilised by additional interactions. For instance, the coordinated F− can be 
additionally stabilised by F−···CH interactions, as in the europium complex reported 
by Butler[75]. The europium complex EuL1-2 based on a cyclen ring and bearing two 
quinoline chromophores in trans-positions has a coordinated water molecule that can 
be replaced by F−, giving rise to a 9-fold increase of luminescence intensity (Fig. 
I.45). In parallel, a large change of the emission profile was observed within the 
relevant range (20–210 µm), typical for water fluorination. Although no anion 
binding was observed in the case of Cl−, Br−, I−, NO3−, HSO4−, HPO42−, and 
CH3CO2−, competitive binding of HCO3− was revealed, resulting in similar 
photophysical changes. The high selectivity towards F− and high stability of the 
formed complex (logKa = 4.1) was attributed to an additional stabilisation through 
formation of relatively strong C−H···F−···H−C interactions between coordinated F− 
and the quinoline moieties. 
 
 
Fig. I.45 Molecular structure of complexes EuL1-2 (left), change of the total emission intensity upon 
addition of F- (middle) and DFT-optimised structure of EuL2 with a bound fluoride anion (right).[75]  
 
Another example, involving stabilisation of fluoride binding by hydrogen bond 
formation, was reported by Tripier[74]. In this case, a fluoride anion bridges two 
cationic cyclen-based europium complexes bearing two picolyl and two acetamide 
pendant arms featuring a linear Eu−F−−Eu bonding array. Upon addition of fluoride, 
two water molecules are displaced from each site by one fluoride ion, giving rise to 
the “sandwich”-like structure, [EuLx2], which is stabilised by π–π stacking 
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interactions between opposite pyridyl rings (Fig. I.46). The fluoride ion gains 
additional stabilisation inside this double-decker structure by formation of 
C−H···F−···H−C hydrogen bonds with pyridyl moieties. When pyridyl moieties 
were substituted with two other acetamide arms, the formation of “sandwich”-like 
structure was not observed and substantially lower affinity towards F− was 
discovered, emphasising the importance of the pyridyl units in enhancing fluoride 
binding. 
 
                       
Fig. I.46 Molecular structure of the ligand (left) and the crystal structure of a dimer [EuFLx2]2, with a 
fluoride anion embedded in between (right).[76] 
 
In a subsequent study[77] Tripier modified the complex by replacing the acetamide 
arms with carboxylate moieties to reduce the overall complex charge, alleviating 
repulsion during formation of the putative dimer. Substituted pyridyl units were 
replaced with indazole moieties, in order to provide additional stabilisation by 
hydrogen bonding between F− and NH groups of indazole. An increased molar 
extinction coefficient also resulted. The dimeric complex, [EuLx3(H2O)], showed 
very high sensitivity (24 nm) and selectivity towards fluoride anions over Cl−, Br−, 
HCO3−, CH3CO2−, and HPO42−, resulting in the 22-fold increase of the overall 
emission intensity, accompanied by a pronounced change of the spectral profile (Fig. 
I.47). Analysis of the crystal structure reveals that the high association constant 
(logKa = 13.0) can be explained by stabilisation of the dimer by four hydrogen bonds 
formed between the nitrogen atoms of the indazole moiety of one complex and the 
oxygen atoms of the carboxylate arms of another, as well as by formation of a 
Eu−F−−Eu bond.  
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Fig. I.47 Molecular structure of the ligand (left), enhancement of the total emission intensity as a 
function of added F- (middle) and the crystal structure of a dimer [EuFLx3]2 with a fluoride anion 
embedded in between (right).[77]  
 
A symmetric europium complex EuLPy based on the cyclen core with four pyridyl 
substituents has been analysed by Faulkner (Fig. I.48)[78], revealing a high affinity 
towards F− (logKa = 5.0). Since no competitive binding studies have been carried out, 
the selectivity of the proposed complex towards fluoride ions remains unclear, 
although additional stabilisation of F− might be expected by formation of hydrogen 
bonds with the nitrogen atoms of the pyridyl groups. 
 
						 	 	 	
Fig. I.48 Molecular structure of the ligand (left), the total emission intensity before (black line) and 
after (red line) addition of F- (middle) and the crystal structure of a EuLPy (right).[78] 
 
Adenine nucleotides - adenosine monophosphate (AMP), adenosine diphosphate 
(ADP) and adenosine triphosphate (ATP) - play an essential role in bioenergetics, 
participating in energy-transfer processes required for normal functioning of the cell. 
In order to create luminescent europium probes that can bind one adenosine 
derivative selectively, steric control should be imposed by ingenious design of the 
ligands, so that the binding interaction involves both the adenosine and phosphate 
parts of the molecule. In general the affinity order, determined by the charge of the 
phosphate moiety, is usually found to be ATP>ADP>AMP, and a different order of 
selectivity between these species remains a challenge. With this in mind, Albrecht[79] 
has studied a coordinatively unsaturated double-stranded helical dinuclear europium 
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complex [EuLx4] that causes a significant 64-fold increase of luminescence intensity 
upon binding AMP molecules with selectivity over ATP and ADP, as well as other 
biologically relevant ions (Fig. I.49). Two strands of bis(tridentate) diamide ligands 
encapsulate two Eu3+ ions, whose coordination spheres are saturated with water 
molecules and nitrate ions. Upon addition of AMP, bound water molecules and 
nitrate ions are replaced by one AMP molecule, coordinated by a nitrogen atom of 
the adenosine group to one Eu3+ ion and by two oxygen atoms of a phosphate group 
to another Eu3+, leading to an increase in the emission intensity of the complex. 
Computational studies suggested that an extension of the phosphate chain in ADP 
and ATP leads to a repulsive interaction; no significant binding was observed in 
these cases. Competitive binding data established the high stability of the 
[EuLx4]*AMP aggregate, consistent with formation of a triple-stranded structure. 
 
	 	
Fig. I.49 Putative binding mode of AMP (left), enhancement of the total emission intensity as a 
function of added AMP (middle) and the selectivity of [EuLx4] towards selected biologically relevant 
anions (right).[79] 
 
By tuning the degree of saturation of the coordination sphere of Eu3+, the selectivity 
towards different nucleotides can be varied. For instance, Schäfferling reported a 
family of europium complexes [Eun-D] (n = 5, 6, 7) with an alkynylpyridine 
sensitiser that differ in the number of acetate arms, giving 5-, 6-, and 7-dentate 
ligands (Fig. I.50)[80]. These complexes showed quite different affinities towards 
AMP, ADP, ATP, and cyclic AMP. The europium complex with a heptadentate 
complex showed no affinity towards either nucleotide, whilst the complex with the 
hexadentate ligand exhibited poor selectivity. The complex with the pentadentate 
ligand apparently showed relatively good selectivity towards ATP over ADP, and a 
low affinity towards AMP, following the order of decreasing charge. The similar 
affinity of the latter complex towards ATP and polyphosphates - the by-product of 
hydrolysis of ATP into AMP - suggests that only the phosphate part of ATP 
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participates in binding to the complex. The system was claimed to be reversible in its 
binding to ATP. However, pentadentate europium complexes are usually rather 
unstable with respect to metal decomplexation and this process may occur in solution 
over time, or as the concentration of the coordinating anion increases. 
 
	 	 	
Fig. I.50 Molecular structures of the complexes [Eun-D] (left), enhancement of the total emission 
intensity of [Eu6-D] (middle) and [Eu7-D] (right) as a function of added ATP.[80]  
 
The ability of a nitrogenous base to participate in π–π stacking interactions can be 
used to discriminate between different nucleotides, for example, pyrimidines and 
purines, as shown by Pierre (Fig. I.51)[81]. A phenanthridine moiety attached to an 
amide arm of the cyclen-based europium complex, [Eu-DOTA-Phen], and terbium 
complex, [Tb-DOTAm-Phen], can participate in favourable π–π stacking 
interactions with nitrogenous base of nucleotides. [Tb-DOTAm-Phen], due to more 
favourable electrostatic interactions, is selective towards tri- over mono- and 
diphosphate nucleotides, whilst neutral [Eu-DOTA-Phen] does not possess that 
selectivity. π–π stacking quenches the excited state of the phenanthridine antenna, 
due to photoinduced electron transfer (PET), leading to a decrease of the total 
emission of Eu3+ and Tb3+. Both, the magnitude of the π–π stacking interactions, the 
efficacy of PET, and hence the sensitivity of the probe depends on the match 
between the LUMO level of the phenanthridine moiety and the HOMO of the 
nucleotide. The more conjugated purines have a higher lying HOMO level than 
related pyrimidines, and hence much lower sensitivity towards the latter was 
observed. 
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Fig. I.51 Molecular structures of [Tb-DOTAm-Phen] (1) and [Eu-DOTA-Phen] (2) (left) and 
enhancement of total emission of [Tb-DOTAm-Phen] along with the proposed binding mechanism of 
GTP (right).[81]  
 
I.5. Circularly-polarised luminescence 
 
The first observation of the difference spectrum of left and right circularly polarised 
luminescence (CPL) was reported in 1948 for sodium uranyl acetate by a Soviet 
physicist Boris Samoilov[82]. In the following years, a comprehensive theoretical 
background of CPL spectroscopy was developed with numerous CPL spectra of 
chiral compounds being reported. The major parameter, which defines how strongly 
the luminescence spectrum is polarised is a dissymmetry factor, gem, which is defined 
as a ratio between the difference of left (IL) and right (IR) circularly polarised 
emission intensities and half of the total emission intensity: 
                                                         
                                                         𝑔!" = ! !!!!!!!!!! . 
 
For the majority of organic compounds and transition metal complexes this values 
lies within the range 10-3-10-2, making recording of CPL spectra for these 
compounds time-consuming and resulting in poor spectral resolution, especially for 
weakly emissive compounds. On the contrary, lanthanide complexes (notably 
terbium and europium) possess much higher dissymmetry factors (0.1-1.4)[83], which 
allow shorter acquisition times and improved spectral resolution. Besides the 
information on the chirality of local environment, which makes CPL spectroscopy 
complementary to circular dichroism (CD) spectroscopy, it also enables resolving 
those transitions which might otherwise be unresolved in the total emission spectrum 
(Fig. I.52)[84].  
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Fig. I.52 Molecular structure of the europium complex and corresponding CPL spectra of both 
enantiomers (SSS-Δ(λλλ) and RRR-Λ(δδδ)). Transitions from 5D1 level are clearly visible.[84] 
 
The primary focus of research on chiral lanthanide complexes in recent years has 
been directed on using macrocyclic ligands, which provide a well-defined and 
relatively rigid coordination environment. Different synthetic strategies have been 
employed to increase the degree of rigidity, and hence increase gem values and 
stability of the complexes against racemisation. Apart from attaching chiral arms to a 
macrocycle, the separation of racemic mixtures of Δ and Λ enantiomers has been 
more recently performed using RP-HPLC with chiral columns (Fig. I.53). 
Furthermore, in racemic mixtures one of enantiomers may be preferentially 
quenched or sensitised upon binding anions or the proteins, thereby giving rise to a 
CPL signal from a racemic mixture with added chiral analyte. Thus, gem values can 
be used to monitor the concentration of added analyte to an aqueous solution 
containing a racemic mixture of lanthanide complex. 
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Fig. I.53 Four different enantiomers of europium complex and possible route of their interconversion 
through arm rotation and ring inversion.[85] 
 
I.5 Aims and scope of the work 		
The aim of the present research project is to design, synthesise, characterise and if 
necessary optimise europium lanthanide macrocyclic complexes as responsive 
reversible and ratiometric probes for pH- and analyte-sensing. The design of the 
probes should rest on the existing knowledge of structure-property relationships in 
lanthanide macrocyclic complexes, whilst significant improvement in selectivity 
towards selected analytes is sought. This research projects aims to create the 
following probes: 
 
i) pH-responsive probes applicable for lysosome-selective monitoring of 
pH in cellulo using an aklynylpyridine chromophore. The use of this 
chromophore in europium complexes resulted in bright, non-toxic and 
photostable complexes, successfully used as cellular stains.[41] By varying 
the nature of substituents the change of pKa values, as well as cellular 
uptake may be modulated. 
 
ii) Protein-selective probes, which are based on strong solvatochormic 
properties of alkynylpyridine and biaryl chromophores. This can give rise 
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to a change of the total emission intensity upon binding to hydrophobic 
binding pockets of the proteins. The use of the mixture of europium and 
terbium complexes should render ratiometric response, as these 
complexes are expected to have significantly different sensitivities to the 
solvent polarity. 
 
 
iii) Metal- and anion-selective probes, which should employ a metal-
specific moiety, and modulate spectral change upon rearrangements in the 
coordination environment. An attempt to introduce and vary the number 
of hydrogen bond donors can possibly vary the affinity of europium 
complexes towards biologically relevant anions, i.e. phosphate, 
nucleotides, citrate, etc. Furthermore, binding of chiral anions should 
induce a CPL signal, which can be also followed as a function of anion 
concentration. 
 
The following four chapters described the synthesis, characterisation and thorough 
photophysical responses of aforementioned classes of molecular lanthanide-based 
probes. Chapter 2 describes a new class of pH-sensitive molecular probes and their 
brief cellular studies. Novel HSA and α1-AGP probes, which switch on upon binding 
to a protein are discussed in Chapter 3. Probes which showed selectivity and high 
affinity towards Zn2+ and nucleotides are reported in Chapter 4. 
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Chapter two 
[\ 
Europium complexes as pH-
sensitive probes  
	 64	
II.1 Lanthanide-based pH-sensitive probes with a 
sulphonamide arm 
 
 
Biologically relevant processes within cells usually occur within a tightly defined pH 
range – typically between 6 and 8. Exceptionally lower pH values are observed in 
lysosomes and endosomes, whose pH value can be as low as 4.0-4.5, in order to 
provide efficient operational conditions for hydrolytic enzymes, to digest unwanted 
biomolecules. For a certain class of usually hereditary diseases grouped under the 
name ‘lysosomal storage diseases’ (LSD), the pH value of lysosomes is elevated. 
This hampers efficient functioning of hydrolytic enzymes, leading to accumulation 
of toxic compounds inside the cell and eventually causing apoptosis of the cell. To 
gain a better insight into the processes accompanying malfunctioning of the cell in 
people with LSD, a molecular probe with high sensitivity within the desired pH 
range is required to track pH changes in response to external stimuli, over a specific 
period of time.  
 
Several pH-sensitive lysosomal luminescent bio-imaging probes are currently 
commercially available, for example LysoSensorTM (Fig. II.1), although they possess 
considerable drawbacks, which limit their wider use. Firstly, these probes are usually 
very prone to photo-bleaching, and therefore long-term experiments with these 
probes are actually excluded. Secondly, the singlet excited states of purely organic 
probes have nanosecond lifetimes, and hence no time-gating is available for these 
probes to subtract residual emission from other organic fluorophores present in the 
cell, or any scattered light from the light source.  
 
                    
Fig. II.1 Molecular stuctures of LysoSensorTM Green DND-153 (left), LysoSensorTM Green DND-189 
(centre) and LysoSensorTM Blue DND-167 (right) 
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These flaws can be overcome in molecular probes based on lanthanide complexes, as 
it was shown that if designed properly these compounds are non-toxic. Emission 
lifetimes for Eu3+ and Tb3+ probes are in a millisecond range and therefore permit 
efficient time-gating. Furthermore, the electronic structure of europium(III) gives 
rise to the presence of several electronic transitions, which differ in their sensitivity 
towards perturbation of the metal coordination sphere. This intrinsic feature of the 
europium ion allows monitoring the relative emission intensities as a function of an 
induced structural rearrangement in the coordination sphere, for example, in response 
to a change in the pH of the medium, and hence provides a ratiometric response.  
 
Examples of ratiometric pH-sensitive lanthanide complexes were pioneered by 
Parker[1],[2], where a sulphonamide arm was used to modulate changes in the 
emission spectrum, following reversible binding of the nitrogen atom to the 
lanthanide ion. By varying the nature of the substituent in the sulphonamide arm, the 
pKa of the complex was adjusted (Fig. II.2). It was emphasised that the primary flaws 
of these systems are the presence of two water molecules, which replace the 
sulphonamide nitrogen once it is protonated at lower pH values, leading to 
quenching of the total emission intensity. Furthermore, the diaqua complex was 
shown to bind oxyanions, which can significantly shift the observed pKa of the 
complex in biological media. Substitution of carboxylate arms with glutarate arms 
inhibited intermolecular anion binding in the q = 2 complex and showed its potential 
for further modifications in order to get a complex excitable at higher wavelengths 
with affordable laser diodes. 
 
  
Fig. II.2 Calibration pH curves for cyclen-based europium complex with a sulphonamide arm with 
three carboxylate (left) and glutarate (right) arms (295 K, I = 0.1 M NaCl).[1] 
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Subsequently, an azathiaxanthone chromophore was introduced to provide efficient 
sensitisation of the complex at 365 nm and even 405 nm (Fig. II.3)[3]. However, 
substitution of one of the glutarate arms with a chromophore restored competitive 
binding of oxyanions (most importantly bicarbonate anions), which impeded ligation 
of the sulphonamide nitrogen and shifted the pKa of the complex towards higher 
values outside the lysosomal range. The complex was tested in cellulo and showed 
localisation in the nucleolus and ribosomes.  
 
  
Fig. II.3 Calibration pH curve for the europium complex bearing an azathiaxanthone chromophore 
(left) and confocal fluorescent microscopy image of NIH-3T3 cells loaded with the complex (right).[3] 
 
In subsequent work, an azaxanthone chromophore was introduced through an amide 
bond and glutarate arms were substituted with chiral amides (Fig. II.4)[4]. It was 
shown that azaxanthone chromophores are trapped by the cells via micropinocytosis 
mechanism, with an initial mitochondrial localisation, followed by trafficking of the 
probe to the lysosome[5].  
 
 
Fig. II.4 Molecular structure of the complexes (left) and variation of the emission dissymmetry factor 
(gem) of [EuL2] as a function of pH (right).[4] 
 
An unusual rise of the total emission intensity was observed upon lowering the pH, 
indicating the removal of PET quenching of the chromophore by an electron-rich p-
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MeOPh substituent in the sulphonamide arm following its protonation. The use of 
chiral arms in the structure modulated a chiral response as a function of pH. 
Significantly lowered values of the emission dissymmetry factor, gem, were observed 
upon protonation of the sulphonamide nitrogen, consistent with a less rigid structure 
of the complex when the sulfonamide nitrogen is replaced with two water molecules. 
As the azaxanthone chromophore was suitable for sensitisation of both europium and 
terbium ions and they possessed different degrees of emission intensity variation 
with pH, their mixture could be successfully used to monitor lysosomal pH in cellulo 
(Fig. II.5). 
 
    
Fig. II.5 Variation of lysosomal pH as a function of time (left), following treatment with nigericin in 
NIH-3T3 cells, monitoring the relative emission intensity of Tb/Eu component along with blue/yellow 
fluorescent intensity of the commercial stain LysoSensorTM DND160 (right).[4] 
 
Despite this progress with azaxanthone-based probes, the advent of EuroTracker® 
dyes with improved photostability and brightness made their use as lysosome-
selective luminescent probes highly attractive. Changes in the structure of the rod-
like chromophore provided opportunities to vary the excitation wavelength as well as 
the nature of ligating atoms[6]. The first attempt to use a sulfonamide arm in 
combination with alkynyl-pyridine chromophore with a methylphosphinate group 
based on a 9-N3 platform resulted in an unexpectedly high pKa for the complex (pKa 
= 7.1 in cellulo), apparently as a result of a specific interaction of the rod-like 
chromophore with albumin. A similar value was observed using a ‘simulated 
extracellular’ ionic background containing added HSA (Fig. II.6)[7]. However, even 
in the absence of oxyanions and added protein, the observed pKa was higher than was 
previously observed for related systems with the same sulphonamide arm (pKa = 
6.5). This enhanced value was attributed to the enhanced steric demand associated 
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with reversible binding of a sulphonamide arm, which resulted in easier protonation 
of the sulphonamide nitrogen. Furthermore, the complex showed an unusual 
localisation to the endoplasmic reticulum (ER), which could possibly be a result of 
the higher pKa of the complex. 
 
	 	
Fig. II.6 Reversible protonation of the sulphonamide arm in the complex (left) and variation of the 
relative emission intensity as a function of pH (right) (295K, I = 0.1 M).[7] 
 
With this background in mind, it was decided to analyse the possibility of using a 
less sterically demanding 12-N4 platform bearing an alkynyl-pyridine chromophore, 
alleviating the steric constraints imposed on reversible sulphonamide ligation, and 
hence leading to a lower pKa of the complex. 
  
II.2 pH-Responsive, Lysosome-Selective Probes 
 
 
Fig. II.7 Molecular of the pH probes [EuL1,3] and [EuL2]Cl2 studied 
 
In order to evaluate the effect of different factors, such as overall charge and the 
nature of the ligating groups a series of three europium complexes was synthesised 
and studied both in vitro and in cellulo (Fig. II.7). A neutral complex [EuL1] with 
two carboxylate arms, a positively charged variant, [EuL2]2+, with two chiral amide 
arms and a neutral complex [EuL3] with chiral amide arms bearing terminal charged 
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carboxylate groups were synthesised by successive alkylation reactions of a di-
substituted cyclen intermediate (Scheme II.1).  
 
         
Scheme II.1 Synthetic pathway for [EuL1-3]. 
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An unsubstituted alkynyl-pyridine chromophore was synthesised in accordance with 
an adopted procedure from reference [8], and its freshly prepared mesylate was 
reacted with a di-substituted cyclen. The major tri-substituted product was reacted 
with a mesylate to introduce the sulphonamide arm, giving the desired ligand. For 
complexes [EuL1] and [EuL3], the ligand was hydrolysed in 0.5 M NaOH, followed 
by neutralisation and complexation with EuCl3, whilst in the case of [EuL2] the 
ligand was dissolved in acetonitrile and then reacted with EuCl3. Complexes [EuL1] 
and [EuL3] were purified using RP-HPLC, whilst [EuL2] was purified by washing 
any excess of the sulphonamide arm with DCM and precipitating any excess metal 
by increasing the pH to 10 with aqueous ammonia. 
 
Table II.1 Photophysical properties of [EuL1-3] in aqueous solution 
 pH = 2.8 pH = 7.8 
 ɛ325nm/M-1cm-1 τ (H2O)/ms τ (D2O)/ms q τ (H2O)/ms τ (D2O)/ms q 
[EuL1] 35 400 0.31 1.32 2.7 0.73 1.06 0.2 
[EuL2]2+ 35 400 0.41 0.79 1.1 0.54 0.68 0.2 
[EuL3] 35 400 0.48 0.98 1.0 0.48 0.58 0.1 
 
Complex [EuL1] showed reversible binding of the sulphonamide arm, which was 
monitored by examining both the lifetime of the excited state and the relative 
intensities of the 5D0→7F2 and 5D0→7F1 transitions in aqueous solution (I = 0.1 M) 
(Fig. II.8). By following changes in the lifetime of the 5D0 excited state, a pKa = 4.1 
was deduced with a lifetime decreasing from τ = 0.72 ms at pH = 6.0 to τ = 0.31 ms 
at pH = 2.5. The change in the relative intensities of the electric-dipole 
hypersensitive 5D0→7F2 transition against the magnetic-dipole transition 5D0→7F1 
revealed a decrease upon lowering the pH, and gave a pKa = 3.8 (Fig. II.9).  
 
The 5D0→ 7F1 transition manifold also experienced considerable changes as a 
function of pH, exhibiting change of the sign of the ligand field parameter 𝐵!!. 
Unfortunately, no evidence from 1H NMR spectra could be provided to demonstrate 
corresponding changes in chemical shifts, as exchange broadened 1H NMR signals 
were observed at lower pH values – the result of fast magnetisation exchange when 
two water molecules replaced the sulphonamide nitrogen. Also, the total emission 
intensity experienced a significant reduction, primarily as a result of efficient 
vibrational quenching by the bound water molecules.  
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Fig. II.8 Variation of the lifetime of the excited 5D0 state of [EuL1] as a function of pH (pKa = 4.1, T 
= 22 °C, 0.1 M NaCl, λex = 325 nm). 
 
 
 
 
Fig. II.9 Variation of ratio between  5D0 → 7F2 (602.5-640.0 nm) and 5D0 → 7F1 (582.5-602.5 nm) 
transitions of [EuL1] as a function of pH (pKa = 3.8, T = 22 °C, 0.1 M NaCl, λex = 325 nm). 
 
As has been already discussed, addition of oxyanions and proteins can significantly 
perturb the reversible binding of the sulphonamide arm in lanthanide complexes, 
shifting the observed pKa towards higher values. To evaluate this change in the 
	 72	
present case, a calibration curve was obtained in a cell lysate that mimics an 
extracellular medium (Fig. II.10). Both the lifetime of the excited state and the 
relative intensities of emission bands were followed, revealing an increased pKa 
value (pKa = 7.1), consistent with specific binding to a protein and/or oxyanions. It is 
worth mentioning that a reciprocal trend in the lifetime was observed upon lowering 
the pH of cell lysate, rising from τ = 0.37 ms at pH = 9.0 to τ = 0.72 ms at pH = 4.0.  
 
 
Fig. II.10 Variation of the emission intensity and the lifetime of [EuL1] in cell lysate (pKa = 7.1, T = 
22 °C, λex = 325 nm). 
 
At the same time, the total emission spectrum experienced quite different 
transformations, with a significant increase of the total emission intensity upon 
lowering the pH of the medium. Although an identical spectral signature was 
observed in both 0.1 M NaCl solution and cell lysate, when the sulphonamide 
nitrogen was bound to Eu3+, at lower pH values their patterns were different, i.e. 
when the sulphonamide nitrogen is unbound (Fig. II.11). In spite of the similar 
change in the B20 sign following the decrease of the pH, the relative intensities of 5D0
→7F2 vs 5D0→7F1 were different. Whereas in the case of 0.1 M NaCl solution the 
relative intensity of the magnetic-dipole 5D0→7F1 transition decreased, in the cell 
lysate it remained virtually the same. This behaviour is indicative of specific binding 
to oxyanions or amino-acids of the serum albumin side chain of the europium(III) 
ion. 
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Fig. II.11 Emission spectra of [EuL1] in the 0.1 M NaCl solution at pH 2.5 (black) and in the cell 
lysate at pH 4.0 (red) (T = 22 °C, 0.1 M NaCl, λex = 325 nm). 
 
In a similar experiment, the impact of added HSA was separately evaluated for a 
related complex [EuL5] (Fig. II.12), which possesses a similar pKa value (pKa = 7.3). 
Such behaviour shows a decisive role of the protein binding in shifting the 
protonation constant of the sulphonamide arm. The binding of the complex [EuL1] to 
HSA was accompanied by a very slight decrease of the total emission intensity 
(PLQY decreased from 6.6% to 6.0%) and led to an induced CPL spectrum (gem = 
0.02 (589 nm)) (Fig. II.13). 
 
                                                 
Fig. II.12 Molecular structure of [EuL5] 
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Fig. II.13 Circularly polarised emission spectrum of [EuL1] (10 µM) in the presence of human SA 
(0.4 mM) (T = 22 °C, λex = 325 nm). 
 
II.3 Cellular studies of [EuL1] 
 
The complex [EuL1] was examined as a luminescent cellular stain in mouse skin 
fibroblast cells (NIH-3T3), using both live cell epifluorescence and confocal 
microscopy. In the incubation medium, 10% foetal calf-serum (FCS) is normally 
added to promote cell growth.  
 
 
Fig. II.14 Emission spectra of [EuL1] (10 µM) in the presence of human SA (red) and bovine SA 
(orange) in the cell growth medium (λex = 365 nm). 
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This medium contains BSA and the expected spectral signature for europium 
emission was observed. The experiment was repeated with HSA added to FCS and 
revealed a 50% rise in the emission intensity (Fig. II.14). This 50% increase was also 
observed by comparing solutions of [EuL1] with added HSA and BSA, revealing the 
same 50% increase of the quantum yield (6.0% with added HSA and 4.3% with 
added BSA). A lysosomal staining pattern was confirmed by co-staining with 
LysoTrackerTM Green, which revealed a very faint signal after 4 h, with an 
increasing brightness after 24 h (Fig. II.15).  
 
 
Fig. II.15 LSCM images (1024x1024 pixel, 100 Hz bidirectional) in NIH-3T3 cells 
showing: (left) predominantly lysosomal staining following a 4 h incubation of 
10 µM complex (λex = 355 nm, λem = 605–720 nm, 8 mW), and  
and (right) following a 24 h incubation, and 5 min incubation 
of LTG (λex = 488 nm, λem = 500–530 nm, 2 mW). 
 
The emission spectrum recorded in cellulo after 24 h showed a spectral signature 
corresponding to the complex with a dissociated sulphonamide nitrogen (Fig. II.16), 
whilst the recorded lifetime of the excited state (τ = 0.36 ms) corresponded to that 
observed in an aqueous solution with 0.1 M NaCl as a background electrolyte (τ = 
0.32 ms), rather than to the lifetime recorded in cell lysate (τ = 0.72 ms). At the same 
time, the emission spectrum and the lifetime of the excited state recorded in a cell 
medium (τ = 0.81 ms) also corresponds to behaviour in 0.1 M NaCl aqueous 
solution, rather than to that in cell lysate. Furthermore, more detailed inspection of 
the emission spectrum (Fig. II.16) revealed a spectral signature that neither 
resembled the one observed in the 0.1M NaCl solution, nor the one observed in the 
cell lysate. These observations raise the question, whether the in vitro measurements 
in a cell lysate is a good model to calibrate the pH probe for use in cellulo, or 
whether another model should be used instead. Unfortunately, the content of 
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lysosomes is too complex to be easily simulated in vitro, and therefore the only 
available option is too use such simplified models. 
 
 
Fig. II.16 The emission spectrum after a 24 h incubation of [EuL1] with NIH-3T3 cells (left) and the 
corresponding decay curve of the emission (right) (λex = 365 nm). 
 
In an attempt to follow the changes in the emission signature and/or lifetime of the 
excited state, nigericin was added to the cell medium in order to alter the pH inside 
the lysosome. Even though, the overall emission intensity of [EuL1] increased 
following the addition of nigericin, the spectral pattern and the lifetime did not 
change following pH variation, suggesting that the pKa of the complex inside the 
lysosome was too high.  
 
II.4 In vitro and in cellulo studies of [EuL2]2+ and [EuL3] 
 
Two other complexes, [EuL2]2+ and [EuL3], bearing two chiral amide arms were 
designed and synthesised featuring a different partial charge on Eu3+ ion. Both 
complexes showed a strong CPL signal induced by the presence of the chiral 
substituents in the amide arms. In each case, upon lowering the pH of the medium a 
gradual decrease of the CPL signal was observed, indicating that a less rigid structure 
was adopted by the complex, once the sulphonamide nitrogen dissociated. The total 
emission spectrum also experienced noticeable changes in the relative intensities of 
the ΔJ=1 and ΔJ=2 bands, as well as in the values of crystal field parameters. 
However, no change of the lifetime of the excited state was observed in either case (τ 
= 0.5 ms for [EuL2]2+ and [EuL3]), even though the total emission intensity 
decreased by half. The spectral signature of the emission spectrum and CPL (Fig. 
II.17) was identical in both cases, although the dissymmetry ratio gem (λ = 589 nm) 
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was three times higher for [EuL2]2+ (gem = 0.19 for [EuL2]2+ vs gem = 0.06 for 
[EuL3], both in 0.1 M HEPES buffer at pH = 7.40).  
              
             
Fig. II.17 Circularly polarised emission spectrum of [EuL2]2+ (9 µM) (T = 22 °C, λex = 325 nm, 0.1 
M HEPES, pH = 7.40). 
 
The much higher value of gem for [EuL2]2+ may simply reflect the shorter distance 
between the stereogenic centre and Eu3+, as the coordination environment is identical 
for each complex. Despite a big difference in the dissymmetry factor with the bound 
sulphonamide arm, upon protonation the CPL signal decreases to nearly zero (Fig. 
II.18), making [EuL2]2+ the more sensitive CPL probe (higher Δgem/ΔpH). The 
observed pKa values for both complexes were quite different (pKa = 3.6 for [EuL2]2+ 
and pKa = 4.9 for [EuL3] (Fig. II.20)), following the difference in the overall charge 
of the complex. No changes of the total emission signature or the CPL pattern were 
observed upon addition of HSA, whilst the total emission intensity and gem value 
decreased slightly. In contrast to [EuL1], no change of the B20 sign was observed 
upon varying the pH of the medium, whilst the relative intensities of the Stark 
components in the ΔJ=1 manifold significantly changed. The total emission intensity 
decreased approximately three times, following the decrease of pH from 7.5 to 2.5.  
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Fig. II.18 Variation of the dissymmetry factor gem (λ = 589 nm) of [EuL2]2+ as a function of pH (pKa 
= 3.6, T = 25 °C, 0.1 M NaCl, λex = 325 nm). 
 
 
Fig. II.19 Variation of the intensity of the emission band (λ = 679 nm) relative to the intensity of 5D0
→7F0 transition at λ = 579 nm of [EuL2]2+ as a function of pH (pKa = 3.5, T = 25 °C, 0.1 M NaCl, λex 
= 325 nm). 
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Fig. II.20 Variation of the dissymmetry factor gem (589 nm) of [EuL3] as a function of pH (pKa = 4.9, 
T = 25°C, 0.1 M NaCl, λex = 325 nm). 
 
Both [EuL2]2+ and [EuL3] were examined as luminescent cellular stains in living 
mouse fibroblast cells (NIH-3T3) and human prostate cancer cells (PC-3), at a 
concentration of 20	µM in the cell growth medium. Unfortunately, already in the cell 
media the total emission intensity of both probes was significantly quenched, whilst 
a 24 h incubation revealed a preferential lysosomal localisation pattern (Fig. II.21). 
Nonetheless, the total emission intensity was too weak to use spectral imaging to 
acquire the emission spectrum or record the decay time in cellulo. No significant 
difference in localisation pattern and brightness was observed between NIH-3T3 and 
PC-3, implying a similar uptake mechanism in both cell lines. 
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Fig. II.21 LSCM images (1024x1024 pixel, 100 Hz bidirectional) of [EuL2]2+ in NIH-3T3 cells (top),  
showing a predominantly lysosomal staining following a 2 h (top left) and  
a 24 h (top right)  incubation of 10 µM complex (λex = 355 nm, λem = 605–720 nm) 
and of [EuL3] (middle) showing a predominantly lysosomal staining  
following a 24 h incubation of 10 µM complex (λex = 355 nm, λem = 605–720 nm),  
and in PC-3 cells (bottom) following a 24h incubation of  
10 µM complex (λex = 355 nm, λem = 605–720 nm)  
and 5 min incubation of LTG (λex = 488 nm, λem = 500–530 nm),  
also showing a lysosomal localisation pattern. 
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II.5 Conclusions 
 
In the present study, three different lysosome-selective pH-responsive probes were 
synthesised and their photophysical properties studied. In spite of the fact that all 
three complexes showed a pKa within the desired range of lysosomal pH, [EuL1] 
showed an elevated pKa outside the required pH region, once the complex was bound 
to a protein, making pH measurements in cellulo impossible. Two other chiral 
probes, [EuL2]2+ and [EuL3], showed drastically quenched emission in the cellular 
growth medium, consistent with the very faint brightness when localised inside the 
lysosome. However, all three probes did show a predominantly lysosomal 
localisation pattern, and therefore by judicious alteration of the ring substituents new 
probes with higher brightness and responsiveness within the lysosomal pH range 
should be able to be obtained.  
 
The alkynyl-pyridine chromophore shows a relatively high affinity towards proteins, 
which is probably one of the reasons for the observed quenching of the europium 
(III)-centred emission. In order to decrease this affinity or at least to alleviate its 
quenching impact, a less conjugated chromophore might be used. One of the 
potential candidates is a biaryl chromophore, successfully used for sensitising both 
europium(III) and terbium(III) emission[9]. The pyridine bearing a carboxylate arm 
with trimethoxybenzene ring on the top is expected to have a broad absorbance band 
with λmax = 325 nm[10], and hence should be relatively bright upon excitation with a λ 
= 355 nm laser in a confocal microscope. The proposed complex based on a cyclen 
core should have two chromophores in trans positions, with a sulfonamide arm in 
between them (Fig. II.22). 
 
The proposed structure should have a q value equal to zero with both a bound and 
unbound sulphonamide nitrogen atom, making it significantly more stable against 
competitive anion binding and should inhibit emission quenching via O-H oscillators 
of bound water molecules at lower pH values. Also, the resulting complex can be 
used as a mixture of europium(III) and terbium(III) complexes, as their pH-sensitive 
behavior is usually different, and therefore by following the ratio between their total 
intensities in cellulo, a ratiometric response can be obtained[4]. 
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Fig. II.22 Molecular structure of a proposed lysosomal probe for pH sensing (Ln = Eu, Tb). 
 
Furthermore, the presemce of the biaryl chromophores makes the synthetic pathway 
significantly easier, as this moiety is stable to both acidic and basic hydrolysis 
conditions – the usual reactions to cleave protecting groups. The proposed synthetic 
route involves dialkylation of the di-Boc-cyclen with two freshly prepared mesylates 
of the chromophore, followed by Boc-deprotection using TFA. In the final step, the 
sulphonamide arm will be introduced by formation of an aziridine in situ in 
acetonitrile (Scheme II.2). 
  
              
Scheme II.2 Proposed synthetic pathway for a new pH-sensing complex. 
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Another possible solution to overcome the problem of competitive anion binding and 
quenching through bound water molecules is to modulate a spectral change without 
changing the coordination number of europium(III). It is difficult to predict the 
effective pKa of the molecular probe once it has entered a lysosome, as it can be 
bound to one of multiple proteins present inside. However, as a starting point of this 
search, a 1,2,3-triazole moiety attached to a pyridine ring can be considered (Fig. 
II.23). Upon protonation of a triazole moiety, a change in polarizability and partial 
charge occurs and therefore may be expected to produce a sufficient change in the 
spectral signature that can be monitored in cellulo. This pH-sensing moiety can be 
attached to either a DO2A platform or to a 9-N3 platform with an alkynyl-pyridine 
chromophore, giving rise either to a 8- or 9-coordinate systems. The latter system 
seems more advantageous because it possesses two chromophores with a 
phosphinite-substituteted pyridine with a 15-nm bathochromically shifted excitation 
maximum. Furthermore, related 9-N3 compounds typically have shown high 
brightness in cellulo[6]. 
 
                                                
 
Fig. II.23 Proposed molecular structures of europium complexes for lysosomal pH-sensing and a 
synthetic pathway for a pH-sensing arm. 
 
 
 
	 84	
 
 
II.6 References 
 
[1] M. P. Lowe, D. Parker, Chem. Commun. 2000, 707–708. 
[2] M. P. Lowe, D. Parker, Inorg. Chim. Acta 2001, 317, 163–173. 
[3] R. Pal, D. Parker, Chem. Commun. 2007, 474–476. 
[4] D. G. Smith, B. K. McMahon, R. Pal, D. Parker, Chem. Commun. 2012, 48, 
8520-8522. 
[5] E. J. New, A. Congreve, D. Parker, Chem. Sci. 2010, 1, 111-118. 
[6] S. J. Butler, M. Delbianco, L. Lamarque, B. K. McMahon, E. R. Neil, R. Pal, 
D. Parker, J. W. Walton, J. M. Zwier, Dalton Trans. 2015, 44, 4791–4803. 
[7] B. K. McMahon, R. Pal, D. Parker, Chem. Commun. 2013, 49, 5363–5365. 
[8] H. Li, F. L. Chadbourne, R. Lan, C.-F. Chan, W.-L. Chan, G.-L. Law, C.-S. 
Lee, S. L. Cobb, K.-L. Wong, Dalton Trans. 2013, 42, 13495-13501. 
[9] T. Nakamura, S. Mizukami, M. Tanaka, K. Kikuchi, Chem. - Asian J. 2013, 8, 
2685–2690. 
[10] J. Hovinen, M. Veli-Matti, H. Hakala, J. Peuralahti, Novel Chelating Agents 
And Highly Luminescent And Stable Chelates And Their Use, 2005, WO 
2005/058877 A1. 
 
  
	 85	
 
 
 
 
 
 
 
Chapter three 
[\ 
Europium complexes for 
selective binding to HSA and  
α1-AGP  
	 86	
III.1 Solvatochromism and emission 
 
 
The presence of electron-donating and electron-withdrawing substituents conjugated 
within the same molecule creates a dipole moment, which upon irradiation with an 
excitation source creates an excited state, where an instant separation of charges 
occurs. This excited state can often serve as an efficient non-radiative quenching 
pathway for other excited states in the molecule, and due to its polar nature its energy 
is very sensitive to the polarity of the surrounding medium. 
 
The fact that the polarity of solvent molecules can drastically affect the 
photophysical properties of its solute molecules was established in the early 20th 
century, when the term ‘solvatochromism’ was coined by Hantzsch.[1] It was 
postulated that any hypsochromic shift of the absorption/excitation/emission band 
upon increasing the solvent polarity is defined as negative solvatochromism, whilst 
any bathochromic shift is attributed to positive solvatochromism. The primary 
rationale behind the solvatochromic effect is the difference in energy between the 
ground and the first excited state caused by solvation changes. If increasing the 
solvent polarity caused the excited state to be better stabilised than the ground state 
then a positive solvatochromism results. On the other hand, preferential stabilisation 
of the ground state over the excited state gives rise to negative solvatochromism.  
 
                              
Fig. III.1 Change of the dipole moment and the energy structure of 2,6-diphenyl-4-(2,4,6-
triphenylpyridinium-1-yl)phenolate upon changing polarity of the solvent.[2] 
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Several attempts to arrange solvents in accordance with their polarities have been 
made resulting in different polarity scales. However, only the scale suggested by 
Reichardt has found widespread use and is now considered as a standard scale. A 
standard betaine dye (2,6-diphenyl-4-(2,4,6-triphenylpyridinium-1-yl)phenolate) was 
selected as a standard to define the scale (Fig. III.1) and its molar transition energy in 
different solvents was used as a measure of polarity: 
 
ET(30)/kcal mol-1 = hc𝜈!"#NA = 28591/(λmax/nm) 
 
However, a normalised scale was later introduced to simplify the analysis of the data; 
water was chosen as the most polar and TMS as the most non-polar solvents, 
necessitating the use of a more lipophilic TMS soluble dye: 
  
ETN = [ET(solvent) – ET(TMS)]/[ET(water) – ET(TMS)] = [ET(solvent)-30.7]/32.4 
 
The data for several hundred different solvents have been tabulated and ETN values 
for a selection of the most commonly used solvents are shown (Fig.III.2).  
 
 
Fig. III.2 Normalised Reichardt’s paramateres ETN for the most common solvents.[2] 
 
Polar molecules showing strong solvatochromic effect found wide application for 
analyses of conformational changes in proteins to which they bind.[3] Once a 
solvatochromic probe has bound to a protein, the effective polarity of the immediate 
environment decreases, giving rise to a corresponding change in the photophysical 
response. If the conformation of the binding pocket in a protein changes as a result of 
applying an external stimulus, with a concomitant change of the exposure of the 
bound probe to water molecules, a further change of the solvatochromic response 
may be detected.  
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III.2 [EuL4] as a serum albumin probe 
 
III.2.1 Solvatochromic properties of [EuL4] 
 
                                                      
Fig. III.3 Molecular structure of [EuL4]. 
 
In this work, the proposed HSA selective probe, [EuL4], possesses a highly polar 
chromophore with a dimethylamino electron donating group and the Eu3+ ion bound 
to the pyridine ring serving as the electron withdrawing group, giving rise to an ICT 
state. The sulfonamide moiety modulates changes in the emission spectrum as a 
function of pH (Fig. III.3). The probe was synthesised in a similar manner to [EuL1]. 
 
                        
Fig. III.4 Variation of europium total emission intensity for [EuL4] with Reichardt’s normalised 
solvent polarity parameter ETN (298 K). 
 
[EuL4] showed only very faint emission intensity in aqueous solution at rt, whilst a 
much brighter Eu3+-centred emission was observed in a solid state and in a frozen 
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aqueous solution. Unsurprisingly, the total emission intensity was strongly dependent 
on the polarity of the solvent, showing a dramatic increase upon decreasing the 
polarity of the solvent (Fig. III.4).  
 
                       
 
Fig. III.5 Emission spectra of [EuL4] in different organic solvents and water, with a magnified region 
of 5D0→7F0 and 5D0→7F1 and corresponding change in the Stark splittings of the 7F1 manifold (298 K, 
λex = 390 nm). 
 
However no significant change in both the absorption and excitation spectra was 
observed upon varying the solvent polarity (λmax ~ 375 nm in all the cases). 
Therefore, no formal assignment of either a positive or negative solvatochromic 
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effect is possible. Apart from the change in the total emission intensity, the spectral 
form experienced considerable changes upon variation of the solvent polarity (Fig. 
III.5). A careful analysis of 5D0→7F1 manifold shows a solvent dependency of the 
crystal field parameters 𝑩𝟎𝟐 and 𝑩𝟐𝟐.  Since no change of the coordination environment 
is expected upon varying solvent, a change in the solvent polarity is likely to be 
responsible for this significant change. In comparison with aqueous solutions, the 
sign of 𝑩𝟎𝟐 changes in organic solvents, being close to zero for acetonitrile solution. 
However, as already shown in the previous chapter, the same change of the emission 
spectrum is observed upon protonation of a sulfonamide arm and therefore it cannot 
be excluded that it is displaced in less polar solvents. 
          
The crystal field parameters, which determine the magnitude of 7F1 splitting to a first 
approximation, depend on the coordinates of the ligating atoms and their effective 
partial charges. It was previously demonstrated that even subtle structural changes 
induced by variation of the solvent polarity and/or hydrogen bonding can result in 
dramatic change of crystal field parameters and hence the luminescence spectral 
form[4]. In other words, the long-standing assumption that crystal field parameters 
can be treated as constants regardless of the solvent used is incorrect, and thus 
emssion spectroscopy has been shown to be a useful means to verify that in each 
specific case. 
 
Being inspired by the strong solvent-dependent photophysical response of [EuL4], 
selected abundant serum proteins were tested as potential ‘sensitisers’ of the 
emission. No significant change in the overall emission intensity was observed in the 
case of ImG, fibrinogen and α1-AGP, but a large increase of the emission intensity 
was observed upon addition of HSA (Fig. III.6). Moreover, a strong induced CPL 
signal was observed upon binding to HSA with gem = -0.2 (λ = 589 nm), which is a 
very high value for dynamically racemic complexes. Similar behaviour was reported 
for an α1-AGP sensor based on a europium complex with a DO2A-derived ligand 
bearing two azaxanthone chromophores[5]. The complex showed a strong CPL signal 
with gem = - 0.23 (λ = 598 nm) upon addition of α1-AGP, which is close to the 
observed value in this system. However as the dissymmetry factor gem is defined 
according to the following expression: 
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𝑔!" = 2(𝐼! − 𝐼!)𝐼! + 𝐼!  
 
the overall emission intensity 𝐼! + 𝐼! from all emissive species is taken into account, 
including those which do not produce any CPL signal. Therefore, the ‘real’ gem value 
for the induced CPL signal may be larger, unless an induced CPL signal is solely due 
to a ‘turned on’ emission. This is exactly the situation observed for [EuL4], as the 
very weak emission from [EuL4] in the absence of HSA can be ignored.   
 
 
            
Fig. III.6 Variation of Eu emission intensity as [EuL4] is added to HSA (295 K, 0.1 M NaCl, 11 µM 
protein; log K = 6.00 (±02); the inset shows the induced CPL spectrum recorded for the protein bound 
complex (λex = 390 nm). 
 
Even though the aforementioned europium complex [EuLx1] with two trans-
azaxanthone ligands showed a stronger response towards α1-AGP, an induced CPL 
signal was also observed upon addition of HSA. Since the coordination environment 
of this complex and [EuL4] share some similarities, i.e. two carboxylate arms and the 
bound pyridine, a similar binding mode in the protein binding site can be expected. A 
comparison between the induced CPL spectra of each complex (Fig. III.7) suggests 
that the helicity of the bound complex is the same in each case, consistent with 
binding to the same pocket. This conclusion is not surpising, bearing in mind the 
similarity in structure of the complexes, including their relative size and lipophilicity.   
	 92	
 
              
Fig. III.7 CPL spectra of the europium complex [EuLx1] reported in ref. [5] (left) and [EuL4] with 
added HSA (right) (295 K, H2O). 
 
Once [EuL4] is bound to HSA, a significant bathochromic shift of the excitation 
maximum was observed to 396 nm (Fig. III.8). The shift of ca. 30 nm, when 
compared to [EuL4] with no added protein, cannot be attributed simply to a change 
of polarity of the immediate surrounding environment, as even in very non-polar 
solvents, such as THF or 1,4-dioxane, the excitation maxima were only slightly 
shifted compared to aqueous solution. This discrepancy may be tentatively explained 
by the proximity of two complexes within the same binding pocket, in line with the 
binding curve depicted above. Indeed, the saturation of the binding curve was 
reached when approximately two equivalents of [EuL4] were added.  
 
It has been shown that rod-like, polar conjugated molecules can stack together, 
ultimately forming either H- or J-aggregates at elevated concentrations[6]. This 
aggregation process gives rise to either a bathochromic (for J-aggregates) or 
hypsochromic (for H-aggregates) shift in absorption/excitation spectra. Usually 
formation of J-aggregates is accompanied by enhancement of total emission 
intensity, whilst emission from H-aggregates is normally quenched. It might seem 
surprising, at first glance, that in the case of [EuL1] (which can be used as a model 
compound for [EuL4] as no significant difference in the aggregation behaviour 
should be expected), a bathochromic shift was accompanied by quenching of the 
total emission, when the complex concentration was increased. However, since the 
formation of J-aggregates lowers the energy position of both singlet and triplet states, 
the gap between the latter and the corresponding 5D0 energy level of Eu3+ decreases, 
enhancing the efficiency of back energy transfer and hence lowering the quantum 
yield for europium emission. With these observations in mind, it can be concluded 
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that the observed ‘turn-on’ reflects a competition between these two processes – 
reduced ICT-mediated quenching by decreasing the polarity of the local environment 
and decreased overall emission intensity through formation of J-aggregates.  
 
                 
 
Fig. III.8 Three-dimensional excitation-emission spectra for [EuL4] (10 µM) in the presence of HSA 
(0.4 mM) (298 K, H2O). 
 
 
 
III.2.2 Binding of [EuL4] to HSA 
 
One of the primary biological functions of serum albumin is the transfer of essential 
exogenous and endogenous drugs. Two primary binding pockets, usually referred to 
as drug sites (DS) 1 and 2 (or warfarin and ibuprofen sites, respectively), have been 
identified and many drugs are known to bind selectively to one of those sites. In 
order to answer the question whether [EuL4] selectively binds to either of these two 
sites, competitive binding studies were undertaken with two DS-1 selective (warfarin 
and iodipamide) and one DS-2 selective (ibuprofen) drugs.  
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A preliminary analysis of the literature suggested that a complex with a bulky 
heterocyclic chromophore is more likely to bind to DS-1[7]. Competitive binding 
studies with iodipamide showed a significant quenching of [EuL4] emission (Fig. 
III.9), although some residual emission was still observed, even after a 10-fold 
excess of the drug was added. This behaviour suggests that more than one binding 
site for [EuL4] exists. The calculated affinity constant for [EuL4], based on this 
competitive method, (logK = 5.29(±03)) agrees reasonably well with the overall 
binding constant for [EuL4] (logK = 6.00(±02)). Competitive binding with warfarin 
also revealed quenching of the emission intensity, but again some residual emission 
was still observed, even after addition of a 10-fold excess of the drug. 
   
                            
Fig. III.9 Variation of europium emission intensity in the presence of HSA showing the fit (line) to 
the data points with added iodipamide ([EuL4] 30 µM; [HSA] 9.0 µM), log K = 5.29(03), λex = 390 
nm, 298 K, pH = 7.40). 
 
Competitive binding studies with ibuprofen (Fig. III.10) also revealed quenching of 
the emission intensity of [EuL4], although the two-step binding curve reached a 
plateau at ca. 50% of the initial intensity. The calculated affinity constant for [EuL4] 
(5.16(±03)) again correlates relatively well with the overall binding constant of 
6.00(±02).  
 
Summarising the competitive binding data, several important conclusions can be 
drawn. Firstly, addition of iodipamide, which possess the highest known affinity for 
HSA (Ka = 2.3x107 M), [8] quenched 80% of the total emission intensity, whilst 
ibuprofen reduced it only by 50%. These findings suggest that [EuL4] binds to both 
DS-1 and DS-2, with an overall site affinity that is of the order of 2x105 M–1. 
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Secondly, at least one additional binding site exists, which judging from the required 
steric demand might be localised in the cleft. However, no cleft-selective drugs are 
known and therefore performing competitive binding studies did not seem feasible. 
Moreover, it was reported that the cleft is a secondary binding site for ibuprofen[9], 
and therefore the competitive binding curve obtained may include replacement of 
[EuL4] from both the primary and secondary sites, including the cleft.  
 
                           
Fig. III.10 Variation of europium emission intensity in the presence of HSA showing the fit (line) to 
the data points with added ibuprofen ([EuL4] 26 µM; [HSA] 9.4 µM, log K = 5.16(03), assuming a 
1:1 binding isotherm, λex = 390 nm, 298 K, pH = 7.40). 
 
     
                                 Fig. III.11 Molecular structures of [EuL1] (left) and [EuL4] (right) 
 
The structure of [EuL4] is closely related to [EuL1] (Fig. III.11), and therefore the 
pKa of the former is expected to be close to that obtained for [EuL1] (pKa ~ 4.0 in 0.1 
M NaCl aqueous solution) and probably slightly higher, due to the presence of a 
stronger donating NMe2 group on top of the chromophore. However, direct 
measurement of the pKa of [EuL4] in the absence of the protein was hampered by its 
low emission intensity, whilst the absorption spectrum did not show any noticeable 
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change. At the same time, the pKa value may experience a dramatic change upon 
binding to the protein, as has been shown in the number of examples[10], including 
[EuL1], where a pKa ~ 7.0 was observed in cell lysate.  
 
A similar situation was observed in the case of [EuL4] (Fig. III.12), where a pKa 
value of 7.2 (±0.1) was calculated in the presence of HSA, which is approximately 3 
units higher than that expected in the absence of HSA. Moreover, nearly a complete 
quenching of the emission intensity was observed below pH 6.0, which can be 
explained by the replacement of the sulfonamide nitrogen by  two water molecules. 
The spectral form of the emission spectrum showed a moderate change in the relative 
intensity of crystal field components upon varying solution pH. However, no change 
of the 𝑩𝟎𝟐 sign was observed, as was the case for [EuL1]. As mentioned before, no 
structural rearrangements of HSA occur at pH values above 6.0, and hence the 
observed pKa was attributed to the reversible binding of the sulfonamide arm. This 
process could be associated with the binding of an amino acid side chain, e.g. the 
carboxylate group in either Asp or Glu in the low pH regime. Unfortunately, the low 
emission intensity at reduced pH values inhibited acquisition of CPL spectra, which 
might have helped to characterise the local environment.   
 
                   
Fig. III.12 The pH dependence of Eu emission in the human serum albumin bound complex (295K, 
0.1 M NaCl, 10 µM [EuL4], λex = 390 nm) fitted as a Boltzmann sigmoid. 
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III.2.3 Binding of  [EuL4] to bovine , rabbit and goat serum albumins 
 
Although human serum albumin shares 76% sequence homology[11] with bovine 
serum albumin, changes in the remaining 24% of amino-acids can give rise to 
significantly different drug-binding properties. The analysis of amino-acid sequences 
in Sudlow’s DS-1 and DS-2 (Fig. III.13) reveals a significant variation of amino 
acids capable of drug binding. As it is hypothesised that [EuL4] primarily binds to 
DS-1, a more detailed consideration of the amino-acids lining this binding pocket has 
been performed. Substitution of Val-122 with Thr-121, as well as Thr-125 with Asp-
124 and Ala-126 with Gly-125 increase the hydrophilicity of this binding pocket in 
BSA and reduce the number of functional groups which can be involved in hydrogen 
bonding with drugs in HSA.  
 
Since the hydrophobicity of the HSA binding pocket is believed to be the key factor 
in ‘switching on’ the emission from [EuL4], similar binding studies were attempted 
with bovine, rabbit (RSA) and goat (GSA) serum albumins. In none of the cases was 
a comparable ‘turn-on’ response observed, making [EuL4] a ‘species selective’ 
probe towards HSA.  
 
              
Fig. III.13 Sequence alignment of HSA, BSA, equine SA and leporine SA. The amino acids in DS-1 
are marked by dark blue and those in DS-2 are marked by cyan.[12] 
 
The emission spectrum of [EuL4] following addition of either HSA or BSA showed 
the same profile, suggesting a very similar coordination environment when protein 
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bound (Fig. III.14). Due to the low emission intensity of [EuL4] in the presence of 
BSA, no CPL spectrum was able to be acquired to probe the immediate environment 
around Eu3+. Analysis of the lifetimes of the europium excited state revealed a 
shorter lifetime for [EuL4] when bound to BSA (0.18 ms), compared to HSA (0.30 
ms). This observation is in line with the lower hydrophobicity of BSA and, as a 
consequence, with a more efficient back energy transfer rates from the resonance 
level of Eu3+ to the ICT state of the ligand.  
 
Table III.1   Selected photophysical properties of [EuL4] and [EuL1] (295 K, H2O) 
Complex [EuL4] [EuL1] 
λ
abs
/nm 365 325 
ε(H
2
O)/M-1cm-1 28,000 35,400 
τH2O
/ms    c 0.73 (pH 6) 
τD2O
/ms    c 1.00 (pH 6) 
τH2O
 + HSA/msa 0.30 
(0.18) 
0.79 
(1.02) 
φEu/% 0 6.6 
φEu + HSA/%
a 0.7 6.0 (4.3)b 
aAdded protein concentration was 0.7 mM;  b value in parenthesis is for added BSA; c   No measurable 
emission in solution. 
 
Analogous measurements performed in D2O showed a predictable increase of the 
total emission intensity in each case (HSA and BSA), and were consistent with the 
presence of the outer sphere water molecules, which contributed to the quenching of 
5D0 excited state (hydration number q equals zero in each case).  
          
Fig. III.14 Emission spectra of [EuL4] (10 µM) in the presence of HSA (0.75 mM) in H2O (green) 
and D2O (blue), as well as in the presence of BSA (0.75 mM) in H2O (black) and D2O (red) (295 K, 
λex = 390 nm). 
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An important consequence of the observed specificity of [EuL4] towards HSA is the 
impact of the selection of the type of the serum used as cell medium, in the 
performance of the luminescent probes studied. As a proof of concept, emission 
intensities of [EuL4] with HSA, BSA and GSA were recorded, revealing a similar 
difference of the overall emission intensity as for in vitro studies (Fig. III.15). At the 
same time, analysis of the lifetimes was also in accord with in vitro experiments, 
showing lower lifetimes for BSA and GSA (0.19 ms and 0.22 ms, respectively) and a 
longer lifetime for HSA (0.47 ms). These results are again consistent with a more 
efficient back energy transfer from Eu3+ to ICT state for the BSA- and GSA-bound 
species. 
 
                         
Fig. III.15 Emission spectra of [EuL4] in the growth medium (10 µM) with added HSA (red), BSA 
(orange) or GSA (magenta) respectively.  
 
III.2.4 Cellular studies of [EuL4] incubated in different serum 
albumins 
 
The complex [EuL4] possesses an N-coordinated sulfonamide group with a pKa 
expected to be in the pH range of the lysosome. The presence of such a group usually 
promotes lysosomal uptake and is often referred as lysosomal trapping.[13] The 
[EuL4] complex was examined as a luminescent cellular stain in living mouse 
fibroblast cells (NIH-3T3) using both live cell epi- and confocal microscopy.  In the 
incubation medium, 10% foetal calf-serum (FCS) is normally added to promote cell 
growth; FCS contains BSA.  Accordingly, different cell growth media were created 
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to replace FCS based on added heat inactivated, purified, culture grade human or 
goat serum.  In the cell medium, the Eu emission could only be easily discerned by 
spectral imaging for the HSA-added preparation.  Following an incubation of 4h in 
respective growth medium containing up to 100 µM [EuL4] and keeping all 
experimental parameters constant, the Eu staining was 20 times brighter for the HS-
medium vs FCS-medium.   
 
 
                   
Fig. III.16 LSCM images (1024 x 1024 pixel, 100Hz bidirectional) in NIH-3T3 cells showing:  
(upper) predominantly lysosomal staining following a 4 h incubation of 10 µM complex [EuL4] (λex = 
355 nm, λem = 605-720 nm, 8 mW),  and 5 min incubation of LysoTracker Green® (λex = 488 nm, λem 
= 500-530 nm, 2 mW),    (ambient lysosomal pH is ca. 4.5); (centre/lower): enhanced image intensity 
following a 5 min incubation with nigericin (200 nM) and LysoTracker Green® (central columns), 
RGB merge highlighting correspondence (scale bar 20 µM). 
 
A study was initiated to allow consideration of the question as to whether it is 
enhanced intracellular uptake in the presence of HSA or enhanced complex 
brightness in cellulo that explains the variation of Eu emission intensity observed by 
microscopy. A lysosomal staining pattern was confirmed by co-staining with 
LysoTracker GreenTM (P >0.83, Fig. III.16).  The brightness of cell images was 
increased by 120% vs FCS medium when the local lysosomal pH (normally around 
4.2-4.5) was adjusted to 6.5, following addition of nigericin (5 min, 200 nM)[14]. 
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Independent measurement of the total Eu intracellular concentration for each 
incubation, was determined by ICP-MS measurements. No significant differences in 
Eu concentrations were observed between incubations of [EuL4] with added HSA 
and BSA (62% and 60% accumulations, respectively).  However, the sample 
incubated with GSA showed a siginificantly lower intracellular concentration (29%).  
 
 
III.2.5 Serum albumin binding studies with [GdL4] 
 
In order to answer the question if the observed ‘turn-on’ response was a result of a 
selective binding of the europium complex with HSA over BSA, the gadolinium 
analogue of [EuL4] was synthesised, and its relaxivity measured as a function of 
added protein at 310 K and 1.4 T.  
 
Water molecules in an aqueous solution of a paramagnetic complex are in constant 
exchange with each other. Of particular interest is the exchange between water 
molecules in the vicinity of the complex - either directly bound to the metal ion or in 
close proximity to it (the latter is usually referred as a second sphere water molecule) 
– and the bulk of an aqueous solution. Once an aqueous solution is brought into an 
external magnetic field, nuclear spins are aligned along the direction of this field (z 
axis). If a short RT pulse is applied perpendicular to the direction of an external 
magnetic field (i.e. along the x axis), a net magnetisation vector is tipped away from 
its initial position by a flip angle (determined by the duration of the pulse), nutating 
along the z axis giving rise to non-zero components of magnetisation vector Mx and 
My along x and y axis, respectively. After the RF pulse has ended, the net 
magnetisation vector recovers its initial direction along the z axis, with a 
characteristic decay time along x (y) axis T1, and a rise time along z axis T2.  
 
The presence of the paramagnetic centre significantly changes the T1 value of water 
molecules. In these solutions the observed relaxation rate 𝟏𝑻𝟏,𝒐𝒃𝒔 can be expressed as a 
combination of diamagnetic and paramagnetic contributions:  
 !!!,!"# = !!!,! + !!!,!. 
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In turn, the paramagnetic term is directly proportional to the concentration (C) of a 
paramagnetic ion (contrast agent) in the solution:  
 1𝑇!,! = 𝑟!𝐶 
 
where r1 is a characteristic of a contrast agent, showing how efficiently it reduces the 
observed relaxation rate 𝟏𝑻𝟏,𝒐𝒃𝒔.  
 
There are several factors which determine the relaxivity of a given contrast agent. 
The number of directly bound water molecules q is the major parameter, varied by 
judicious ligand design. The interplay between maximising the q value and retaining 
stability of the complex towards decomplexation is the primary challenge in the 
design of new contrast agents. Another highly important parameter is the mean 
residence time of a directly bound water molecule τm – the less time the water 
molecule remains bound to a paramagnetic metal ion, the faster is the exchange rate 
with bulk water and hence the more efficient the transfer of relaxation enhancement 
to the bulk solution (although the residence time should be long enough to 
accomplish full relaxation of the bound water molecule). The last parameter that can 
be altered by chemical design is the rotational correlation time τr - reciprocal of the 
tumbling rate of the molecule in the solution. Enhancement of the tumbling rate is 
frequently exploited by increasing the molecular weight of the probe by attaching to 
macromolecules, for instance proteins.  
 
Several examples on the improvement of the tumbling rate, and hence the observed 
relaxation rate have been reported, following binding of gadolinium complexes to 
serum albumins. In some cases, introducing molecular fragments known for their 
high affinity towards serum albumin may result in high affinity of the overall hybrid 
towards it. Bearing this in mind, Caravan showed that coupling an ibuprofen moiety 
– a well-known example of the drug transferred by HSA in human plasma - to the 
DO3A derivative [Gd(7)(H2O)]- via a primary amine arm (Fig. III.17) leads to a 5-
fold increase of the observed relaxation rate (from 4.8 mM−1 s−1 to 22.4 mM−1 s−1, at 
37 °C) upon addition of HSA, concomitant with displacement of one bound water 
molecule by an amino-acid side chain, e.g. Glu[15]. 
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Fig. III.17 Molecular structures of [Gd(6a)(H2O)2], [Gd(6b)(H2O)2], [Gd(7)(H2O)]- and the related 
[Gd(DO3A)(H2O)2].[15] 
 
A similar enhancement was observed in related DO2A structures, where two water 
molecules are bound in the absence of added protein, and therefore the overall gain 
in relaxivity rate upon protein binding was less pronounced (13.5 and 12.7 mM−1s−1 
at 37 °C and 60 MHz for [Gd(6a)(H2O)2] and [Gd(6b)(H2O)2], respectively), 
showing the competition before two aforementioned factors contributing to the 
observed relaxation rate – number of bound water molecules and the molecular 
weight of the aggregate.    
 
Serum albumin proteins of different species are usually not distinguished and the 
more accessible bovine serum albumin is most commonly used for binding studies. 
However, deviations in amino-acid sequences between serum albumins of different 
species may give rise to differences in binding properies of the same drug. The only 
known example of such a study with a gadolinium contrast agent binding to different 
serum albumins was made by Caravan using MS-325 (also known under its trade 
names Gadofosveset®, Vasovist® and Ablavar®)[16]. It was shown that plasma of 
different mammals showed different enhancement of the observed relaxivity upon 
binding to MS-325, along with significantly different binding affinities (Fig. III.18), 
following the order human > pig ~ rabbit > dog ~ rat ~ mouse.  
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Fig. III.18 Molecular structure of MS-325 (top left), molecular fraction of bound MS-325 as a 
function of added MS-325 in different plasmas (top right) and change of the observed relaxivity as a 
function of added MS-325 for different plasmas (bottom).[16] 
 
Careful analysis revealed that these differences are largely caused by deviations in 
the albumin concentration in plasma among selected species, whilst titration with 
isolated serum albumins apparently showed only minor differences in affinity 
between species.  
 
Binding studies using bovine and human serum albumins were carried out with 
[GdL4], revealing similar binding constants of 3.28 (±0.2) and 3.51 (±0.1) 
respectively, although the observed relaxivity at saturation for HSA and BSA was 
different – 6.8 mM−1s−1 and 4.2 mM−1s−1 at 37 °C and 60 MHz (Fig. III.19). This 
difference may be attributed to a differing fatty acid content in the commercially 
supplied serum albumins used for binding studies, and more detailed studies using 
albumins from different vendors are required to make a conclusion on the nature of 
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this discrepancy. At the same time, the observed relaxivity for the unbound [GdL4] 
was unusually low (1.5 mM−1s−1 at 37 °C and 60 MHz), in line with the absence of 
bound water at pH 7.4, and apparently a minimal contribution of the second-sphere 
water to the observed relaxivity value.  
 
 
Fig. III.19 Variation of the relaxivity of [GdL4] following incremental addition of HSA (logKb = 
3.28(0.2)) and BSA (logKb = 3.51(0.2)). The line shows the fit to the data points, using an iterative 
non-linear least-squares fitting to 1:1 binding model, 310 K, pH = 7.40 (PBS buffer). 
 
Addition of three drugs, which are known to bind to the FA-1 and FA-2 pockets of 
HSA (see Chapter 1), ibuprofen, warfarin and iodipamide was made in large excess, 
but did not affect the relaxivity of [GdL4]*SA aggregate. This finding along with 
lower binding constants obtained from relaxivity titration curves suggest that the 
primary binding site(s) in the cases of HSA and BSA are photophysically ‘dark’ 
sites, which do not induce a luminescent response, when [EuL4] is bound to either of 
the proteins. The observed ‘switch on’ response of the europium complex can be 
attributed to binding to another site, with a two orders of magnitude higher affinity 
than the average value calculated from relaxivity data. 
 
It was previously shown that a sulfonamide arm can reversibly bind to the lanthanide 
ion, changing the hydration number as a function of pH. Even though no change of 
hydration number was observed, when bound to a protein, pH variation may trigger 
conformational changes, and hence result in a change of relaxivity. The pH 
dependence of the relaxivity of [GdL4] in the presence of 2.2 equivalents of HSA 
was analysed (Fig. III.20), revealing a pKa of 6.3, which is higher than the value 
observed for [EuL1] in 0.1 M NaCl (pKa = 4.0), but lower than the pKa for [EuL4] 
bound to HSA as observed from emission studies. The latter observation is consistent 
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with the assumption that the optically ‘bright’ binding site is different to the primary 
binding site, but this conclusion is not unambiguous.    
 
                     
Fig. III.20 Variation of the relaxivity of [GdL4] as a function of pH, in the presence of  2.2 
equivalents of HSA (pKa = 6.3(0.1), T = 37 °C, 0.1 M NaCl). 
 
No q value could be obtained from [EuL4]*HSA, when the sulfonamide moiety is 
unbound, due to the quenching of the emission at lower pH values. At the same time, 
only minor relaxivity changes as a function of pH were observed, suggesting that no 
water molecule is bound over the whole pH range analysed. In a paper of Helm and 
Caravan, gadolinium complexes with DO3A-derived ligands bearing a sulfonamide 
arm were added to a solution of HSA and the relaxivity was followed as a function of 
pH[17]. A pKa value of ca. 6.5 was observed for each complex (Fig. III.21), and no 
water molecules directly bound to the metal ion were observed from photophysical 
studies of the europium analogue.  
 
							 	 	
Fig. III.21 Variation of q value as a function of pH in the absence of HSA and pH dependence of 
relaxivity in the absence (n) and in the presence (▲) of HSA for a glutarate derivative.[17]  
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Whilst reversible binding of a sulfonamide arm may well give rise to the observed 
change in the relaxivity upon varying pH (e.g. through replacing a protonated 
sulfonamide with an amino acid side chain of the protein), unravelling a more 
detailed explanation for pH dependent changes of relaxivity requires additional 
NMRD experiments. Helm and Caravan revealed that the distance between a long-
lived water in the second sphere of hydration changed as a function of pH, allegedly 
due to reversible binding of sulfonamide arm. A similar explanation could be 
possible for [GdL4], although additional NMRD experiments are required to verify 
this assumption. 
 
At the same time, a recent study showed that HSA unfolding is a pH driven process 
with a pKa of ca. 4.5[18]. This finding allows us to rule out the influence of any pH-
driven rearrangement of HSA on the observed relaxivity change and attribute the 
observed variation to the reversible binding of the sulfonamide arm. 
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II.3 [LnL5] as α1-AGP sensing probe 
 
III.3.1 Synthesis and photophysical studies 
 
α1-AGP is the second most abundant protein in human plasma after serum albumin, 
comprising up to 3-4% of the total serum protein contents. Its role in drug transport 
has attracted a lot of attention, as well as its concentrational changes in response to 
inflammatory processes in the body. In contrast to HSA, α1-AGP has only one drug 
binding site, which is known to accommodate a large variety of different endogenous 
and exogenous drugs[19].  
 
 
Fig. III.22 Molecular structures of [EuLx1] (left) described in ref. [5] along with [LnL5] (centre) and 
[YbL6] (right) described in the present work. 
 
Change of the local polarity of an α1-AGP selective probe with a strong ICT 
component might be expected to give rise to a ‘switch-on’ response upon protein 
binding. Analysis of the literature showed that the only α1-AGP-selective 
luminescent probe was designed by Parker and was alluded to in Chapter 2[5]. 
Screening of several compounds resulted in the design of probes [LnL5] and [YbL6], 
which are structurally related to both [EuL4] and probe [EuLx1] (Fig. III.22). In 
every case, a DO2A-based motif is used, along with a pyridine-based chromophore. 
In [LnL5] and [YbL6]1 a sulfonamide arm was added to impart pH-sensitivity and 
give an additional functional group suitable for hydrogen bonding to amino-acids of 
the protein inside the binding pocket. 
 
																																																								1 Ytterbium complex [YbL6] was only briefly studied and it revealed similar affinity towards α1-AGP. 
Two bands comprising the 2F7/2 → 2F5/2 transition showed change of their relative emission intensities 
upon binding to bovine α1-AGP, consistent with dissociation of the sulphonamide nitrogen and 
binding to an amino-acid of the protein side chain.	
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Scheme III.1 Synthetic procedure for [LnL5]. Yields for each step are given. An analagous synthetic 
procedure was used for [YbL6] (see Experimental section). 
 
The synthetic procedures for preparation of [LnL5] and [YbL6] complexes were 
analogous to those used to synthesise [LnL1] and [LnL5] (Scheme III.1). In the first 
step, a biaryl chromophore precursor was prepared via a Suzuki cross-coupling 
reaction in a microwave reactor, using Pd(dppf)2Cl2 for [LnL5] and Pd(TPP)2Cl2 for 
[YbL6] as the catalyst. An attempt to use Pd(TPP)4 as a catalyst was made following 
the report of procedures[20],[21] for a closely related chormophore with diethyl 4-
bromopyridine-2,6-dicarboxylate in anhydrous DMF, but only very low conversion 
was observed even after 48 h, using a conventional route and in a modified 
procedure undertaken in a microwave reactor with either anhydrous DMF or 
anhydrous 1,4-dioxane as a solvent at 140 °C for 1 h. When 2,4,6-trimethoxy (2,4,6-
trimethoxyphenyl)boronic acid was coupled, a significant amount of by-product – 
1,3,5-trimethoxybenzene – was observed, which hampered purification using RP-
HPLC and required additional purification step using silica flash chromotography. 
On the other hand, reaction with (4-(dimethylamino)phenyl)boronic acid showed 
complete conversion according to LC-MS analysis and the product was readily 
	 110	
purified using silica flash chromotography. In each case, the isolated ester was 
reduced in EtOH within 2 h, using an excess of NaBH4 under reflux. 
 
 
Fig. III.23 Two products obtained in the reaction mixture upon addition of sulfonamide. 
 
The alkylation of the diethyl ester of DO2A with the freshly prepared mesylate 
derivative of the aryl chromophore resulted in preferential formation of the desired 
trialkylated product, according to LC-MS analysis; subsequent purification of the 
product was performed using RP-HPLC. The next step – introducing of a 
sulfonamide arm – resulted in the mixture of the desired product as well as a by-
product, where the generated aziridine had reacted twice (Fig. III.23). This step was 
not easily controlled, and the ratio between the desired product and the by-product 
varied significantly in different attempts. The mixture composition had a big impact 
on their ease of separation using RP-HPLC. A pure product was finally isolated for 
NMR characterisation. In other cases, the crude mixture was hydrolysed in 0.5 M 
aqueous NaOH solution, neutralised and the complex was synthesised by adding an 
excess of the corresponding LnCl3 salt. The complexation reaction was accomplished 
in few minutes at rt. Any excess lanthanide salt was precipitated in a form of 
Ln(OH)3 by raising the pH to 10 and separated on a centrifuge. The reaction mixture 
was purified using RP-HPLC with a Chromolith® C18 column without buffer, 
showing a single peak in the UV trace, which corresponded to the desired complex. 
The resulting complex, [EuL5], was characterised by 1H NMR (Fig. III.24) and 1H-
1H COSY spectroscopy (see Appendix). The yttrium analogue [YL5] was also 
synthesised to determine the diamagnetic contribution to the observed shifts in the 1H 
NMR spectrum of [EuL5], and assisted in the assignment of the spectrum.  
 
N HN
NN
O
O
O
O
N
O
O
O
N N
NN
O
O
O
O
N
O
O
O
NH
Ms
MsO N
H
Ms
K2CO3
MeCN
80 °C
18h
+
N N
NN
O
O
O
O
N
O
O
O
N
Ms
N
H
Ms
	 111	
 
Fig. III.24 1H NMR spectra of [EuL5] (top) and [YL5] (bottom) (D2O, 295 K, 9.4 T for [EuL5] and 
278 K, 11.7 T for [YL5]). 
 
Assignment of the signals for [YL5] was carried out at 278 K to reduce the spectral 
broadening. As at least two species were in dynamic exchange, Nuclear Overhauser 
Effect Spectroscopy (NOESY, Fig. III.25) and Rotating-frame Overhauser Effect 
Spectroscopy (ROESY, Fig. III.26) experiments were carried to assign observed 
chemical shifts. The NOESY experiment allows assigning signals from protons that 
are close in space to be pinpointed. Moreover, the technique, commonly designated 
as EXSY (Exchange Spectroscopy), helps to assign protons that are in chemical and 
conformational exchange.  
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Fig. III.25 1H-1H NOESY spectrum of [YL5] (D2O, 278 K, 11.7 T). 
 
 
Fig. III.26 1H-1H ROESY spectrum of [YL5] (D2O, 278 K, 11.7 T). 
 
As the Nuclear Overhauser Effect (NOE) approaches zero for molecules with 
molecular masses of 700-1200 Da[22], the ROESY experiment is often used to 
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provide similar information on signals that are close in space or in exchange. In 
contrast with NOE, which is positive for small molecules and negative for 
macromolecules, the Rotating-frame Overhauser Effect (ROE) is always positive 
regardless of the molecular mass, and therefore turned out to be the better technique 
for assigning proton NMR signals in [EuL5] (see Appendix). 
 
        
Fig. III.27 Emission spectra of [EuL5] in different organic solvents and water with a magnified region 
of 5D0→7F1 manifold (298 K, λex = 390 nm). 
 
The europium complex [EuL5] showed very weak emission in aqueous solution, 
which was unaffected by degassing the solution, suggesting no triplet character in the 
quenching state. However, as in the case of [EuL4], the emission intensity was 
enhanced upon lowering the polarity of the solvent and was also accompanied by 
changes in the spectral signature (Fig. III.27). Similar changes of 5D0→7F1 splitting 
(change of 𝑩𝟎𝟐sign) were observed on going from water through acetonitrile to 1,4-
dioxane, probably indicating the change of the coordination environment from a 
twisted square antiprism to a square antiprism. It was recently reported that free 
rotation around the C-C bond in a similar integral biaryl chromophore can give rise 
to a TICT state, which can efficiently quench the emission of lanthanide 
complexes[22]. However, no significant change in the emission intensity or lifetime of 
excited state was observed for both the europium and terbium complexes upon 
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changing solvent from pure methanol to the pure glycerol, which is ca. 200 times 
more viscous, ruling out the involvment of a TICT excited state, as a quenching 
mechanism in aqueous solution.  
 
            
Fig. III.28 Change of the total emission intensity upon addition of bovine α1-AGP to [EuL5] ([EuL5] 
11 µM; log K = 4.71(0.1), assuming a 1:1 binding isotherm, λex = 310 nm, 298 K, 0.1 M HEPES, pH 
= 7.40). 
 
A significant increase of the emission intensity upon addition of α1-AGP (Fig. III.28) 
suggests that an ICT state may be responsible for the observed quenching in aqueous 
solution. Substantially smaller changes of the observed emission intensity were 
observed upon addition of HSA, BSA, human antitrypsin, firbrinogen and ImG. 
Thus, this probe can be considered to be selective for α1-AGP sensing.  
 
III.3.2 Protein binding studies of [LnL5] 
 
Stepwise addition of bovine α1-AGP to [EuL5] gave rise to a dramatic increase of the 
emission intensity, along with a change in spectral form (Fig. III.29). The pH-
dependent behaviour was analysed and a very high pKa  = 8.2 was estimated by 
following changes in the lifetime of the excited state with pH, attributed to a 
reversible binding of sulfonamide arm (Fig. III.30).  
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Fig. III.29 Change of the total emission intensity upon addition of [EuL5] to bovine α1-AGP ([bovine 
α1-AGP] 25 µM; log K = 5.52(0.1), assuming a 1:1 binding isotherm, λex = 310 nm, 298 K, 0.1 M 
HEPES, pH = 7.40). 
 
															 				
Fig. III.30 pH calibration curves for [EuL5] (18 µM) following the lifetime of the europium 5D0 state 
with bovine α1-AGP (λex = 310 nm, H2O, 295 K). 
 
The induced CPL signal was also recorded, as a function of pH. At higher pH values 
when the sulfonamide arm is bound, a mirror image of the CPL signal of [EuL4] 
with added HSA was observed. The total emission spectrum was also identical to 
[EuL4] with a bound sulfonamide but without added protein. Moreover, analogous 
	 116	
binding studies with human α1-AGP showed a mirror-image CPL signal when 
compared to added bovine α1-AGP with an identical fingerprint to the [EuL4]*HSA 
adduct (Fig. III.31). The opposite signs of the induced helicities for [EuL4]*HSA 
and [EuL5]*[human α1-AGP] on the one hand and [EuL5]*[bovine α1-AGP] on the 
other, indicate a tightly bound complex inside the binding pocket, preserved even 
when the sulfonamide arm dissociates at lower pH values. 
 
                         
                        
Fig. III.31 Induced CPL spectra of [EuL5] bound with human and bovine α1-AGP, when the 
sulfonamide arm is bound (pH = 9.3, top) and unbound (pH = 3.6, bottom) to Eu3+ ion (λex = 310 nm, 
D2O, 295 K). 
 
The identical nature of the CPL spectra for [EuL4]*HSA and [EuL5]*[human α1-
AGP], as well as their total emission spectra is not surprising, bearing in mind their 
similar coordination environment, which is not significantly perturbed by structural 
variation of the top half of the biaryl chromophore. To support this assumption, 1H 
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NMR spectra of [EuL1] and [EuL5] were superimposed, showing a remarkable 
similarity in chemical shifts between two complexes, in the absence of added protein 
(Fig. III.32).  
 
            
 
          Fig. III.32 1H NMR spectra of [EuL1] (maroon) and [EuL5] (turquoise) (D2O, 295 K, 9.4 T). 
 
However, once the sulfonamide arm was protonated, the CPL signals were no longer 
mirror images and their total emission spectra were also different. This behaviour 
suggests that the sulfonamide arm was probably replaced by a carboxylate group 
from the side chain of a protein, that is different for the bovine and human species.  
 
Similar titration experiments were performed with the human version of α1-AGP, 
which is comprised of two genetic variants, F1/S and A. It has been shown that there 
is a significant difference in binding affinities between these two modifications,[23] 
with the variant A having a considerably lower affinity than F1/S due to a smaller 
binding pocket and hence its contribution is usually ignored.[24]  
 
The binding curve obtained (Fig. III.33) following addition of human α1-AGP to 
[EuL5] showed  a similar 1:1 binding constant (4.14(0.1) vs. 4.71(0.1)) when 
compared to bovine α1-AGP, even though the sulfonamide arm remained bound 
when the complex was added to a protein. In a reciprocal experiment, when the 
complex [EuL5] was added to human α1-AGP (Fig. III.34), a close resemblance with 
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the behaviour of the bovine species was also observed (log K values were 5.85(0.1) 
vs. 5.52(0.1) respectively). This observation should not be surprising, given that the 
curve reached saturation after addition of two equivalents of [EuL5]. At the same 
time, a lower binding constant K for human α1-AGP may either indicate the presence 
of a tighter binding pocket in the case of bovine α1-AGP, for instance by replacing a 
sulfonamide with a carboxylate of a protein side-chain. 
 
                
Fig. III.33 Change of the total emission intensity upon addition of human α1-AGP to [EuL5] ([EuL5] 
9 µM; log K = 4.14(0.1), assuming a 1:1 binding isotherm, λex = 310 nm, 298 K, 0.1 M HEPES, pH = 
7.40). 
              
Fig. III.34 Change of the total emission intensity upon addition of [EuL5] to human α1-AGP ([human 
α1-AGP] 25 µM; log K = 5.85(0.1), assuming a 1:1 binding isotherm, λex = 310 nm, 298 K, 0.1 M 
HEPES, pH = 7.40). 
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The observed induced CPL signal following binding of [LnL5] to α1-AGP is caused 
by preferential binding of one enantiomer, the enantiomers of [EuL5] co-exist in 
dynamic equilibrium at ambient temperature in aqueous solution (Fig. III.35).  
 
                
Fig. III.35 Equilibrium between different isomers present in tetra-substitueted cyclen derivatives 
(SAP – square antiprism; TSAP – twisted square antiprism).[25] 
 
Once the complex is bound to a protein, its conformational flexibility is restricted by 
steric constraints, and an induced CPL signal can be recorded. α1-AGP species differ 
in their drug binding pockets and therefore showed different binding preferences 
towards enantiomers – bovine α1-AGP preferentially stabilizes the Δ(δδδδ) 
enantiomer, whilst human selectively binds Λ(λλλλ). This assignment of 
configuration is based on previously reported emission spectra for structurally related 
enantiopure europium(III) complexes (Fig. III.36).[26] 
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Fig. III.36 Comparison between CPL spectra recorded for [EuL5] in the presence of human and 
bovine α1-AGP at pH = 9.30 (left) and CPL spectra of complexes reported in [26], where Δ(δδδδ) 
enantiomer (blue) refers to [EuL5] with added bovine α1-AGP and the Λ(λλλλ) enantiomer (black) is 
preferentially bound when [EuL5] is added to human α1-AGP. 
            
In order to further exemplify this selective binding process, the terbium complex 
[TbL5] was synthesised, which showed a strong emission intensity in both the 
absence and presence of human and bovine α1-AGP. Only a minor enhancement of 
the total emission intensity was observed following addition of α1-AGP, and 
therefore the unbound racemic species, which were quenched in the case of [EuL5], 
are now emissive.  
 
Very weak CPL signal was observed for [TbL5] at higher pH with sulfonamide arms 
bound, when added to both human and bovine α1-AGP. In contrast, once the 
sulfonamide nitrogen dissociates at lower pH, a strong CPL signal was detected for 
both α1-AGP species (Fig. III.37). Similarly to [EuL5], opposite helicities were 
observed following addition of  human and bovine α1-AGP. The binding curve 
obtained for [TbL5] (Fig. III.38) with added bovine α1-AGP showed a slightly higher 
binding affinity than in the case of [EuL5] (log K = 5.14(0.1)). Such behaviour may 
be attributed to the existence of more than one binding site in the protein. As [TbL5] 
was not quenched via an ICT state, those binding pockets which remained ‘dark’ 
upon binding [EuL5] now may become visible.     
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Fig. III.37 Induced CPL spectra of [TbL5] (8 µM) bound with human and bovine α1-AGP, when the 
sulfonamide arm is unbound (λex = 310 nm, 0.1 M HEPES, pH = 7.40, 298 K). 
 
                        
Fig. III.38 Change of the emission dissymmetry factor upon addition of bovine α1-AGP to [TbL5] 
([TbL6] 8µM; log K = 5.14(0.1), assuming a 1:1 binding isotherm, λex = 310 nm, λem = 545 nm, 298 
K, 0.1 M HEPES, pH = 7.40). 
 
Lanthanide complexes with sterically small carboxylate arms tend to be prone to Δ/Λ 
racemisation, and therefore even if one of the enantiomers selectively binds to a 
protein, a dynamic equilbrium will be quickly established in the remaining solution, 
leading to racemisation of unbound complexes. Thus, the observed CPL signal can 
be produced only by complex that is bound to a protein. It was not possible to 
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establish the number of complexes bound per protein molecule and therefore the 
most emissive bound complex in the diastereomeric adducts determines the observed 
CPL. Therefore, it might be possible that there is no significant difference in binding 
enantioselectivity between bovine and human α1-AGP, but the different bound 
enantiomers have differing emission brightness, giving rise to opposite helicities in 
the CPL spectrum. 
 
Analysis of the pH behaviour (Fig. III.38) of [EuL5] with both human and bovine α1-
AGP was performed and compared to the pH calibration curve for [TbL5] in the 
absence of protein (Fig. III.40). A dramatic increase of pKa was observed only in the 
case of bovine α1-AGP (8.4(0.1) vs. 4.2(0.1) for [TbL5] in 0.1M NaCl), whilst a 
more modest variation was observed for human α1-AGP (4.6(0.1)). Moreover, at pH 
values above 8.5 for both [EuL5]*[bovine α1-AGP] and [TbL5]*[bovine α1-AGP] a 
strong quenching of the emission intensity was observed, along with a very low 
lifetime of the 5D4 state for [EuL5]*[bovine α1-AGP] (0.20 ms). Such a short 
lifetime is consistent with the occurrence of an additional quenching pathway. The 
large difference in pKa values suggests the presence of a functional group inside the 
binding pocket, with a pKa around 8.5, which quenches strongly when it is 
deprotonated.  
 
                             
 
Fig. III.38 Equilibria present in the [LnL5]/ α1-AGP system, showing protonated and non-protonated 
forms. 
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Fig. III.39 pH calibration curves for [EuL5] (6 µM) following the relative intensities of two bands 
(602-615 nm vs. 615-638 nm) of 5D0→7F2 transition manifold in the emission spectrum with human 
α1-AGP (λex = 310 nm, 298 K), τ(pH = 3.79) = 0.91 ms, τ(pH = 6.41) = 0.78 ms  
 
 
Fig. III.40 pH calibration curves for [TbL5] (5 µM) following the lifetime of an excited state 5D4 
(0.1M NaCl, λex = 310 nm, 298 K). 
 
In order to provide a reasonable explanation of the difference in pKa values between 
human and bovine α1-AGP,  a more detailed analysis of the binding pocket of human 
and bovine α1-AGP, as well as its comparison with DS-1 binding site in HSA (which 
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also showed a significant enhancement of pKa when compared to a free complex. 
However, the analysis of the amino acid sequence of bovine α1-AGP is hindered by 
the presence of different homologous proteins with substantial discrepancies in 
amino acid content[27]. Fortunately, several amino acids are preserved in selected 
homologous of bovine α1-AGP, particularly Trp25 (Trp26 in bovine α1-AGP), which 
has been shown to participate in binding incorporated drugs via hydrophobic 
interactions (Fig. III.41)[28].  
 
       
Fig. III.41 Computer docking simulations of two human α1-AGP-bindings drugs – diazepam (left) 
and progesterone (right), showing interactions with side chain amino-acids.[28] 
 
At the same time, by juxtaposing the amino acids in the drug binding pocket of 
bovine and human α1-AGP (Fig. III.42), several acidic residues can be identified 
which can potentially increase a pKa of a sulfonamide arm by stablising its 
protonated form.  
 
 
Fig. III.42 Alignment of two homologues of human α1-AGP (ORM-1 and ORM-2) with bovine α1-
AGP (Bos Taurus) 
 
One of the potential candidates is Tyr101 which is replaced with Gln100 in both 
modifications of human α1-AGP (ORM-1 and ORM-2). Tyr84 can preferentially 
bind a sulphonamide oxygen via hydrogen bonding in the phenolic moiety (Fig. 
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III.43). Once the phenolic moiety of tyrosine is deprotonated, this hydrogen bonding 
interaction disappears and the sulfonamide nitrogen can bind to Eu3+. The pKa 
observed then relates to proton transfer to the phenol, and not protonation of the 
sulphonamide nitrogen in [EuL5]. In turn, glutamine residue present in both human 
modifications of α1-AGP is a worse hydrogen bond donor than a phenolic OH-group 
in tyrosine and therefore it cannot stabilise the mesylate group on a sulfonamide in 
its unbound form. However, this assumption requires docking simulations, which are 
currently not possible, since no crystal structure of any of bovine α1-AGP 
homologues has been reported so far. 
               
 
Fig. III.43 Putative mechanism behind an enhanced pKa of [LnL5] with bovine α1-AGP in the 
sulphonamide bound complex, the proximate phenolate quenches the luminescence by electron 
transfer. 
 
 
III.3.3 Competitive drug-binding studies of [EuL5]*α1-AGP 
 
α1-AGP along with serum albumin plays a crucial role in drug delivery, and multiple 
studies have been carried out to establish its binding properties with essential drugs. 
Since the concentration of α1-AGP varies in response to inflammatory processes, the 
dosage of prescribed drugs should be changed accordingly, and therefore a detailed 
knowledge of drug binding affinities to α1-AGP is required. Unfortunately, very little 
data is avaliable on systematic comparison of drug binding affinities between human 
and animal α1-AGP. However, the number of approved drugs is constantly rising, 
and therefore the data on drug binding properties is expected to be in demand. 
 
In the present work, three drugs - lidocaine, bupivacaine and imatinib – were  chosen 
for their different binding affinities, spanning the affinity range from log K = 
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4.4(0.1) for lidocaine (Fig. III.45, III.46) to log K = 6.4(0.1) for imatinib. 
Competitive binding studies were performed for the europium complex, [EuL5], 
bound to both human and bovine α1-AGP. The full recovery of the initial weak 
metal-centred emission was observed in every case, after an excess of the drug was 
added.  
 
 
Fig. III.44 α1-AGP-selective drugs discussed in the present work. 
 
In the case of [EuL5]*[bovine α1-AGP] with added lidocaine and bupivacaine, a 
change of the spectral form was also observed, as the sulfonamide arm was 
protonated at pH = 7.40, when the complex is bound to a protein. At the same time, 
the spectral signature of [EuL5]*[human α1-AGP] did not change following the 
displacement of the complex from the protein by added drug. However, following 
the addition of imatinib to both α1-AGP species, the emission intensity was lower 
than the intensity of [EuL5] without an added protein. Moreover, no change of the 
spectral form was observed in the case of [EuL5]*[bovine α1-AGP], suggesting that 
in [EuL5] the sulphonamide nitrogen was still protonated, and the complex was 
apparently still in the binding pocket. To further support this hypothesis, a similar 
experiment was carried out using [TbL5], which had also revealed a strong 
quenching of the emission intensity with an unchanged gem value. The efficient 
quenching of the emission intensity observed for both ([EuL5] and [TbL5]) indicates 
that a new ICT state may have been introduced that quenches the singlet excited state 
of the chromophore.  
 
The fact that imatinib did not displace [EuL5] from α1-AGP was reflected in lower 
values of the observed binding constants for both human and bovine species (log K = 
5.6(0.1) and log K = 4.8(0.1), respectively), than  was expected (log K = 6.4(0.1)). 
The observed quenching constant corresponds to a charge-transfer quenching process 
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within the binding pocket, rather than to the quenching due to displacement. In the 
case of bupivacaine, very similar binding constants were observed (log K = 5.6(0.1) 
for human α1-AGP and log K = 5.9(0.1) for bovine α1-AGP), whilst binding 
constants for lidocaine were also very close (log K = 4.4(0.1) for human α1-AGP and 
log K = 4.5(0.1) for bovine α1-AGP). Both values observed for human α1-AGP are in 
a good agreement with previously reported data (log K = 4.4(0.1) for lidocaine and 
log K = 5.7(0.1) for bupivacaine)[29], whilst very close values observed for two 
species suggests similar binding motifs. Drug binding data are summarised in Table 
III.2. 
 
Table III.2 Binding affinities of [EuL5], lidocaine, bupivacaine and imatinib to 
bovine and human α1-AGP (pH = 7.40, 298 K). Literature values are given in 
parentheses[29] 
 [EuL5] lidocaine bupivacaine imatinib 
human α1-
AGP 
4.1 4.4 (4.4) 5.6 (5.7) 5.6 (6.4) 
bovine α1-
AGP 
4.7 4.5 5.9 4.8 
 
 
             
Fig. III.45 Variation of europium emission intensity in the presence of bovine α1-AGP showing the fit 
(line) to the data points with added lidocaine ([EuL5] 3 µM; [bovine α1-AGP] 122.0 µM, log K = 
4.54(0.1), assuming a 1:1 binding isotherm, pH = 7.40, λex = 310 nm, 0.1 M HEPES, 298 K). 
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Fig. III.46 Variation of europium emission intensity in the presence of bovine α1-AGP showing the fit 
(line) to the data points with added lidocaine ([EuL5] 3 µM; [human α1-AGP] 122.0 µM, log K = 
4.39(0.1), assuming a 1:1 binding isotherm, pH = 7.40, λex = 310 nm, 0.1 M HEPES, 298 K). 
 
Acute phase proteins, including α1-AGP, derive their name from their concentration 
dependence in response to external acute processes, primarily inflammation. 
Elevated levels of α1-AGP in human plasma may indicate the occurrence of 
inflamation processes in a body and can rise up to 5-fold, compared to a normal 
concentration in serum[30]. Therefore, monitoring the level of α1-AGP in human 
serum can be a useful tool for diagnosing the onset or occurrence of inflammatory 
processes in patients.  
 
The development of the emission probe is associated with several difficulties, such 
as the presence of different proteins, which can compete with α1-AGP for binding the 
probe, as well as residual emission from conjugated amino acids. Moreover, it is 
highly desirable to have a ratiometric response, as the precise determination of the 
probe concentration in the sample is not always possible. The suggested probe 
[EuL5] was succesfully tested in vitro and time-gating the europium emission 
response provides effective subtraction of any residual emission from emissive 
organic moieties. However, this ‘turn-on’ probe did not show a change of the 
emission spectral form, and also showed a very limited change in the lifetime of the 
excited 5D0 state.  
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Fig. III.47 Change of the total emission spectrum of [EuL5]/[TbL5] (22 µM/2 µM) ‘cocktail’ upon 
addition of bovine α1-AGP to bovine serum (pH = 7.40, λex = 310 nm, 298 K). 
 
 
Fig. III.48 Change of the total emission spectrum of [EuL5]/[TbL5] (22 µM/2 µM) ‘cocktail’ upon 
addition of human α1-AGP to human serum (pH = 7.40, λex = 310 nm, 298 K). 
 
A possible solution to these problems is the use of a so-called ‘cocktail’ mixture – a 
combination of [EuL5] and [TbL5] complexes with a certain ratio between them 
([EuL5]/[TbL5] = 22µM/2µM). Since the total emission of [TbL5] was only weakly 
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dependent on the amount of added α1-AGP, the relative intensities of the 5D4→7F5 
transition in the Tb3+ complex and the 5D0→7F2 hypersensitive transition of Eu3+ 
complex were monitored as a function of added α1-AGP in a serum background. The 
concentration was varied between 0.5-6 mg/mL, covering a 10-fold rise of  α1-AGP 
concentration (Fig. III.47-III.48). No time-gating was performed for recording the 
emission spectrum, since negligible protein-based emission was observed in each 
case. A quasi-linear dependence was observed in both human and bovine serum, 
whilst the binding constant was lower than that observed during in vitro experiments. 
In addition, the total emission intensity of the ‘cocktail’ in serum was lower than for 
the same concentration of  [EuL5] and [TbL5] in aqueous solution for the same 
concentration of added α1-AGP. Taken together, these observations indicate that 
competitive binding with other proteins does take place, and leads to a reduced 
emission intensity. To evaluate quantitatively the impact of the emission quenching 
by other proteins, the change of the total emission intensity was monitored upon 
binding [TbL5] to both human (Fig. III.49) and bovine (Fig. III.50) serum albumins. 
The choice of terbium was made because [EuL5] did not show a strong luminescence 
signal in the absence and presence of serum albumin.  
 
                                  
Fig. III.49 Quenching of the total emission intensity of [TbL5] (8 µM) upon addition of HSA. The 
apparent binding constant is logK = 3.41(0.1) (pH = 7.40, 0.1 M HEPES, λex = 310 nm, 298 K). 
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Fig. III.50 Quenching of the total emission intensity of [TbL5] (8 µM) upon addition of BSA. The 
apparent binding constant is logK = 3.24(0.1) (pH = 7.40, 0.1 M HEPES, λex = 310 nm, 298 K). 
 
Following addition of serum albumin to [TbL5], quenching of the total emission 
intensity was observed. A similar effect was observed upon addition of BSA. 
Analysis of both binding curves revealed a rather low binding constant, similar for 
both human and bovine serum albumin and lower than those measured for α1-AGP. 
However, since the concentration of HSA is approximately one order of magnitude 
higher than the concentration of α1-AGP in human plasma, this effect will potentially 
hamper determination of α1-AGP, especially if its concentration changes 
significantly. Even though HSA is not usually considered as an acute phase protein, 
its concentration can still vary in response to different external factors. For instance, 
ageing is accompanied by a decrease of HSA concentration, whilst the concentration 
of  α1-AGP remains the same.[31] At the same time, both proteins were shown to be 
useful markers in predicting the survival in post-operative patients. A low 
concentration of HSA suggested a poorer outcome.[32] With all these factors in mind, 
the effect of varying both HSA and α1-AGP was monitored by following the change 
of the total emission intensity of the [EuL5]/[TbL5] ‘cocktail’ (21µM/ 0.8µM) 
following separate incremental additional of each protein (Fig. III.51). 
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Fig. III.51 Variation of the ratio of the terbium 5D4→7F5 and the europium 5D0→7F2 transitions in 
[LnL5] as a function of added HSA and α1-AGP (λex = 310 nm, 298 K) 
 
The concentration of human α1-AGP was varied 4-fold compared to its normal value, 
whilst the concentration of HSA was increased up to a factor of 2. The relative 
intensities of the 5D4→7F5 transition of Tb3+ and the 5D0→7F2 hypersensitive 
transition of Eu3+ were monitored as a function of added α1-AGP and HSA in serum. 
At no added α1-AGP, only a minor change in the emission intensity was observed in 
response to addition of HSA. However, at higher concentration of added α1-AGP, a 
drop of the relative emission intensity was observed. Moreover, the overall intensity 
of the emission spectra also gradually decreased for both europium and terbium 
components, in line with previously reported experiments involving addition of 
HSA. 
 
The observed changes of the binding curve for different concentrations of added 
HSA at elevated concentrations of α1-AGP may be due to more complicated 
regulatory processes in human blood, and the simple addition of lyophilised protein 
to serum is probably a gross simplification. Real serum samples from patients with 
different levels of α1-AGP and HSA should be analysed and their concentrations 
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determined by independent methods. At the same time, the proposed α1-AGP probe 
can be developed further, by adding an additional reference compound, which does 
not bind to either of two proteins. The resulting system may by used to monitor 
concentrations of two proteins simultaneously, since the responses of [EuL5] and 
[TbL5] towards each of the two proteins are different. The proposed system can be 
employed to monitor the deviation of both α1-AGP and HSA in serum, over a broad 
range of physiologically relevant concentrations. 
 
 
III.3.4 α1-AGP binding of [DyL5] 
 
Dysprosium complexes have attracted much less attention as bio-imaging probes 
than their europium and terbium counterparts, primarily due to their lower emission 
quantum yields. On the other hand, dysprosium complexes are the most attractive 
among ‘secondary’ lanthanides emitting in the visible range – samarium, thulium and 
praseodymium. The lowest excited state of Dy3+ is 4F9/2, which is close in energy to 
the 5D4 level of Tb3+, and therefore ligands sensitising terbium emission are also 
often good sensitisers for dysprosium emission. However, compared to other 
lanthanide ions, lower lying energy states are spanning a wider range of values up to 
12000 cm-1, making an energy gap of only 10000 cm-1 between the lowest excited 
and the highest ‘ground’ state. It is not surprising therefore that the Dy3+ excited state 
in complexes is prone to vibrational quenching via energy transfer to proximate O-H 
oscillators. Another feature of such an energy diagram is the presence of 
luminescence signals in both the visible and near-IR part of the emission spectrum, 
even though the potential of dysprosium complexes as IR-emitters has not been fully 
recognised. 
 
In the visible part of the spectrum, three transition manifolds are usually observed – 
4F9/2→6HJ, J = 13/2, 11/2, 9/2. The latter transition is usually significantly weaker 
than the other two and is often observed just as a weak broad band. With regard to 
susceptibility of the emission spectrum in response to perturbation of coordination 
environment, none of these three transitions can strictly be classified as 
hypersensative and this is probably another reason why dysprosium complexes have 
found such a limited application in ratiometric bio-imaging.[33] 
 
	 134	
In the present study, the dysprosium complex [DyL5] was synthesised and its 
photophysical behaviour was investigated. The complex showed an increase of the 
total emission intensity upon addition of human α1-AGP (Fig. III.52), which might 
be attributed to an expulsion of the second sphere water molecules, when bound to 
the protein. No change of the spectral form was observed upon addition of the 
protein, in line with previous findings. Such behaviour corresponds to an absence of 
change in the coordination environment when human α1-AGP is added to [DyL5] in 
HEPES (0.1M, pH = 7.40). When the sulfonamide hydrogen is protonated, the 
observed emission profile underwent a drop in intensity.  
 
           
Fig. III.52 Variation of the total emission intensity of [DyL5] (6 µM) as a function of added human 
α1-AGP (pH = 7.40, 0.1 M HEPES, λex = 310 nm, 298 K).  
 
III.4 Conclusion and future studies 
 
In the present study, two europium-based luminescent ‘turn-on’ probes [EuL4] and 
[EuL5] have been synthesised for the selective detection of HSA and α1-AGP, 
respectively, both of which showed high protein selectivity. Their principle of action 
is based on the efficient quenching of the ligand singlet excited state by an ICT state. 
The energy of the ICT is dependent on the polarity of the local environment. Once 
each of the complexes is bound to a protein, the local polarity is decreased. At the 
same time, the ICT state energy is elevated and can no longer quench the Eu3+-
centred emission as efficiently, as it is in a less polar medium. This observation may 
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allow these probes to be used in studies of protein conformations, as the degree of of 
the exposure of the binding pocket to water should modulate the observed total 
emission intensity.  
 
Circularly-polarised luminescence spectroscopy has been used to probe the chiral 
environment in binding pockets of both proteins, resulting in a very unexpected 
opposite handednesses of the CPL spectrum of [EuL5], when bound to human and 
bovine α1-AGP, respectively. This indicated that different enantiomers have been 
locked in binding pockets of different variants of the protein, even though their 
different amino-acid content resulted in similar binding affinities. Furthemore, this 
discrepancy in amino-acide sequence around the binding pocket led to a considerable 
change of the pKa of [EuL5], which was explained by an interaction between 
sulphonamide arm and Tyr-84, which is present in bovine version, but not in human. 
Such a detailed analysis of the difference between binding pockets in human and 
bovine α1-AGP has not been performed before, and provides a better understanding 
of possible interactions between molecular probes and amino-acid lining up the 
binding pocket.  
 
These differences were analysed further by running competitive binding experiments 
of [EuL5]*α1-AGP with popular drugs, which are know to be carried in blood by α1-
AGP. Similar values were obtained for lidocaine and bupivacaine despite the 
difference in amino-acid content of two proteins. This series can be extended further 
by using other drugs, which can provide a better insight into binding essential drugs 
to α1-AGP, and hence its metabolism in livestock. 
 
As terbium and europium complexes, due to the different redox potential and 
resonance levels of the excited state, showed significantly different dependence on 
the solvent polarity, their mixture produced a ratiometric response. This ‘cocktail’ 
has been used to monitor the concentration of α1-AGP in bovine and human serum, 
which may find practical application for monitoring its level in patients with 
inflammation diseases.  
 
The induced CPL signal in both [EuL4] and [EuL5] can be used to elucidate 
structural changes in the proteins, as even subtle changes of conformation around the 
binding pocket are very likely to cause changes in their CPL spectral signature. To 
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improve the observed dissymmetry ratio, bulkier substituents, e.g. phosphinate arms, 
can be introduced to lock the conformation of the Δ or Λ enantiomer (Fig. III.53). 
Moreover, it is interesting to compare the changes in the coordination polyhedron 
upon binding/dissociation of the sulphonamide nitrogen in a diphosphinate analogue 
with [EuL5], and check if the postulated TSAP⇆SAP transition is also observed. 
 
                  
Fig. III.53 Molecular structure of proposed α1-AGP-selective probes, with enhanced gem values. 
 
The competitive binding studies between [EuL5]*[human α1-AGP] or  
[EuL5]*[bovine α1-AGP] and common drugs showed similar binding affinities, 
irrespective of the nature of the α1-AGP species used. These studies can be extended 
further, by expanding the number of species studied and should be followed by both 
total emission intensity and CPL. Furthermore, the pKa values of the complex in the 
presence of different α1-AGP species should be measured, and their comparison with 
amino-acid composition could shed the light on the residues directly involved in 
binding to the complex.  
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IV.1 Luminescent probes for biologically relevant anions 
 
The selective detection of biologically relevant anions in complex mixtures is a 
challenging task, given the typically narrow concentration range of target species and 
the presence of chemically related and hence competing anions. In order to create a 
probe with a high signal-to-noise ratio, an amplification of the signal is needed to 
allow discrimination between the resting state of the probe and the state with the 
analyte bound. When luminescent probes are taken into consideration, a change of 
the total emission intensity and/or shift of the emission/excitation bands are the usual 
‘read-outs’ to signal the binding event, and their magnitude can be altered by 
judicious design of the probe.  
 
Concentrations of biologically important anions, e.g. carbonate, citrate, lactate, 
phosphate, AMP, ADP, ATP, can be monitored in aqueous media through reversible 
binding involving electrostatic, H-bonding and weaker non-bonding interactions. In 
some cases, a common luminescent platform can be employed, which is customised 
depending on the required species to be analysed. For instance, a 3,3’-bipyridyl-
modified ruthenium(II) complex has been used as a platform, to which different 
functional groups can be attached for sensing either Zn2+ or oxo-anions (Fig. IV.1)[1]. 
Anions were reversibly bound by H-bonding and Coulombic interactions of the 
attached guanidinium and ammonium moieties.  
 
 
Fig. IV.1 Molecular structure of 3,3’-bipyridyl-modified ruthenium(II) complex with different 
sensing moieties attached and the list of anions used for binding studies.[1] 
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In contrast to metal ions, anions more often possess both different shapes and sizes, 
making their selective recognition slightly easier by designing complementary 
binding pockets in the molecular probes. For example, a chiral receptor featuring two 
[9]aneN3 moieties bridged by an (S)-BINOL linker showed selectivity towards (S,S)-
tartaric acid over the (R,R)/meso forms (Fig. IV.2)[2]. Six nitrogens of two [9]aneN3 
rings stabilised two carboxylate groups of tartaric acid by H- and electrostatic-
bonding, whilst binding of the hydroxyl groups of  tartrate with tertiary amines 
provided for enantioselectivity towards the (R,R)/meso forms of tartaric acid. Once 
the analyte was bound, the emission intensity experienced a significant rise due to 
the removal of PET quenching of the BINOL linker. 
 
 
Fig. IV.2 Binding mode of the probe and its selectivity towards different anions after adding 10 
equivalents of each substrate (pH = 7.0, water).[2] 
 
In a similar fashion, a bis-pyridinium calix[4]pyrrole derivative was used for the 
selective detection of pyrophosphate through displacement of a chromenolate anion, 
giving rise to an enhancement of the emission intensity upon elimination of PET 
quenching (Fig. IV.3)[3]. The size of the pyrophosphate anion matched that of the 
cavity formed inside the calix[4]pyrrole between two pyridinium moieties and was 
stabilised by H-bonding with pyrrole hydrogens and a Coulombic interaction with 
the pyridinium nitrogen atoms.  
 
However, purely organic systems usually show low binding affinities in water, as a 
result of relatively low H-bond energies. Anions in aqueous solution are strongly 
solvated and are stabilised via a network of H-bonds. Therefore, a large binding 
energy must compensate for the enthalpy of hydration in order for binding to the 
molecular probe to occur. One of the possible solutions to this problem is to bind the 
anion to a metal centre, leading to formation of a strong metal-oxygen bond.  
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Fig. IV.3 Proposed switching-on mechanism upon addition of pyrophosphate in acetonitrile.[4] 
 
A dipicolylamine-appended sensor Zinpyr-1, initially proposed by Lippard for zinc 
sensing in cellulo, was used for the selective binding of the pyrophosphate anion 
involving two coordinated zinc ions (Fig. IV.4)[5]. Gradual addition of pyrophosphate 
led to an increase of the total emission intensity, along with a bathochromic shift of 
emission. The bridging binding mode to two metal centres ensured high selectivity 
towards bidentate pyrophosphate over monodentate hydrogenphosphate.  
 
  
Fig. IV.4 Putative binding mechanism of pyrophosphate by a bimetallic zinc complex Zn2+-Zinpyr-1 
(H2O, pH = 7.40).[5] 
 
The primary limitation of most reports of anion binding to transition metal ion 
centres is the absence of a ratiometric response and the presence of residual emission 
from other fluorophores in the reaction mixture. Even though a shift of the emission 
intensity is sometimes observed upon binding of the analyte in these systems, its 
magnitude is usually small and prevents efficient ratiometric read-outs. Certain 
lanthanide complexes do not have these drawbacks and can provide a strong 
	 143	
ratiometric response if suitably designed, with millisecond lifetimes, allowing 
efficient time-gating of the emission intensity signal.  
  
Fig. IV.5 Molecular structure of EuroTracker® probe used for anion binding studies and putative 
binding modes for different anions.[6] 
 
A series of EuroTracker® probes with rod-like alkynyl-pyridine chromophores 
based on [9]aneN3 platform has been used for anion-binding studies (Fig. IV.5)[7]. A 
coordinated water molecule was displaced by a bound analyte, increasing the overall 
emission intensity along with a significant change of the spectral fingerprint. By 
following the relative intensitiy of the hypersensitive, electric-dipole allowed 
5D0→7F2 transition,  the concentration of the bound analyte could be monitored.  
 
  
Fig. IV.6 Molecular structure of sialic acid with two pyranose forms and the probe used for its 
sensing.[8] 
 
Additional stabilisation and selectivity can be achieved if metal binding is 
augmented by weaker interactions, e.g. H-bond formation or boron-carbohydrate 
interactions. Bearing this in mind, a phenylboronic acid moiety was attached to the 
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[9]aneN3 platform with two alkynyl-pyridine chromophores and binding studies with 
sialic acid were carried out (Fig. IV.6)[8]. By comparing binding data for this 
complex and its analogue without the phenylboronic acid moiety, the cooperative 
binding of a terminal diol group of sialic acid to the boronic acid residue and an 
amide carbonyl oxygen to europium was hypothesised.  
 
This concept was developed further, and the reversible intramolecular binding of a 
pyridine moiety in response to external stimuli was suggested. It has been previously 
reported by Pope, that a pyridine with an appended dipicolylamine moiety on a 
DO3A platform could efficiently sense zinc ions by significantly perturbing the 
europium emission profile[9]. The same principle can be employed for sensing 
anions, assuming that apart from direct binding to the lanthanide metal, an anion 
molecule can be stabilised by H-bonding with three pyridine moieties and a 
protonated tertiary amine nitrogen. With this in mind, the initial structure proposed 
by Pope was modified and a chromophore arm was added to provide sensitisation 
using a 355 nm diode laser, whilst the substituents at the tertiary amine centre were 
varied in order to modulate affinity.  
 
IV.2 Novel anion-binding probes [EuL7-9] 
 
 
Fig. IV.7 Molecular structure of the probe proposed by Pope[9] (left) and the series of probes [EuL7-9] 
discussed in the present study (right). 
 
The complexes [EuL7-9] (Fig. IV.7) were synthesised as shown on Scheme IV.1. The 
alkynyl-pyridine chromophore was synthesised in accord with a previously reported 
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procedure[7]. In this sequence, the freshly prepared mesylate was slowly added to a 
DO2A ester intermediate, yielding mostly a tri-substituted product. A picolylamine 
arm was prepared by mixing three equivalents of 2,6-bis(chloromethyl)pyridine with 
the corresponding secondary amine. The resulting chloride was reacted with a tri-
substituted 12-ane N4 platform, giving the ester derivatives of the ligands L7-9, which 
were hydrolysed in aqueous base overnight at 60°C, neutralised and complexed with 
EuCl3 to give the desired complexes [EuL7-9]. 
 
 
Scheme IV.1 Synthetic pathway for complexes [EuL7-9]. 
 
 
Any excess metal ion was precipitated in the form of Eu(OH)3 by adding aqueous 
ammonia solution, followed by neutralisation with 1M HCl. All attempts to purify 
the desired complex on RP-HPLC failed, either due to extremely broad and 
unresolved bands in the UV-trace when no buffer was used, or a change of the 
emission spectrum of the resulting complex when ammonium bicarbonate or formic 
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acid were used as a buffer, indicating binding of bicarbonate or formate to the 
complex. Therefore, no further purification steps were attempted and the complexes 
studied were used as proposed, with an uncontrolled amount of NaCl. 
 
Preliminary studies revealed the high affinity of the parent probe, [EuL7], towards 
phosphate and glyphosate - N-(phosphonomethyl)glycine – one of the most 
extensively used herbicides in the world. At physiological pH in HEPES buffer (0.1 
M, pH = 7.4) phosphate is present as an almost equal mixture of H2PO4- and HPO42-, 
whilst the glyphosate phosphonate OH-group (pKa = 5.6) is mostly deprotonated[10]. 
At this pH, very similar binding curves were observed for both phosphate and 
glyphosate, suggesting that a similar binding mechanism was occurring in each case. 
However, once the pH was lowered to 5.9 in 0.1M MES buffer, the phosphate was 
mainly present in the H2PO4- form, whilst the glyphosate phosphonate OH was still 
partially deprotonated, giving higher electrostatic affinity, and hence stronger overall 
binding (Fig. IV.8). 
 
  
Fig. IV.8 Binding curves of [EuL7] for phosphate and glyphosate binding in HEPES (0.1 M, pH = 
7.40; left) and MES (0.1 M, pH = 5.90; right). 
 
Analogous measurements were carried out for various carboxylates (e.g. citrate, 
lactate, acetate), although binding affinities turned out to be considerably lower than 
for phosphate and glyphosate. This trend is normally observed for lanthanide 
complexes, with a bidentate binding mode normally observed for carboxylate anions 
and monodentate for phosphates[6].  
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IV.3 Binding of nucleotides 
 
 
                           
Fig. IV.9 Molecular structure of the nucleosides AMP, ADP and ATP. 
                              
Adenosine triphosphate (ATP) plays an essential role in biological processes, 
supplying energy by transferring a phosphate group from adenosine triphosphate to a 
target molecule (e.g. glucose) and subsequent reduction to adenosine diphosphate 
(ADP, Fig. IV.9 - IV.10). The high energy of the phosphoester bond is released upon 
cleavage (30.5 kJ/mol at physiological conditions) and varies depending on the 
concentration of Mg2+ ions, which promote hydrolysis by activating the P-O bond. 
Further hydrolysis of ADP to AMP is also possible, releasing a second phosphate 
molecule. 
 
 
Fig. IV.10 A simplified hydrolysis scheme of ATP to ADP with release of the hydrogenphosphate 
anion.  
  
The ratio between the concentrations of ADP and ATP is of significant importance 
for cellular metabolism and determines the direction of multiple reactions. For 
example, in the citric acid cycle, a lowered ATP/ADP ratio triggers oxidation of a 
substrate by isocitrate dehydrogenase[11]. Therefore, easily accessible tools for 
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monitoring the ATP/ADP ratio on a cellular level are important and have commercial 
significance, with new sensors appearing regularly.  
 
A recent example, which has been reported is Perceval, which involves a fusion 
protein, consisting of a bacterial regulatory protein GInK1 and a modified green 
fluorescent protein GFP, originally developed by Yellen (Fig. IV.11)[12]. The GInK1 
protein possesses three nucleotide binding sites for binding both ADP and ATP, but 
only binding of ATP causes a local conformational change, giving rise to changes of 
fluorescent signal of the coupled GFP. 
 
  
Fig. IV.11 Ribbon representation of one subunit of the GlnK1 protein without a ligand (gray and blue) 
or with Mg2+-ATP (grey, green and yellow, with the ligand in ball- and-stick form) and the ratio 
between fluorescent intensities upon excitation at 490 nm vs 405 nm and addition of ADP and ATP 
molecules. [12] 
 
In the present study, three nucleotides – AMP, ADP and ATP – were added to 
[EuL7-10] and the corresponding change of emission intensity and lifetime was 
monitored. To follow the changes in the emission spectrum upon addition of a 
nucleotide, the electric-dipole transition 5D0→7F2 resolved into two bands and their 
relative intensity was monitored. 
 
As no reliable fitting to a 1:1 binding model was possible, only an approximate 
evaluation of the affinity order was carried out. The highest affinity was observed for 
[EuL7] with a pyridine moiety bearing a dipicolylamine substituent. After addition of 
1.0 equivalent of AMP and ADP, saturation of the binding curve was observed, 
suggesting a 1:1 binding mode with a nucleotide molecule (Fig. IV.12). A higher 
affinity was observed for AMP, which also gave rise to the biggest spectral change 
reflected in the highest value of the ratio between the two bands. A rise of the total 
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emission intensity was observed, in line with displacing one water molecule from 
coordination sphere.  
 
             
Fig. IV.12 Binding curves for [EuL7] upon addition of AMP, ADP and ATP ([EuL7] 5 µM, 0.1 M 
HEPES, pH = 7.40, 298 K, λex = 335 nm). No satisfactory fitting to a 1:1 model was possible. 
 
Addition of ADP led to smaller spectral changes, even though the binding affinity 
was nearly the same. The lifetime of an excited state experienced a two-fold rise – in 
accord with a reduced PET quenching of the chromophore by the tertiary amine . 
Similarly to AMP addition, the total emission intensity exhibited a 14-fold increase, 
reaching a plateau at ca. 1.0 equivalent of ADP added. In the case of the bulkiest 
nucleotide studied – ATP – a shallower binding curve was observed, approaching a 
plateau only after three equivalents of ATP was added, suggestive of a 1:1 binding 
mode. A similar rise in the lifetime and overall emission intensity was observed in 
this case as well, whilst the spectral change was close to that observed for ADP. In 
all three cases, the total emission intensity was enhanced after addition of Zn2+, 
accompanied by minor changes of the spectral form. This rise of the emission 
intensity may be again attributed to a reduced PET quenching of the chromophore, 
consistent with the increase of the observed europium lifetime in each case. 
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Fig. IV.13 Spectral change of [EuL7] upon addition of AMP ([EuL7] 5 µM, 0.1 M HEPES, pH = 
7.40, 298 K, λex = 335 nm). 
 
Upon addition of nucleotides, all four primary transitions 5D0→7Fj (j = 1-4) 
experienced considerable changes (Fig. IV.13). In the magnetic dipole allowed 
transition 5D0→7F1 two Stark components replaced the three seen in the initial 
complexes, suggesting a change in the local ligand field. The ligand field splitting 
defined as the distance between the Stark splitting components also reduced in size 
in accord with a change in the coordination environment upon binding a phosphate 
group. Analysis of the number of Stark components for other transitions is more 
complicated and was not carried out. 
 
The most striking change in spectral behaviour was revealed after recording CPL 
spectra for [EuL7] with each of the nucleotides bound. Zinc ions were added in each 
case to increase the total emission intensity, and allowed faster acquisition of data 
with enhanced resolution, although the spectral signature were the same with and 
without added Zn2+. The spectra of the complexes with AMP and ADP showed 
identical CPL spectra, whilst the CPL spectrum of the complex with ATP revealed 
an inversed helicity (Fig. IV.14). Moreover, the intensity of CPL signal decreased in 
the order AMP (gem = 0.070) >ATP (gem = 0.042) > ADP (gem = 0.032).   
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Fig. IV.14 CPL spectra of [EuL7] with added AMP and ATP ([EuL7] 5 µM, 0.1 M HEPES, pH = 
7.40, 298 K, λex = 335 nm). 
 
The aforementioned photophysical data allow a binding mode of nucleotides to 
[EuL7] to be hypothesised. As will be shown later, the presence of two picolyl 
moieties is essential for attaining high binding affinity. Therefore, the synchronous 
involvement of both pyridine rings in H-bonding with a nucleotide seems to be a 
reasonable assumption. The similarity of both the lifetime of the excited state and the 
emission spectral form in each case suggests that binding occurs via the terminal 
phosphonate group. The adenine residue is located further away from the metal on 
going from AMP to ADP, whilst different binding modes in the case of ADP and 
ATP probably account for the observed inverse order of gem values (gem (ADP) < gem 
(ATP)). However, in all the cases a 1:1 binding mode is expected (Fig. IV.15).  
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Fig. IV.15 Proposed binding modes of AMP to [EuL7]. 
 
In both cases, it is highly likely that two picolyl moieties bind at least one water 
molecule through H-bonding, which in turn form H-bonds with a phosphonate 
oxygen of the nucleotide. A synergistic effect of multiple hydrogen bonds and direct 
binding to the metal centre leads to a very high affinity for the probe.  
 
Table IV.1 Lifetimes (in H2O and D2O), q values and QY for [EuL7] 
 τ(H2O), ms τ(D2O), ms q 
water 0.46 0.79 0.8 
Zn2+ 0.45 1.28 1.4 
Zn2++AMP 0.97 1.48 0 
Zn2++ADP 0.99 1.45 0 
Zn2++ATP 0.97 1.56 0 
                                      
 
                                     
Fig. IV.16 Molecular structures of [EuL7] (left) and [EuL8] (right). Nucleotide binding moieties are 
depicted in red. 
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The complex [EuL8] has one of the picolyl arms replaced by an ethyl group (Fig. 
IV.16), compared to the parent complex [EuL7]. This change resulted in a 
considerably lower affinity towards nucleotides (ca. 2-3 orders of magnitude lower), 
emphasizing the significance of both picolyl arms in phosphate binding (Fig. IV.17). 
Moreover, a two-fold shorter lifetime (0.2 ms vs 0.4 ms) was observed in the absence 
of nucleotide, suggesting the presence of a more efficient quenching pathway upon 
replacing one of picolyl arms with an ethyl group. It is possible that the lower steric 
demand imposed by an ethyl group allows more efficient O-H quenching through 
formation of a more well-defined second and outer hydration sphere.  
          
 
Fig. IV.17 Comparison in proposed binding modes of AMP between [EuL7] (left) and [EuL8] (right). 
 
At the same time, analysis of the emission spectra revealed spectral signatures in the 
presence and in the absence of AMP very close to those obtained for [EuL7], in line 
with the proposed similar binding mode for both complexes. Indeed, in the absence 
of the bound anion, a pyridine nitrogen is bound to Eu3+, leading to a coordination 
number of [8+1]. Once the anion binds to europium, the triaza moiety dissociates and 
is replaced by phosphonate oxygen, retaining the coordination number [8+1]. 
Therefore, for both [EuL7] and [EuL8], the spectral form should be unaffected by 
change of the substituents at the tertiary nitrogen atom. 
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Fig. IV.18 Binding curves for [EuL8] upon addition of AMP, ADP and ATP ([EuL8] 5 µM, 0.1 M 
HEPES, pH = 7.40, 298 K, λex = 335 nm). Binding constants obtained assuming 1:1 binding 
mechanism were as follows: log K = 4.1 for AMP, log K = 4.6 for ADP and log K = 3.3 for ATP.  
 
However, a closer inspection of the emission spectra of [EuL8] with different bound 
nucleotides revealed significant differences in their spectral form (Fig. IV.18-IV.19). 
If the situation upon addition of AMP was similar to that observed for [EuL7] with 
all three nucleotides, addition of ADP and ATP caused smaller spectral changes. It 
might be possible that the bulkier nucleotides cannot cause sufficient conformational 
change to encourage dissociation of the NCH2Py moiety from Eu3+, leaving it in 
between an initial unbound conformation and an idealised final conformation where 
the pyridine ring has dissociated. At the same time, binding affinities in each case 
were of similar magnitude. Unfortunately, no indications of binding stoichiometry 
can be inferred confidently from these binding curves due to their low affinities. 
However, analysis of the CPL spectra and the similarity of each molecular structure 
suggest a binding mode analogous to that observed for [EuL7], which bind each 
nucleotide in 1:1 stoichiometry.  
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Fig. IV.19 Emission spectra of [EuL8] (black), upon addition of nucleotides (red) - AMP (top), ADP 
(centre) and ATP (bottom). ZnCl2 was added after every experiment (blue) increasing the total 
emission intensity ([EuL8] 5 µM, λex = 335 nm, 0.1 M HEPES, pH = 7.40, 298 K). 
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Despite changes in the emission spectra for three nucleotides once the binding curve 
reached a plateau, addition of Zn2+ (ca. 60 µM) dramatically changed the spectrum of 
[EuL8]*ADP and especially [EuL8]*ATP, making their spectral signature very 
similar. Furthermore, the overall emission intensity in every case was also similar, 
indicating a close resemblance of their coordination polyhedra. A tentative binding 
motif following addition of Zn2+ was proposed (Fig. IV.20), which involves binding 
of the Zn2+ ion by two pyridine nitrogen atoms, a tertiary nitrogen and a hydroxyl 
ion. The latter was suggested to participate in H-bonding with phosphonate oxygen, 
providing a high affinity of the resulting aggregate. 
 
 
Fig. IV.20 Schematic showing proposed binding for [EuL7] and [EuL8] with AMP following addition 
of Zn2+. 
 
To verify the proposed binding mode, zinc chloride was added to the complex first, 
forming [EuL8]*Zn and then ADP or ATP was added. In both cases, similar binding 
constants were calculated (Fig. IV.21), which were two orders of magnitude higher 
than those estimated for binding ADP and ATP without pre-added zinc. The 
observed difference, which is consistent with the proposed binding model, 
corresponds to additional stabilization of a bound phosphonate group by a 
coordinated zinc ion. In each case, more than a two-fold rise of the Eu3+ lifetime was 
observed, although a significant (three-fold) rise of the emission intensity was 
observed only upon addition of ADP, whilst adding ATP did not change the total 
emission intensity of the complex. 
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Fig. IV.21 Binding curves for [EuL8]*Zn upon addition of ADP (top, log K = 5.5(0.1)) and ATP 
(bottom, log K = 5.1(0.1)) ([EuL8] 5 µM, 0.1 M HEPES, pH = 7.40, 298 K, λex = 335 nm). 
 
However, detailed analysis of the three spectra revealed that the emission spectra for  
[EuL8]*ADP and [EuL8]*ATP were identical, whilst that of [EuL8]*AMP was 
slightly different. As with [EuL7], the crystal field splitting parameter decreased 
upon binding the nucleotide with zinc, whilst the number of Stark splitting 
components also reduced. The latter observation again may indicate the higher point 
symmetry of Eu3+ with bound nucleotides. In every case, the lifetime of the 
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europium excited state rose from 0.2 ms to 1.1 ms, in line with the removal of a PET 
quenching of the chromophore excited state.  
 
           
Fig. IV.22 CPL spectra of [EuL8] with added ADP and ATP ([EuL8] 5 µM, ZnCl2 60 µM, 0.1 M 
HEPES, pH = 7.40, 298 K, λex = 335 nm). 
 
Analysis of the CPL spectra of the three adducts revealed behaviour identical to 
[EuL7], with [EuL8]*AMP and [EuL8]*ADP having the same helicity, whilst the 
complex [EuL8]*ATP exhibited the opposite chirality (Fig. IV.22). The intensity of 
the CPL signal was similar for AMP and ATP (gem = 0.012) and three times higher 
for ADP (gem = 0.038), suggesting a slightly different binding mode for ADP.  
 
Table 2 Lifetimes (in H2O and D2O), q values and QY for [EuL8]  
 τ(H2O), ms τ(D2O), ms q 
water 0.22 0.29 1.0 
Zn2+ 0.47 1.30 1.3 
Zn2++AMP 1.09 1.47 0 
Zn2++ADP 1.09 1.51 0 
Zn2++ATP 1.10 1.49 0 
 
Since the complex [EuL8]*Zn2+ showed higher binding affinity towards ADP over 
ATP, its potential for monitoring the ADP/ATP ratio was assessed by recording CPL 
spectra at different stoichiometries (Fig. IV.23). Samples with ADP/ATP ratios 
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ranging from 4:1 to 1:2 were prepared, their CPL spectra analysed and the observed 
gem value (λ = 592 nm) were plotted as a function of the concentration of added ATP. 
The observed quasi-linear curve showed a gradual decay from gem = 0.36 for pure 
ADP to gem = 0.05 for two equivalents of ATP added. Even though a significant 
change of the dissymmetry factor was observed, the total emission intensity 
decreased upon increasing the total nucleotide concentration. In a separate 
experiment, the total concentration of nucleotides was kept constant and similar 
values for gem as a function of ADP/ATP ratio were observed. Apparently, the 
observed quenching of the complex at elevated concentration of nucleotides is 
explained by a π-π interaction between the chromophore and the nitrogenous base of 
the nucleotide. This problem can be potentially overcome by using a less electron-
rich chromophore, for example one with a biaryl chromophore, as reported in the 
previous chapter. 
 
             
Fig. IV.23 Variation of -gem (λ = 592 nm) as a function the ADP/ATP ratio for [EuL8] ([EuL8] 10 
µM, ZnCl2 100 µM, 0.1 M HEPES, pH = 7.40, 298 K, λex = 335 nm). 
 
To complete the structural variation of this series of complexes, the complex [EuL9] 
bearing a diethylamine substituent (Fig. IV.24) was synthesised and its binding 
properties were analysed. A very weak binding affinity was observed for each 
nucleotide, accompanied by only minor changes in their Eu3+ emission spectra. 
Subsequent addition of ZnCl2 changed neither the spectral fingerprint, nor the total 
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emission intensity. Due to a relatively weak emission intensity signal, no CPL signal 
could be recorded over a 2 h acquisition timescale, whilst low binding affinities 
limited quantitative studies. Indeed, the maximum water solubility of these 
nucleotides is ca. 50 mg/mL, and was not sufficient to reach saturation. Nonetheless, 
similarly to previously discussed complexes a very similar emission fingerprint was 
observed for the initial complex with no added nucleotide, whilst a similar increase 
of the relative intensity of the first Stark component in the 5D0→7F2 transition was 
observed. 
 
                                    
Fig. IV.24 Molecular structure of [EuL9]. Putative anion-binding moieties are depicted in red. 
 
These findings support the assumption of the cooperative involvement of both 
picolyl arms in binding the nucleotide through a H-bonded array. Removal of both 
pyridine groups decreased the binding affinity to values expected for a neutral 8-
coordinate lanthanide complex. On the other hand, the protonated tertiary amine on 
its own does not seem to be sufficient to stabilise bound nucleotides via H-bonding, 
as shown in the behaviour of [EuL9]. Generally speaking, it is not necessary for a 
bound atom to dissociate in order to produce a significant change of the emission 
spectrum. It is also possible to modulate the spectral form by varying the electron 
density and/or polarisability of donor atoms. With this in mind, the complex [EuL10] 
was designed and synthesised, featuring a 1,2,3-triazole moiety with an attached 
dipicolylamine arm in the 4-position. The same arm has already been used by Liu in 
TPETH-2Zn to detect zinc ions in cellulo, with a putative coordination motif 
involving binding to two pyridine nitrogen atoms, the tertiary nitrogen and the 3-
nitrogen atom of triazole moiety (Fig. IV.25)[13]. Therefore, it was assumed that a 
triazole moiety could bind to Eu3+ through its 1-nitrogen, whilst the 3-nitrogen atom 
can participate in hydrogen bonding along with the dipicolylamino group. Binding to 
the 3-nitrogen should change the electronic distribution within the heterocyclic ring 
and henceforth alter the emission spectrum of the complex. 
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Fig. IV.25 Molecular structure of TPETH-2Zn (left) and [EuL10] (right). Putative anion-binding 
moieties are depicted in red.[13] 
 
The complex [EuL10] was synthesised in accordance with a multi-step procedure 
(Scheme IV.2). First, commercially available 2-azidoethanol was converted to its 
mesylate and was reacted with the DO2A bis t-butyl ester. The resulting mixture 
consisted of the desired tri- and a tetra-substituted product. The crude mixture was 
reacted with N,N-bis(pyridin-2-ylmethyl)prop-2-yn-1-amine, which was synthesised 
in accordance with a literature procedure[14]. The resulting crude mixture was 
purified using RP-HPLC, yielding a mixture of two products – the desired tri-
substituted moiety and a tetra-substituted by-product with two triazole arms.  
 
 
Scheme IV.2 Synthetic pathway for complexes [EuL10]. 
 
The desired product 10-1 were separated on an alumina column and a freshly 
prepared sample of the chromophore mesylate 1-Ms was added to give a tetra-
substituted ligand, which was purified using RP-HPLC. The resulting ligand was 
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hydrolysed in 0.5M NaOH, neutralised and purified using RP-HPLC with 
ammonium bicarbonate buffer. The buffer was removed by freeze-drying. The 
resulting colourless hydrolysed ligand was complexed with EuCl3 and precipitated as 
an off-white solid upon storing in a fridge at 4°C overnight.  
 
Anion-binding studies with [EuL10] and selected nucleotides were carried out, and 
spectral changes were monitored (Fig. IV.26). Although a similar binding affinity to 
that observed for [EuL7] was expected, a much lower binding constant was observed 
in each case (all K are of the order 102 vs. 106-7 for [EuL7] and 104 for [EuL8]). 
Different spectral changes were observed upon binding different nucleotides. Again, 
the biggest change was observed upon binding of AMP, followed by ADP and ATP. 
The binding constants were calculated for each nucleotide by fitting the variation in 
relative emission intensities, using non-linear iterative least squares analysis. 
 
            
Fig. IV.26 Binding curves for [EuL10] upon addition of AMP, ADP and ATP ([EuL10] 8 µM, 0.1M 
HEPES, 0.1 M HEPES, pH = 7.40, 298 K, λex = 335 nm). log K = 2.2 for AMP, log K = 2.3 for ADP 
and log K = 2.1 for ATP. 
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Fig. IV.27 Emission spectra of [EuL10] (black) and following addition of nucleotides (red) - AMP 
(top left), ADP (top right) and ATP (bottom). ZnCl2 was added after every experiment (blue) and 
slightly increased the total emission intensity ([EuL10] 8 µM, 0.1 M HEPES, λex = 335 nm, pH = 7.40, 
298 K). 
 
	 164	
In each case, a rise of the total emission intensity was observed – highest with AMP 
and lowest with ATP (Fig. IV.27). Addition of ZnCl2 (up to a 10-fold excess) only 
slightly increased the emission intensity, without changing the form of the spectral 
signature. Addition of extra zinc (II) ions led to a gradual decrease of the emission 
intensity, probably due to competitive binding to the nucleotide. In every case, the 
emission lifetime increased up to a limit of 1.0-1.1 ms, consistent with replacing a 
coordinated water molecule and partially eliminating PET quenching.  
 
Table 3 Lifetimes (in H2O and D2O), q values and QY for [EuL10]  
 τ(H2O), ms τ(D2O), ms q 
water 0.51 1.12 0.97 
AMP 0.86 1.54 0.3 
ADP 0.94 1.48 0.2 
ATP 0.80 1.44 0.4 
 
Regarding the changes in the coordination environment, no significant change in the 
number of Stark splitting components was observed, in line with the assumption that 
the 1,2,3-triazole moiety is bound to Eu3+ with and without added nucleotide. An 
observed variation of the ligand field splitting can be explained by elongation of 
Eu3+-X (X = O, N) bonds upon increasing coordination number, e.g. when a 
nucleotide phosphate moiety binds to europium. The fact that addition of Zn2+ ions 
did not change the emission pattern, in contrast with previously discussed 
complexes, suggests the inaccessibility of the bound nucleotide towards Zn2+ binding 
(Fig. IV.28). On the other hand it could be a result of a more rigid structure, which 
cannot be easily perturbed by addition of Lewis acids.  
 
                          
    Fig. IV.28 Schematic showing proposed binding [EuL10] with AMP following addition of Zn2+. 
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In every case a strong CPL signal was recorded, with the same spectral signature for 
each nucleotide (Fig. IV.29). In contrast to the behaviour of complexes [EuL7] and 
[EuL8], the same sign of gem was found indicating the same helicity for AMP, ADP 
and ATP. The asymmetry ratio rose in the order AMP (gem (591 nm) = 0.24) < ADP 
(gem (591 nm) = 0.29) < ATP (gem (591 nm) = 0.50). This finding is consistent with 
an increasing distance between Eu3+ and the nearest stereogenic centre of the 
nucleotide from ATP to AMP. This conclusion is counterintuitive, as a reducing 
length of a phosphate chain should bring them closer together and give rise to higher 
gem values. The only plausible explanation for this phenomenon is that a different 
binding mode exists for ATP, compared to AMP and ADP, that allows the chiral 
sugar moiety to approach the europium ion more closely, and hence give rise to a 
higher gem value. 
 
        
Fig. IV.29 CPL spectra of [EuL10] with added AMP, ADP and ATP ([EuL10] 8 µM, ZnCl2 60 µM, 
0.1 M HEPES, pH = 7.40, 298 K, λex = 335 nm). 
 
To evaluate the impact of complex charge on anion binding and Zn2+ behaviour, a 
positively charged complex [EuL11]+ (Fig. IV.30) was synthesised according to a 
procedure employed for the synthesis of [EuL7-9], the only difference being that a 
chromophore without a carboxylate group was used.  
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Fig. IV.30 Molecular structure of [EuL11]+. Putative anion-binding moieties are depicted in red and 
monodentate pyridine ring is depicted in blue. 
 
The resulting complex was expected to have a coordination number of 8 and an 
overall positive charge (doubly positive charge if protonation of a tertiary amine of a 
sensing moiety is also considered). However, isolation of the complex proved 
difficult, as all attempts to raise the pH of the solution above 8.0 resulted in 
irreversible chemical transformation of the complex, causing a significantly 
decreased emission intensity. Competitive and apparently irreversible bicarbonate 
binding was suggested to be responsible for this change, although displacing of the 
bicarbonate by bubbling argon through the solution did not restore the initial 
emission spectrum.  Therefore, it was not possible to remove any excess free Eu3+ 
and the complex was used without any further purification.  
 
A very high affinity towards phosphate and glyphosate was observed, which was 
accompanied by changes in the relative emission intensity and lifetime. However, 
due to problems with handling and storage, no more detailed analyses of [EuL11]+ 
were carried out. 
 
IV.4 Binding of Zn2+ ions to [EuL7-8] 
 
Zinc is the second most abundant transition metal in our bodies after iron, 
participating in multiple biological processes, including gene expression, 
stabilisation of DNA, signaling between cells, and wound healing. The zinc-
deficiency in childhood and adolescence due to low dietary zinc intake often leads to 
severe pathologies, such as anaemia, hypogonadism and dwarfism[15]. Even though 
significant progress has been made in unraveling the biological role of zinc in living 
cells, the monitoring of its concentration and flux might help to address the 
remaining questions. Despite a relatively high concentration of zinc in human cells 
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(0.2-0.3 mM), the concentration of ‘free’ zinc, which is not bound to a protein and 
available for binding with a molecular probe, is usually several orders of magnitude 
lower.  
 
However, there are a few exceptional cases, when the concentration of ‘free’ (labile) 
Zn2+ is unusually high, as for example in prostatic fluid. The reason for such a high 
concentration of Zn2+ ions in prostatic fluid (ca. 3 mM in healthy individuals[16]) is 
still debatable, but is connected to the secretory function of the prostate gland[17]. It 
was established that prostate malignancies are usually accompanied by low 
concentrations of both Zn2+ and citrate anions in secreted prostate fluid and can be 
potentially used to detect early stages of prostate cancer. One of the possible ways to 
analyse prostatic fluid samples is to use fluorescent probes, which can produce a 
change in the emission signal as a function of zinc concentration. However, the 
primary requirement for these probes is their insensitivity towards citrate anions, 
whose concentration also usually changes in the presence of cancerous cells.  
 
A series of lanthanide complexes was developed for the selective binding of citrate 
ions[18], which was deemed a simpler strategy to monitor the presence of 
malignancies in prostate fluid, as the emission signal from lanthanide complexes is 
usually unaffected by the concentration of Zn2+, unless special zinc-binding groups 
are introduced. By varying the charge of a series of complexes with 12-N4 based 
heptadentate ligands along with the steric demand associated with the nature of the 
ring substituents, selectivity and binding affinity towards citrate was modulated. 
Upon addition of citrate the relative intensities of Eu3+ emission bands changed and 
this change was followed as a function of citrate concentration. The best results were 
obtained for a singly charged complex with two amide arms and an azaxanthone 
ligand. The accuracy of the probe was verified by comparing readings obtained with 
this probe and by independent ELISA assay measurements (Fig. IV.31). 
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Fig. IV.31 Molecular structures of complexes studied as citrate-binding probes and comparison 
between concentration determination by using probe [Eu.L3]+.[18] 
 
Although the proposed citrate probe showed encouraging results for determination of 
citrate levels in real prostate fluid samples, the need to improve the magnitude of the 
spectral change, as well as to induce a significant change of the lifetime of the Eu3+ 
excited state upon binding the analyte, stimulated a search for alternatives. The 
complexes [EuL7-8] were thus assessed as potential probes, as they can detect zinc by 
modulating a significant change of the emission spectrum (Fig. IV.32) and show a 
two-fold increase of the lifetime upon binding Zn2+ in the case of [EuL8]. 
 
       
Fig. IV.32 Assumed binding mode of Zn2+ to [EuL7]. 
 
The analysis of the binding curve of [EuL7] with added Zn2+ revealed 1:2 binding 
stoichiometry (Fig. IV.33-IV.34), suggesting that Zn2+ bridges two europium 
complexes with 6 nitrogen atoms of the pyridine moieties comprising an octahedral 
coordination environment. A very high binding affinity to Zn2+ ions was observed 
(log K = 7.5) accompanied by no change in the Eu3+ emission lifetime (τ = 0.46 ms). 
However, this value should be treated with extra caution, as it was calculated 
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assuming 1:1 binding model, and therefore can be considered only as an 
approximation. 
 
                
Fig. IV.33 Change of the emission spectrum upon binding Zn2+ to [EuL7] ([EuL7] 5 µM, 0.1 M 
HEPES, pH = 7.40, 298 K, λex = 335 nm). The binding affinity (log K = 7.5) was fitted in 1:1 binding 
model. 
 
                     
Fig. IV.34 Job plot for [EuL7] following the addition of Zn2+ ([EuL7] 5 µM, 0.1 M HEPES, pH = 
7.40, 298 K, λex = 335 nm). 
 
A similar binding stoichiometry and affinity were observed for Ni2+, whilst no 
binding curve could be obtained for Cu2+ due to severe PET quenching of the 
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europium emission. Addition of a large excess of alkali-earth metals, such as Ca2+ 
and Mg2+ and transition metals, such as Cr3+ and Mn2+ only slightly changed the total 
emission intensity, and did not affect the spectral signature.   
 
Complex [EuL8] showed a similar form of binding curve, but it was not possible to 
assess the binding stoichiometry using a Job plot due to an insufficiently high 
binding affinity. The total emission intensity underwent a significant 10-fold rise, 
along with a change of the spectral pattern, whilst the lifetime of the excited state 
doubled upon addition of Zn2+ from 0.22 ms to 0.46 ms (Fig. IV.35-IV.36).  
 
      
Fig. IV.35 Change of the emission spectrum upon binding Zn2+ to [EuL8] ([EuL8] 8 µM, 0.1 M 
HEPES, pH = 7.40, 298 K, λex = 335 nm). The binding affinity (log K = 5.6) was fitted in 1:1 binding 
model. 
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Fig. IV.36 Change of the lifetime of an excited state 5D0 upon binding Zn2+ to [EuL8] ([EuL8] 5 µM, 
0.1 M HEPES, pH = 7.40, 298 K, λex = 335 nm, λem = 613 nm). 
 
The analysis of binding stoichiometries of [EuL7] and lower affinity of [EuL8] 
allowed the proposed structures (Fig. IV.37) to be promulgated.  
 
 
 
Fig. IV.37 Putative binding motifs of Zn2+ for [EuL7], showing 2:1 complexation mode. 
 
In the case of [EuL7], the most likely binding mode involves six pyridine nitrogens, 
defining an octahedron. The two tertiary nitrogen centres are further away from the 
coordinated Zn2+ and do not participate in binding. A similar binding motif with a 
zinc atom coordinated by two dipicolylamine moieties has been reported previously 
with a Zn2+ complex bearing a btpa ligand (Fig. IV.38)[19]. However, in that structure 
the high steric demand encouraged the two tertiary nitrogen atoms to bind to the zinc 
atom, leaving two picolyl arms unbound. In contrast with [EuL7], a tetrahedral 
configuration is proposed involving two picolyl nitrogens, a tertiary amine nitrogen 
atom and a bound water molecule is suggested for [EuL8] (Fig. IV.39), in line with 
1:1 binding stoichiometry evidenced from the obtained Job plot (see Appendix).  
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Fig. IV.38 Molecular structure of btpa ligand and the structure of its complex with Zn2+.[19] 
 
Another potential tetrahedral binding mode can be considered involving two picolyl 
nitrogen atoms and two water molecules without direct participation of the tertiary 
amine nitrogen.  
 
                         
Fig. IV.39 Putative binding motifs of Zn2+ for [EuL8], showing 1:1 complexation mode. 
 
In order to establish the potential use of these probes in sensing zinc (II) ions in 
prostatic fluid, a titration of [EuL8] vs. added Zn2+ was performed, in the presence of 
40 mM citrate at pH=7.40. A much shallower binding curve was observed in this 
case (Fig. IV.40), and the spectral signature was unaffected by the presence of the 
citrate. This behaviour indicates that citrate ions compete with [EuL8] for binding 
zinc ions to same extent. It has been shown that citrate form stable complexes 
(primarily [Zn(cit)]- with with log β = 5.02 (3))[20] with first row transition metals, 
including zinc, over a the wide range of pH values. As both the concentration of Zn2+ 
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and citrate anions is lowered in patients with prostate cancer, this can interfere with 
interpretation of the data obtained.  
 
 
Fig. IV.40 Change of the emission spectrum of [EuL8] upon binding Zn2+ in the presence of trisodium 
citrate ([EuL8] 8 µM, citrate 40 mM, 0.1 M HEPES, pH = 7.40, 298 K, λex = 335 nm). 
 
 
IV.5 Conclusions and future work 
 
The selective binding of target anions by lanthanide complexes is governed by the 
combined effects of steric complementarity, overall charge and the presence of 
certain functional groups that participate in electrostatic or H-bond interactions. In 
the present study, it was demonstrated with [EuL7-11] that by subtle structural 
alterations, a significant change in nucleotide affinity can be gained. On the other 
hand, steric factors may also be responsible for discrimination e.g. with ADP and 
ATP, which produced CPL signals of opposite signs upon binding to [EuL7-8]. 
Furthermore, different levels of signal amplification (i.e. total emission intensity) 
were observed across the nucleotide series, which was also attributed to size 
exclusion. It was also shown that the binding of Zn2+ ions resulted in the formation 
of bimetallic complexes [EuL7]2*Zn2+ and [EuL8]*Zn2+, which showed an 
enhanced affinity to the nucleotides. At the same time, variation in the number of 
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donor atoms in the Zn2+ binding site, provided an efficient means for tuning Zn2+ 
binding affinity. 
 
The selective detection observed for ADP over ATP, makes further development of 
probes based on [EuL7-8] highly attractive. They have potential applications as 
cellular probes for tracking the ADP/ATP ratio using chiral confocal luminescence 
microscopy. The major drawback of proposed systems, is their rather low brightness 
and the quenching of the chromophore by protein binding and other electron-rich 
molecules. One possible solution to overcome these issues is to use a biaryl 
chromophore, which is able to sensitise Tb3+ emission with a significantly higher 
quantum yield. Such a complex should require less time to acquire a high CPL signal 
(Fig. IV.41).  
 
                                  
Fig. IV.41 Proposed molecular probe for detecting the ratio between ADP and ATP in cellulo (R = 
Py, Et). 
 
Further structural alterations should be also aimed at increasing the dissymmetry 
factor, gem, by rigidifying the structure. It has been reported that introducing 
phosphinate arms can significantly increase the rigidity of lanthanide complexes 
based on macrocyclic ring platforms[21]. Therefore, by substituting carboxylate arms 
in both the chromophore and cyclen ring, higher gem values may be achieved, thereby 
enhancing the sensitivity of the ADP/ATP probe (Fig. IV.42). Furthermore, 
substitution of the carboxylate arm with a phosphinate should bathochromically shift 
the excitation wavelength of the complex by approximately 10 nm, making it 
brighter under the 355 nm laser that is often used in a confocal microscope.  
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Fig. IV.42 Proposed molecular probe with phosphinate arms for detecting the ratio between ADP and 
ATP in cellulo (R = Py, Et). 
 
Even though probes [EuL7-8] combine both an affinity towards nucleotides and Zn2+ 
ions, the utility of these probes for detecting Zn2+ in cellulo is significantly hampered 
by their high affinity towards different bioactive anions. The intrinsic drawback of 
these systems for binding metal ions is a close proximity of the binding pocket to the 
lanthanide ion, notwithstanding the benefit for high anion affinity. At the same time, 
a relatively short distance between Zn2+ ion and lanthanide is usually necessary to 
provide a significant perturbation of the coordination environment, which causes a 
concomitant photophysical change. Therefore, the ideal Zn2+-sensitive probe should 
be designed in such a way that on the one hand, metal binding causes sufficient 
alteration of the coordination environment of the lanthanide to track these changes 
spectroscopically, and on the other, it is not hindered by competitive binding of 
interfering anionic species.  
 
Recently, Mishra reported gadolinium probes for relaxometric detection of calcium 
and zinc ions, where an amide arm bearing a metal-sensitive moiety was attached to 
the DO3A moiety[22]. Photophysical studies of the Eu3+ analogue revealed that 
despite a relatively long distance between Eu3+ and the carbonyl group, its reversible 
binding as a function of added metal produced a noticeable change of the spectral 
signature that can be followed ratiometrically. In addition, a relatively long distance 
between the binding moiety and Ln3+ should exclude any competitive binding with 
anions at biologically relevant concentrations. 
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Fig. IV.43 Proposed zinc (II) sensors EuZnSen1 and EuZnSen2 and the schematic of the reversible 
Zn2+-binding mechanism for EuZnSen2. 
 
With this structure in mind, novel luminescent zinc-selective probes for cellular 
imaging based on a DO2A platform are proposed here (Fig. IV.43), which employ 
the biaryl chromophore and an amide arm bearing a dipicolylamine moiety. Two 
complexes with different charges and coordination numbers along with their 
synthetic pathway are suggested below (Scheme IV.3). The complex with an overall 
positive charge and coordination number 8 should have a lower affinity than the 
corresponding neutral complex with a coordination number of 9. 
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Scheme IV.3 Suggested synthetic pathway for EuZnSen1. 
 
To modulate significant changes in the emission spectrum of Eu3+ as a function of 
added analyte, alterations in the coordination sphere of Eu3+ are usually involved. 
However, in order to perturb the electronic distribution on the lanthanide ion, it is 
sufficient to alter the polarisability or partial charge on the already ligated atoms 
without their dissociation. Pyridine-containing moieties are often used as a binding 
arm in lanthanide complexes, due to the ease of their functionalisation. Although, a 
high partial charge on the nitrogen atom makes electrophilic substitutions into the 
ring a challenging task, even subtle alterations of the electronic distribution in the 
ring should give rise to considerable changes in the emission spectrum of the bound 
lanthanide ion. Henceforth, introduction of the dipicolylamine moiety in a para-
position should result in a zinc-responsive probe, which can modulate spectral 
changes in response to added Zn2+ (Fig. IV.44). 
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Fig. IV.44 Reversible Zn2+-sensing for the proposed molecular probe. 
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V.1 Materials and Methods 	
All solvents used were laboratory grade and anhydrous solvents, when required, 
were freshly distilled over the appropriate drying agent. Water was purified by the 
‘PuriteSTILLplus’ system, with conductivity of ≤4 µS cm−1. All reagents used were 
purchased from commercial suppliers (Aldrich, Fisher Scientific, Fluorochem, 
Apollo Scientific) and were used without further purification unless otherwise stated. 
Reactions requiring anhydrous conditions were carried out using Schlenk-line 
techniques under an atmosphere of argon. DO2A-tret-butyl ester[1], DO2A-ethyl 
ester[2], methyl 6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)picolinate[3], 1-(6-
(Chloromethyl)pyridin-2-yl)-N,N-bis(pyridin-2-ylmethyl)methanamine[4] and (4-
bromopyridin-2-yl)methanol[5] were synthesised according to previously reported 
procedures,. A synthesis of sulphonamide arm is performed in accordance with 
literature procedure[6]. Synthesis of di-substituted cyclen with chiral amide arms was 
described elsewhere[7],[8]. 
 
V.1.1 Optical measurements 	
Absorption spectroscopy  
 
UV/Vis absorption measurements were recorded using a Perkin-Elmer Lambda 900 
absorption spectrophotometer, using matched quartz cells. 
 
Luminescence 
 
Emission spectra were measured using a Horiba-Jobin Yvon Fluorolog-3® and 
Horiba-Jobin Yvon Fluoromax-3®. The steady-state luminescence was excited by 
unpolarised light from a 450W xenon CW lamp and detected at an angle of 90° for 
diluted solution measurements (10 mm quartz cell) by a red-sensitive Hamamatsu 
R928 photomultiplier tube. Spectra were reference corrected for both the excitation 
source light intensity variation (lamp and grating) and the emission spectral response 
(detector and grating). Phosphorescence lifetimes (> 30 µs) were obtained by pulsed 
excitation using a FL-1040 UP Xenon Lamp. Luminescence decay curves were fitted 
by least-squares analysis using Origin®. Luminescence quantum yields ϕ were 
measured in diluted aqueous solution with an absorbance lower than 0.3, using an 
integrating sphere. The apparent binding constant of the selected anion was 
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calculated according to equation, using Origin2015™ software and non-linear 
iterative least squares regression.  
 
 
 
 
 
 
 
[X]: the total concentration of protein in the solution 
[Eu]: the total concentration of the complex 
K: the binding constant 
F: the ratio of selected peaks 
F0: the ratio at the beginning                
F1: the final ratio 
[EuX]: the concentration of the appropriate SA or drug -coordinated complex 
[Xf]: the concentration of free SA or drug in the mixture 
[Euf]: the concentration of the free complex 
 
Circularly Polarised Luminescence 
 
CPL spectra were recorded on a custom built spectrometer consisting of a laser 
driven light source (Energetiq EQ-99 LDLS, spectral range 170 to 2100 nm) coupled 
to an Acton SP2150 monochromator (600 g/nm, 300 nm Blaze) allowing excitation 
wavelengths to be selected with a 6 nm FWHM band-pass. The collection of the 
emitted light was facilitated (90° angle set up, 1 cm path length quartz cuvette) by a 
Lock-In Amplifier (Hinds Instruments Signaloc 2100) and Photoelastic Modulator 
(Hinds Series II/FS2AA). The differentiated light was focused onto an Acton SP2150 
monochromator (1200 g/nm, 500 nm Blaze) equipped with a high sensitivity cooled 
Photo Multiplier Tube (Hamamatsu H10723-20 PhotoSensor red corrected). The 
detection of the CPL signal was achieved using the field modulation lock-in 
technique. The electronic signal from the PMT was fed into the lock-in amplifier 
(Hinds Instruments Signaloc 2100). The reference signal for the lock-in detection 
was provided by the PEM control unit. The monochromators, PEM control unit and 
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lock-in amplifier were interfaced with a desktop PC and controlled by Labview2011 
code. 
 
V.1.2 Confocal Microscopy  
  
Cell microscopy imaging of the complexes studied in cells was achieved using a 
custom built epiflorescence microscope (modified Zeiss Axiovert 200M), using a 
Zeiss APOCHROMAT 63x/1.40 NA objective, combined with a low voltage 365 nm 
pulsed UV LED focused and collimated excitation source (1.2W). For rapid spectral 
acquisition, the microscope was equipped at the X1 port with a Peltier cooled 2D-
CCD detector (Ocean Optics), used in an inverse 100 Hz time gated sequence. The 
spectrum was recorded from 400-800 nm with a resolution of 0.24 nm and the final 
spectrum was acquired using an averaged 10,000 scan duty cycle.  
 
Probe lifetimes were measured on the same microscope platform using a cooled 
PMT detector (Hamamatsu H7155), mounted on the X2 port. Both the control and 
detection algorithm were written in LabView2014. Time gated images were recorded 
using a high resolution cooled EO-1312M CCD camera (Thor labs). All duty cycle 
and gating sequences were established and controlled by in house LabView 
software4.  
 
High resolution Laser Scanning Confocal Microscopy (LSCM) images were 
recorded on a modified Leica SP5 II microscope, equipped with a new SIM 
technique called PhMoNa4. In order to achieve excitation with maximal probe 
emission, the microscope was coupled by an optical fibre to a Coherent  CW laser 
(Nd:YAG, 355 nm), operating at 8 mW power. A He/Ne or Ar ion laser was used 
when commercially available organelle-specific stains (e.g. LysoTrackerGreenTM) 
were used to corroborate cellular compartmentalisation profiles.  
 
The microscope was equipped with a triple channel imaging detector, comprising 
two conventional PMT systems and a HyD hybrid avalanche photodiode detector. 
The latter part of the detection system, when operated in the BrightRed mode, is 
capable of improving imaging sensitivity above 550 nm by 25%, reducing signal to 
noise by a factor of 5. The pinhole was always determined by the Airy disc size, 
calculated from the objective in use (HCX PL APO 63x/1.40 NA αBlue), using the 
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lowest excitation wavelength (355 nm). Scanning speed was adjusted to 200 Hz in a 
unidirectional mode, to ensure both sufficient light exposure and enough time to 
collect the emitted light from the lanthanide based optical probes (2048 x 2048 frame 
size, a pixel size of 62 x 62 nm and depth of 298 nm). Spectral imaging on this Leica 
system is possible with the xyλ-scan function, using the smallest allowed spectral 
band-pass (5 nm) and step-size (3 nm) settings. However, much improved spectral 
imaging in cells was achieved using a custom built and Peltier cooled CCD detector 
(Ocean Optics, HR2000plus) synchronised to the X1 port. 
 
The europium complexes (10 µM) were incubated with NIH-3T3 cells for up to 24h 
to allow complex uptake within the lysosomes; this localisation profile was verified 
by co-incubation with LysoTrackerGreen.   
 
Live cell cultures studies  
 
A detailed investigation of the cellular behaviour of each complex was conducted 
using NIH 3T3 mouse skin fibroblast cell using epi-fluorescence and laser scanning 
confocal microscopy. Initial cell line was sourced from American Type Culture 
Collection (NIH 3T3 CRL-1658) and have been established and maintained in a 
category 2 cell culture facility according to established standardised protocol for 12 
months; they have been periodically monitored for mycoplasma contamination. Cells 
were maintained in exponential growth as monolayers in F-12/DMEM (Dulbecco's 
Modified Eagle Medium) 1:1 that was supplemented with 10% fetal bovine serum 
(FBS) or human or goat serum where appropriate. Cells were grown in 75 cm2 
plastic culture flasks, with no prior surface treatment. Cultures were incubated at 37 
°C, 10% average humidity and 5% (v/v) CO2. Cells were harvested by treatment with 
0.25% (v/v) trypsin solution for 5 min at 37 ºC. Cell suspensions were pelleted by 
centrifugation at 1000 rpm for 3 min, and were re-suspended in fresh medium by 
repeated aspiration with a sterile plastic pipette. Microscopy cells were seeded in 
untreated iBibi 100 µL live cell channels and allowed to grow to 40% to 60% 
confluence, at 37 ºC in 5% CO2. At this stage, the medium was replaced and cells 
were treated with the studied Eu-complex and co-stains as appropriate, present in the 
final imaging medium. For live cell imaging, DMEM/F12 media lacking phenol red 
was used from this point onwards using a purpose build incubator housing the 
microscope maintaining 37 ºC, 5% CO2 and 10% humidity. 
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V.1.3 HPLC analysis 
 
HPLC analysis and purification were performed at 295 K using a Shimadzu system 
(degassing unit DGU-20A5R, Prominence semi-preparative liquid chromatograph 
LC-20AP, Prominence UV/Vis detector SPD-20A and communications bus module 
CBM-20A). The solvent system used was ammonium bicarbonate buffer (25 mM, 
pH = 7) / methanol [isocratic 10 % methanol in buffer (3 min), linear gradient to 
100% methanol (10 min), isocratic 100 % methanol (5 min)] or formic acid buffer 
(0.1%) / Acetonitrile [isocratic 10 % acetonitrile in buffer (3 min), linear gradient to 
100% Acetonitrile (10 min), isocratic 100 % acetonitrile (5 min)] flow: 2 ml / min 
for analytical mode on XBridge C18 column, 4.6 x 100 mm, i.d. 5 µm, and 17 ml / 
min for preparative mode on XBridge C18 column, 19 x 100 mm, i.d. 5 µm. 
 
V.1.4 Electrospray mass spectral analysis and accurate mass 
determinations 
  
Electrospray mass spectra and accurate masses were recorded on a TQD mass 
spectrometer or a QTOF Premier mass spectrometer respectively, both equipped with 
an Acquity UPLC, a lock-mass electrospray ion source and an Acquity photodiode 
array detector (Waters Ltd, UK), acetonitrile was used as the carrier solvent. Solvent 
system used for TQD was water (0.1 % formic acid) / Acetonitrile (0.1 % formic 
acid) [5 % acetonitrile (0.2 min), linear gradient to 95 % Acetonitrile (3.8 min), 
isocratic 95 % acetonitrile (0.5 min), linear gradient to 5% acetonitrile (0.5 min)], 
flow: 0.6 ml / min on Acquity UPLC BEH C18 column, 2.1 x 50 mm, i.d. 1.7 µm. 
Solvent system used for QTOF was ammonium bicarbonate buffer (25 mM, pH = 7) 
/ Acetonitrile [2 % acetonitrile in buffer (3 min), linear gradient to 40% Acetonitrile 
(6 min), linear gradient to 100% Acetonitrile (4 min), isocratic 100 % acetonitrile (2 
min)] or water (0.1 % formic acid) / Acetonitrile (0.1 % formic acid) [linear gradient 
to 99 % Acetonitrile (5 min), isocratic 99 % acetonitrile (1 min), linear gradient to 
100 % water (0.1 min), isocratic 100 % water (0.9 min)], flow: 0.6 ml / min on an 
Acquity UPLC BEH C18 column, 2.1 x 50 mm, i.d. 1.7 µm. 
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V.1.5 NMR Analysis 
 
1H and 13C NMR spectra were recorded on a Bruker Avance-400 (1H 400.052 MHz 
and 13C 100.603 MHz) spectrometer. Spectra were recorded in commercially 
available deuteriated solvents. 13C and 1H chemical shift values are quoted in ppm 
relative to trimethylsilane and all coupling constants are given in Hz. Assignment of 
the spectra was achieved using COSY, NOESY, ROESY, HSQC and HMBC 
experiments. The operating temperature of the spectrometers (usually 295 K) was 
measured with the aid of an internal calibration solution of ethylene glycol.  
 
Relaxivity measurements were carried out at 310 K, 60 MHz (1.4 T) on a Bruker 
Minispec mq60 instrument. The mean value of three independent measurements was 
recorded. The relaxivities of the compounds were calculated as the slope of the 
function shown in the eqn (1) below,                                                        !!!,!"# = !!!,! + 𝑟![𝐺𝑑𝐿!]      (1) 
 
where T1,obs is the measured T1, T1,d is the diamagnetic contribution of the solvent 
(calculated to be 4.0 ms) and [GdL4] is the concentration in mM of the appropriate 
Gd3+ complex (n = 1–6). Errors for all relaxivity values were less than 0.3 mM−1s−1. 
 
The apparent binding constant for the interaction of the Gd3+ complexes with Human 
Serum Albumin (HSA), Bovine Serum Albumin (BSA), iodipamide and ibuprofen 
was calculated using eq. (2) below: 
 
                                     𝑋 =  (!!!!)/(!!!!!)! ! !"!! × !!!!!!!!!![!"!!]× !!!!!!!!! !!! (!!!!)(!!!!!)     
 
                                                                𝐾 =  !"∙!!! !"!                                    (2) 
 
where [X] is the total concentration of serum albumin in the solution; [Gd.L1]: the 
total concentration of the complex; K: the binding constant; R: relaxation rate of a 
given concentration of X; R0: the initial relaxation rate; R1: final relaxation rate; 
[Gd.X]: the concentration of the serum albumin-coordinated complex; [Xf]: the 
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concentration of free serum albumin in the mixture; [Gdf]: the concentration of the 
free complex. 
 
V.2. Synthesis 
 
(4-((4-Methoxyphenyl)ethynyl)pyridin-2-yl)methanol, 1 
 
                                                    
 
(4-Bromopyridin-2-yl)methanol (0.67 g, 3.56 mmol) and 4-ethynylanisole (0.70 mL, 
5.40 mmol) were dissolved in anhydrous THF (15 mL) under argon, followed by 
addition pyrrolidine (0.40 mL) and Pd(TPP)2Cl2 (0.25 g, 0.36 mmol). The reaction 
mixture was stirred at 50 °C for 18 h and the solvent was removed under reduced 
pressure. The crude material was purified on a silica column (100% DCM to 
50%DCM-50%EtOAc), giving an orange solid (0.85 g, 100% yield); 1H NMR (295 
K, 400 MHz, CDCl3) ẟH 8.50 (1H, d, 3JH-H = 5.0 Hz, H6), 7.48 (2H, d, 3JH-H = 9.0 Hz, 
H10), 7.38 (1H, br s, H3), 7.25 (1H, d, 3JH-H 5.0, H5), 6.90 (2H, d, 3JH-H = 9.0 Hz, H11), 
4.76 (2H, s, H1), 3.83 (3H, s, H13); 13C NMR (295 K, 100 MHz, CDCl3) ẟC 160.4 
(C12), 159.5 (C2), 148.4 (C6), 133.5 (C4), 132.6 (C10), 124.0 (C3), 122.2 (C5), 114.2 
(C9), 114.0 (C11), 94.4 (C8), 85.7 (C7), 64.2 (C1), 55.3 (C13); m/z (HRMS+) 240.1027 
[M+H+]+ (C15H14N2O requires 240.1025). 
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Di-tert-butyl 2,2'-(4-((4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-
1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate, 1-1 
 
                                             
 
(4-((4-Methoxyphenyl)ethynyl)pyridin-2-yl)methanol, 1 (103 mg, 0.43 mmol) was 
dissolved in anhydrous THF (5 mL) under argon, followed by addition of anhydrous 
triethylamine (130 µL, 0.90 mmol) and methenesulfonyl chloride (55 µL, 0.70 
mmol). The reaction mixture was stirred for 2 h at rt and the solvent was removed at 
reduced pressure. The crude material was dissolved in dichloromethane (20 mL) and 
washed with water (2 x 10 mL). The organic phase was dried over MgSO4 and the 
solvent was removed under reduced pressure. The crude yellow oil of 1-Ms was 
dissolved in anhydrous acetonitrile (5 mL) and was slowly added upon cooling 
(ice/acetone bath) and vigorous stirring to the solution of DO2A-tBu ester (172 mg, 
0.43 mmol) and K2CO3 (83 mg, 0.60 mmol) in dry acetonitrile (10 mL). The reaction 
mixture was stirred for 18 h allowing the reaction mixture to reach rt and was 
purified using reverse phase HPLC (10% water to 100% water in MeOH over 9 min, 
0.1% formic acid). Collected fractions were neutralised using ammonia solution, the 
solvent was removed under reduced pressure and acetonitrile (20 mL) was added. 
The insoluble ammonium formate was filtered off and the filtrate was collected. The 
solvent was removed under reduced pressure giving clear oil (60 mg, 37% yield); 1H 
NMR (295 K, 400 MHz, CDCl3) ẟH 8.41 (1H, d, 3JH-H = 5.0 Hz, H6), 7.51 (2H, d, 3JH-
H = 9.0 Hz, H10), 7.47 (1H, br s, H3), 7.37 (1H, d, 3JH-H = 5.0 Hz, H5), 6.92 (2H, d, 
3JH-H = 9.0 Hz, H11), 3.97-2.52 (22H, m br, H1, H14, cyclen), 3.85 (3H, s, H13), 3.16-
2.62 (20H, m, H14, cyclen), 1.48 (18H, s, H17); 13C NMR (295 K, 100 MHz, CDCl3) 
160.9 (C12), 157.5 (C2), 147.9 (C6), 135.2 (C10), 133.8 (C4), 125.4 (C3), 124.9 (C5), 
114.4 (C9), 113.2 (C11), 97.8 (C8), 86.6 (C16), 84.8 (C7), 58.7 (C1, C14), 55.5 (C13), 
51.6-43.3 (cyclen), 28.5 (C17);  m/z (HRMS+) 622.3965 [M+H+]+ (C35H52N5O5 
requires 622.3968). 
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[EuL1] 
                                             
 
Di-tert-butyl 2,2'-(4-((4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate, 1-1 (57 mg, 0.09 mmol) was dissolved in 
dry acetonitrile (10 mL), followed by addition of K2CO3 (25 mg, 0.18 mmol) and 2-
(methylsulfonamido)ethyl methanesulfonate (20 mg) was added. The oil bath was 
heated up to 80 °C and the reaction flask was immersed inside the bath. The reaction 
mixture was stirred for 18 h and the formation of the desired product was confirmed 
by LC-MS analysis. The solvent was removed under reduced pressure and 
dichloromethane (15 mL) was added, filtered and the solvent was removed under 
reduced pressure. The crude was dissolved in methanol (4 mL) and aqueous NaOH 
solution (2.5 M, 2 mL) was added. The mixture was stirred at 60 °C for 3 h. The 
reaction mixture was neutralised by careful addition of concentrated HCl and EuCl3 
(52 mg, 0.2 mmol) was added. The reaction mixture was stirred at 60 °C for 3 h and 
the product was purified using reverse phase HPLC (0-3 min 10% water, 3-13 min 
10% water to 100% water in MeOH, NH4HCO3 buffer (2 g/L), tr = 10.5 min), 
yielding a white powder (22 mg, 36% yield over 2 steps); m/z (HRMS+) 779.1898 
[M+H+]+ (C30H40N6O7S151Eu requires 779.1878); λabs = 325 nm; ε(H2O) = 35400 M
-
1cm-1; τ(H2O) = 0.73 ms (pH = 6), τ(D2O) = 1.00 ms (pD = 6.4); φEu = 6.6%.  
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LC-MS UV trace of [EuL1] (5% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
95% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 3.8 min 
 
2,2'-(4-((4-((4-Methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)bis(N-((S)-1-phenylethyl)acetamide), 2-1 
 
                                              
 
(4-((4-Methoxyphenyl)ethynyl)pyridin-2-yl)methanol, 1 (39 mg, 0.16 mmol) was 
dissolved in anhydrous THF (4 mL) under argon, followed by addition of anhydrous 
triethylamine (30 µL, 0.21 mmol) and methanesulfonyl chloride (15 µL, 0.19 mmol). 
The reaction mixture was stirred for 2 h at rt and the solvent was removed at reduced 
pressure. The crude material was dissolved in dichloromethane (20 mL) and washed 
with water (2 x 10 mL). The organic phase was dried over MgSO4 and the solvent 
was removed under reduced pressure. The crude yellow oil of 1-Ms was dissolved in 
anhydrous acetonitrile (5 mL) and was slowly added upon cooling (ice/acetone bath) 
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and vigorous stirring to the solution of 2,2'-(1,4,7,10-tetraazacyclododecane-1,7-
diyl)bis(N-((S)-1-phenylethyl)acetamide) (80 mg, 0.16 mmol) and K2CO3 (83 mg, 
0.60 mmol) in dry acetonitrile (10 mL). The reaction mixture was stirred for 18 h 
allowing to reach rt and was purified using reverse phase HPLC (10% water to 100% 
water in MeOH over 9 min, 0.1% formic acid). Collected fractions were neutralised 
using ammonia solution and the solvent was removed under reduced pressure. The 
residue was dissolved in water (10 mL) and the pH was increased up to 14 by 
addition of 1M NaOH solution. The aqueous solution was washed with DCM (3 x 10 
mL), organic fractions were combined and dried over MgSO4. The solvent was 
removed under reduced pressure to give a desired product as a thick yellow oil (28 
mg, 24% yield); 1H NMR (295 K, 700 MHz, CDCl3) ẟH 8.46 (1H, m, H6), 7.50 (2H, 
d, 3JH-H = 9.0 Hz, H10), 7.30 (4H, d, 3JH-H = 8.0 Hz, H19), 7.25 (4H, t, 3JH-H = 8.0 Hz, 
H20), 7.20 (1H, m, H5), 7.18 (2H, m, H21), 7.14 (1H, m, H3), 6.89 (2H, d, 3JH-H = 9.0 
Hz, H11), 5.13 (2H, m, H16), 3.83 (3H, s, H13), 3.52 (2H, m, NH), 3.11 (4H, m, H14), 
2.87-2.53 (18H, m, H1, cyclen), 1.47 (6H, d, 3JH-H = 7.0 Hz, H17); 13C NMR (295 K, 
176 MHz, CDCl3) ẟC 170.3 (C15), 160.3 (C12), 157.5 (C2), 149.2 (C6), 143.7 (C4), 
143.3 (C18), 133.5 (C10), 128.5 (C20), 127.2 (C21), 126.4 (C19), 125.3 (C3), 124.0 (C5), 
114.1 (C11), 114.0 (C9), 94.5 (C8), 85.6 (C7), 59.9 (C14), 55.3 (C13), 53.1-51.3 (C1, 
cyclen), 48.3 (C16), 21.4 (C17); m/z (HRMS+) 716.4290 [M+H+]+ (C43H54N7O3 
requires 716.4288).    
 
[EuL2]Cl2 
 
                                     
                                                      
2,2'-(4-((4-((4-Methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclo-
dodecane-1,7-diyl)bis(N-((S)-1-phenylethyl)acetamide), 2-1 (28 mg, 0.039 mmol) 
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was dissolved in dry acetonitrile (7 mL), followed by addition of K2CO3 (20 mg, 
0.25 mmol) and 2-(methylsulfonamido)ethyl methanesulfonate (8 mg, 0.039 mmol). 
The reaction mixture was immersed into an oil bath preliminary heated up to 80°C 
and stirred at this temperature for 18 h. The reaction mixture was filtered off and 
EuCl3 (37 mg, 0.14 mmol) was suspended and the reaction mixture was stirred at 70 
°C for 18 h. The solution was decanted and the solid was washed three times with 
DCM and then dissolved in 4 mL of water. Any excess of Eu3+ was precipitated in 
the form of Eu(OH)3 by adjusting the pH up to 10 with 0.1 M NaOH. The solid was 
separated by centrifugation, the solution was neutralised by addition of 0.1M HCl 
and freeze-dried to give a desired complex as an off-white solid; m/z (HRMS+) 
985.3461 [M+H+]+ (C46H58N8O5S151Eu requires 985.3449); λabs = 325 nm; ε(H2O) = 
35400 M-1cm-1; τ(H2O) = 0.54 ms (pH = 8), τ(D2O) = 0.68 ms (pD = 8.4); φEu = 
1.9%. 
 
(S)-Ethyl 2-(2-(7-(2-(((R)-1-ethoxyethyl)amino)-2-oxoethyl)-4-((4-((4-methoxy-
phenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecan-1-yl) 
acetamido)propanoate, 3-1 
 
                                   
 
Methyl 6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)picolinate, 1 (196 mg, 0.82 
mmol) was dissolved in dry THF (5 mL), followed by addition of dry triethylamine 
(0.1 mL, 0.72 mmol) and MsCl (45 mL, 0.57 mmol). The reaction mixture was 
stirred at rt for 1 h and the solvent was removed under reduced pressure. The crude 
material was redissolved in 15 mL of DCM and was washed with water (2 x 15 mL). 
The organic fraction was dried over MgSO4 and the solvent was removed under 
reduced pressure, dried and redissolved in dry acetonitrile (5 mL). (S)-ethyl 2-(2-(7-
(2-(((R)-1-ethoxyethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-
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yl)acetamido) pro-panoate (400 mg, 0.82 mmol) was dissolved in dry acetonitrile (15 
mL) and K2CO3 (100 mg, 0.72 mmol) was added. The reaction was cooled down 
using ice bath and stirred for 5 min. The 1-Ms solution was added dropwise within 5 
min. The reaction mixture was allowed to reach rt and stirred for 18 h. The reaction 
mixture was filtered and purified on RP-HPLC (10% to 100% acetonitrile (+0.1% 
formic acid) in water (+0.1% formic acid) over 9 min). The fractions containing the 
desired product were combined and neutralised with aqueous ammonia solution. The 
solvent was removed under reduced pressure, dried and redissolved in acetonitrile. 
Ammonium formate was filtered off and the solvent was removed under reduced 
pressure, giving a colourless oil (169 mg, 30% yield); 1H NMR (295 K, 400 MHz, 
CDCl3) ẟH 8.60 (1H, m, H6), 7.51 (2H, d, 3JH-H = 9.0 Hz, H10), 7.45 (1H, d, 3JH-H = 
7.0 Hz, H5), 7.32 (1H, m, H3), 6.92 (2H, d, 3JH-H = 9.0 Hz, H11), 4.47 (2H, p, 3JH-H = 
7.0 Hz, H16), 4.15 (4H, t, 3JH-H = 7.0 Hz, H20), 3.97 (2H, m, NH), 3.85 (3H, s, H13), 
3.34-2.79 (22H, m, H1, H14, cyclen), 1.32 (6H, d, 3JH-H = 7.0 Hz, H17), 1.25 (6H, t, 
3JH-H = 7.0 Hz, H21); 13C NMR (295 K, 100 MHz, CDCl3) ẟC 172.9 (C18), 170.5 (C15), 
160.6 (C12), 156.9 (C2), 149.7 (C6), 133.6 (C10), 133.1 (C4), 125.7 (C3), 124.6 (C5), 
114.2 (C11), 113.7 (C9), 95.6 (C8), 85.2 (C7), 61.4 (C20), 58.6 (C14), 57.8 (C1), 55.4 
(C13), 54.2-45.9 (cyclen), 48.1 (C16), 17.5 (C17), 14.1 (C21); m/z (HRMS+) 708.4106 
[M+H+]+ (C37H54N7O7 requires 708.4085).         
 
[EuL3] 
      
                                   
 
(S)-Ethyl 2-(2-(7-(2-(((R)-1-ethoxyethyl)amino)-2-oxoethyl)-4-((4-((4-methoxy-
phenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecan-1-yl) acetamido) 
propanoate, 3-1 (92 mg, 0.14 mmol) was dissolved in dry acetonitrile (10 mL), 
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followed by addition of K2CO3 (50 mg, 0.63 mmol) and 2-(methylsulfonamido)ethyl 
methanesulfonate (28 mg, 0.137 mmol). The reaction mixture was immersed into an 
oil bath preliminary heated up to 80 °C and stirred at this temperature for 18 h. The 
solution was filtered off and the solvent was removed under reduced pressure and the 
residue was redissolved in 0.1 M NaOH (4 mL) and stirred at 60 °C for 2 h. The 
solution was neutralised and EuCl3 (37 mg, 0.14 mmol) was dissolved and the 
reaction mixture was stirred at 60 °C for 18 h. Any excess of Eu3+ was precipitated in 
the form of Eu(OH)3 by adjusting the pH up to 10 with 0.1 M NaOH. The solid was 
separated by centrifugation, the solution was neutralised by addition of 0.1M HCl 
and the residue was purified using reverse phase HPLC (0-3 min 10% water, 3-13 
min 10% water to 100% water in MeOH, NH4HCO3 buffer (2 g/L)), yielding white 
powder (15 mg, 11% yield over 2 steps); m/z (HRMS+) 921.2625 [M+H+]+ 
(C36H50N8O9S151Eu requires 921.2620); λabs = 325 nm; ε(H2O) = 35400 M
-1cm-1; 
τ(H2O) = 0.48 ms (pH = 8), τ(D2O) = 0.58 ms (pD = 8.4); φEu = 1.3%. 
 
 
HPLC UV trace of [EuL3] (10% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
100% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 10 min 
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(4-((4-(Dimethylamino)phenyl)ethynyl)pyridin-2-yl)methanol, 2 
 
                                                  
 
(4-Bromopyridin-2-yl)methanol (0.22 g, 1.18 mmol) and 4-ethynyl-N,N-
dimethylaniline (0.20 g, 1.40 mmol) were dissolved in anhydrous THF (10 mL) 
under argon, followed by addition of pyrrolidine (0.50 mL) and Pd(TPP)2Cl2 (0.10 g, 
0.14 mmol). The reaction mixture was stirred at 50 °C for 24 h and the solvent was 
removed under reduced pressure. The crude material was purified on a silica column 
(100% DCM to 50%DCM-50%EtOAc), giving a pale brown oil (0.23 g, 77% yield); 
1H NMR (295 K, 400 MHz, CDCl3) ẟH 8.49 (1H, d, 3JH-H = 6.0 Hz, H6), 7.44 (2H, d, 
3JH-H = 9.0 Hz, H10), 7.34 (1H, br s, H3), 7.26 (1H, d, 3JH-H = 6.0 Hz, H5), 6.67 (2H, d, 
3JH-H = 9.0 Hz, H11), 4.77 (2H, s, H1), 3.03 (6H, s, H13); 13C NMR (295 K, 100 MHz, 
CDCl3) ẟC 159.1 (C2), 151.0 (C12), 148.3 (C6), 133.2 (C10, C4), 123.9 (C3), 122.0 
(C5), 111.7 (C9), 108.4 (C11), 96.3 (C8), 85.3 (C7), 64.1 (C1), 40.1 (C13); m/z 
(HRMS+) 253.1344 [M+H+]+ (C16H17N2O requires 253.1341). 
 
Di-tert-butyl 2,2'-(4-((4-((4-(dimethylamino)phenyl)ethynyl)pyridin-2-
yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate, 4-1 
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(4-((4-(Dimethylamino)phenyl)ethynyl)pyridin-2-yl)methanol, 2 (64 mg, 0.25 mmol) 
was dissolved in anhydrous THF (5 mL) under argon, followed by addition of 
anhydrous triethylamine (30 µL, 0.21 mmol) and methanesulfonyl chloride (15 µL, 
0.19 mmol). The reaction mixture was stirred for 2 h at rt and the solvent was 
removed under reduced pressure. The crude material was dissolved in 
dichloromethane (20 mL) and washed with water (2 x 10 mL). The organic phase 
was dried over MgSO4 and the solvent was removed under reduced pressure. The 
crude yellow oil of 2-Ms was dissolved in anhydrous acetonitrile (5 mL) and was 
slowly added upon cooling (ice/acetone bath) and vigorous stirring to the solution of 
DO2A-tBu (102 mg, 0.26 mmol) and K2CO3 (50 mg, 0.36 mmol) in dry acetonitrile 
(10 mL). The reaction mixture was stirred for 18 h allowed to reach rt and was 
purified using reverse phase HPLC (10% water to 100% water in MeOH over 9 min, 
0.1% formic acid). Collected fractions were neutralised using aqueous ammonia 
solution, the solvent was removed under reduced pressure and acetonitrile (20 mL) 
was added. The insoluble ammonium formate was filtered off and the filtrate was 
collected. The solvent was removed under reduced pressure to afford a clear oil (60 
mg, 37% yield); 1H NMR (295 K, 400 MHz, CDCl3) ẟH 8.62 (1H, d, 3JH-H = 5.0 Hz, 
H6), 7.44 (2H, d, 3JH-H = 9.0 Hz, H10), 7.34 (1H, br s, H3), 7.27 (1H, d, 3JH-H = 5.0 Hz, 
H5), 6.68 (2H, d, 3JH-H = 9.0 Hz, H11), 3.73 (2H, s, H1), 3.04 (6H, s, H13), 3.16-2.62 
(20H, m, H14, cyclen), 1.45 (18H, s, H17); 13C NMR (295 K, 100 MHz, CDCl3) ẟC 
170.6 (C15), 157.6 (C2), 150.7 (C12), 149.5 (C6), 133.2 (C10, C4), 125.2 (C3), 123.9 
(C5), 111.7 (C9), 108.2 (C11), 96.4 (C8), 85.3 (C7), 81.5 (C16), 56.6 (C1), 54.6-46.6 
(C14, cyclen), 40.1 (C13), 28.2 (C17); m/z (HRMS+) 635.4282 [M+H+]+ (C36H55N6O4 
requires 635.4285). 
 
[LnL4] (Ln = Eu, Gd) 
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Di-tert-butyl 2,2'-(4-((4-((4-(dimethylamino)phenyl)ethynyl)pyridin-2-yl)methyl)-
1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate, 4-1 (54 mg, 0.09 mmol) was 
dissolved in dry acetonitrile (10 mL), followed by addition of K2CO3 (40 mg, 0.29 
mmol) and 2-(methylsulfonamido)ethyl methanesulfonate (17 mg) was added. The 
oil bath was heated up to 80 °C and the reaction flask was immersed into the bath. 
The reaction mixture was stirred for 18 h and the formation of the product was 
confirmed by LC-MS analysis (m/z (HRMS+) 756.4459 [M+H+]+ (C39H62N7O6S 
requires 756.4482)). The solvent was removed under reduced pressure and 
dichloromethane (15 mL) was added, filtered and the solvent was removed under 
reduced pressure. The crude was dissolved in methanol (4 mL) and aqueous NaOH 
solution (2.5 M, 2 mL) was added. The mixture was stirred at 60 °C for 3 h. The 
reaction mixture was neutralised by careful addition of concentrated HCl and LnCl3 
(0.2 mmol) was added. The reaction mixture was stirred at 60 °C for 3 h and the 
product was purified using reverse phase HPLC (10% water to 100% water in MeOH 
over 9 min, NH4HCO3 buffer (2 g/L), tr = 7.6 min), yielding the desired complex as 
yellow powder (16 mg for [EuL4] and 18 mg for [GdL4], 24% and 27% yield over 2 
steps, respectively); m/z (HRMS+) 792.2199 [M+H+]+ (C31H43N7O6S151Eu requires 
792.2194), m/z (HRMS+) 795.2204 [M+H+]+ (C31H43N7O6S154Gd requires 
795.2204); τ1r ([GdL4]) = 1.43 mM-1s-1 (pH = 7.0); λabs ([EuL4]) = 365 nm, ε(H2O) = 
28000 M-1cm-1, τH2O = 0.30 ms (with HSA). 
 
 
LC-MS UV trace of [EuL4] (5% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
95% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 3.8 min 
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Methyl 4-(2,4,6-trimethoxyphenyl)picolinate, 3 
                                                                   
                                                            
 
2,4,6-Trimethoxyphenyl boronic acid (200 mg, 0.94 mmol), methyl 4-
bromopicolinate (160 mg, 0.74 mmol), caesium carbonate (350 mg, 1.07 mmol) and 
Pd(dppf)2Cl2 (20 mg, 0.027 mmol) were placed into a microwaveable vial, sealed, 
evacuated and refilled with argon. Dry 1,4-dioxane (1.5 mL) was added and two 
freeze-pump-thaw cycles were carried out to degas the solution. The reaction mixture 
was microwaved at 150 °C for 40 min. The crude product was purified on a silica 
column (0% to 5% of MeOH in DCM), giving a mixture of the desired product and 
2,4,6-trimethoxybenzene as a side product. The fractions containing both compounds 
were combined and purified on RP-HPLC (10% to 100% acetonitrile (+0.1% formic 
acid) in water (+0.1% formic acid) over 10 min). The fractions containing the desired 
product were combined and neutralised with aqueous ammonia solution. The solvent 
was removed under reduced pressure, dried and redissolved in acetonitrile. 
Ammonium formate was filtered off and the solvent was removed under reduced 
pressure, giving an off-white solid (75 mg, 33% yield); 1H NMR (295 K, 400 MHz, 
CDCl3) ẟH 8.72 (1H, d, 3JH-H = 4.5 Hz, H1), 8.18 (1H, m, H10), 7.50 (1H, dd, 3JH-H = 
4.5 Hz, 4JH-H = 1.5 Hz, H2), 6.24 (2H, s, H7), 4.03 (3H, s, H13), 3.90 (3H, s, H9), 3.76 
(6H, s, H5); 13C NMR (295 K, 100 MHz, CDCl3) 165.9 (C12), 161.8 (C8), 158.2 (C6), 
148.6 (C1), 129.8 (C2), 128.2 (C10), 108.4 (C4), 90.8 (C7), 55.8 (C5), 55.4 (C9), 52.8 
(C13); m/z (HRMS+) 304.1187 [M+H+]+ (C16H18NO5 requires 304.1185).     
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(4-(2,4,6-Trimethoxyphenyl)pyridin-2-yl)methanol, 4 
 
                                                                          
 
Methyl 4-(2,4,6-trimethoxyphenyl)picolinate, 3 (150 mg, 0.50 mmol) was dissolved 
in 5 mL of ethanol (200 proof) and NaBH4 (130 mg, 3.42 mmol) was added. The 
reaction mixture was boiled under reflux at 78 °C for 2 h and the reaction mixture 
was quenched by adding water (35 mL). The solution was washed with DCM (3 x 40 
mL), organic fractions were combined and dried over MgSO4 and the solvent was 
removed under reduced pressure giving a desired product as an off-white solid (112 
mg, 82% yield). 1H NMR (295 K, 400 MHz, CDCl3) ẟH 8.55 (1H, 3JH-H = 5.0 Hz, 
H1), 7.25 (1H, m, H10), 7.23 (1H, dd, 3JH-H = 5.0 Hz, 4JH-H = 1.4 Hz), 6.24 (2H, s, H7), 
4.80 (2H, s, H12), 3.89 (3H, s, H9), 3.75 (6H, s, H5); 13C NMR (295 K, 100 MHz, 
CDCl3) ẟC 161.6 (C8), 158.2 (C6), 158.0 (C11), 147.5 (C1), 143.7 (C3), 125.4 (C2), 
123.4 (C10), 109.4 (C4), 90.9 (C7), 64.2 (C12), 55.8 (C5), 55.4 (C9); m/z (HRMS+) 
276.1245 [M+H+]+ (C15H18NO4 requires 276.1236).           
 
Diethyl 2,2'-(4-((4-(2,4,6-trimethoxyphenyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate, 5-1 
 
                                                   
 
(4-(2,4,6-Trimethoxyphenyl)pyridin-2-yl)methanol, 4 (56 mg, 0.20 mmol) was 
dissolved in 5 mL of dry THF, followed by addition of 0.1 mL of dry triethylamine 
(0.72 mmol) and 0.045 mL of MsCl (0.58 mmol). The reaction mixture was stirred 
for 1 h at rt and the solvent was removed under reduced pressure. The crude material 
N
O
O O
OH
1
2
3
9
10
11
12
5
4
8
6
7
1 2
3
9 10
11
12
5
4
86
7
NH N
NN
O
O
O
O
N
O
O
O13
14
15 16
	 200	
was dissolved in DCM (25 mL), washed with water (2 x 25 mL) and dried over 
MgSO4. The solvent was removed under reduced pressure, dried and dissolved in dry 
acetonitrile (3 mL). DO2A-ethyl ester (100 mg, 0.29 mmol) was dissolved in dry 
acetonitrile (9 mL) and K2CO3 was added (150 mg, 1.09 mmol). The reaction 
mixture was cooled down using an ice bath and stirred for 5 minutes, followed by 
dropwise addition of the 4-Ms within 5 min. The reaction mixture was allowed to 
reach rt and stirred for 18h. The reaction mixture was filtered and purified on RP-
HPLC (10% to 100% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) 
over 10 min). The fractions containing the desired product were combined and 
neutralised with aqueous ammonia solution. The solvent was removed under reduced 
pressure, dried and redissolved in acetonitrile. Ammonium formate was filtered off 
and the solvent was removed under reduced pressure, giving a transparent oil (50 
mg, 42% yield); 1H NMR (295 K, 700 MHz, CDCl3) ẟH 8.60 (1H, 3JH-H = 5.5 Hz, 
H12), 7.19 (2H, m, H3, H11), 6.20 (2H, s, H8), 4.11 (4H, t, 3JH-H = 7.0 Hz, H15), 3.85 
(3H, s, H10), 3.72 (2H, m, H1), 3.70 (6H, s, H6), 3.23 (4H, s, H13), 3.11-2.62 (16H, m, 
cyclen), 1.23 (6H, 3JH-H = 7.0 Hz, H16); 13C NMR (295 K, 176 MHz, CDCl3) ẟC 171.4 
(C14), 161.6 (C9), 158.0 (C7), 156.2 (C2), 148.7 (C12), 143.5 (C4), 126.8 (C11), 125.5 
(C3), 109.3 (C5), 90.8 (C8), 60.5 (C15), 57.1 (C1), 55.7 (C6), 55.6 (C13), 55.4 (C10), 
54.7, 51.0, 50.5, 46.3 (cyclen), 14.2 (C16); m/z (HRMS+) 602.3557 [M+H+]+ 
(C31H48N5O7 requires 602.3554).      
 
Diethyl 2,2'-(4-(2-(methylsulfonamido)ethyl)-10-((4-(2,4,6-
trimethoxyphenyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-
diyl)diacetate (L5) 
 
                                                              
 
Diethyl 2,2'-(4-((4-(2,4,6-trimethoxyphenyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclo-dodecane-1,7-diyl)diacetate, 5-1 (50 mg, 0.083 mmol) was dissolved in 
dry acetonitrile (5 mL), followed by addition of K2CO3 (28 mg, 0.20 mmol) and 2-
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(methylsulfonamido)ethyl methanesulfonate (18 mg, 0.083 mmol). The reaction 
mixture was immersed into an oil bath and heated up initially to 80 °C and stirred at 
this temperature for 18 h. The reaction mixture was filtered and purified on RP-
HPLC (10% to 100% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) 
over 10 min). The fractions containing the desired product were combined and 
neutralised with aqueous ammonia solution. The solvent was removed under reduced 
pressure, dried and redissolved in acetonitrile. Ammonium formate was filtered off 
and the solvent was removed under reduced pressure, giving a transparent oil (25 
mg, 42% yield); 1H NMR (295 K, 700 MHz, CDCl3) ẟH 8.53 (1H, 3JH-H = 5.0 Hz, 
H12), 7.30 (1H, m, H3), 7.27 (1H, dd, 3JH-H = 5.0 Hz, 4JH-H = 1.5 Hz, H11), 6.19 (2H, s, 
H8), 4.14 (2H, m, H1), 4.13 (4H, q, 3JH-H = 7.0 Hz, H15), 3.85 (3H, s, H10), 3.72 (6H, 
s, H6), 3.48 (2H, m, H18), 3.40 (4H, s, H13), 3.30 (2H, m, H17), 3.22 – 2.92 (16H, m, 
cyclen), 2.96 (3H, s, H19), 1.24 (6H, t, 3JH-H = 7.0 Hz, H16); 13C NMR (295 K, 176 
MHz, CDCl3) ẟC 170.7 (C14), 166.6 (C9), 161.8 (C7), 153.1 (C2), 148.7 (C12), 144.0 
(C4), 128.0 (C3), 126.2 (C11), 90.9 (C8), 108.6 (C6), 60.8 (C15), 59.1 (C1), 56.0 (C13), 
55.8 (C6), 55.4 (C10),  53.4 (C18), 53.1, 52.8, 49.9, 49.8 (cyclen), 39.1 (C19), 38.7 
(C17), 14.1 (C16); m/z (HRMS+) 723.3771 [M+H+]+ (C34H55N6O9S requires 
723.3751).         
 
[LnL5] (Ln = Eu, Tb, Dy, Y) 
                                                
 
The ligand, L5, (0.020 mmol) was dissolved in aqueous NaOH solution (0.5 M, 4 
mL) and stirred at 60 °C for 2 h. The solution was neutralised by addition of 1 M 
HCl and LnCl3 (0.030 mmol) was added. The reaction mixture was stirred at rt for 1 
h and pH was adjusted to 6.5. The reaction mixture was stirred for another hour and a 
desired complex was purified on RP-HPLC (Chromolith® column, 0% to 100% 
acetonitrile in water). The combined fractions were freeze-dried to give a desired 
complex as an off-white solid in quantitative yield.  
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[EuL5]: m/z (HRMS+) 815.2113 [M+H+]+ (C30H44N6O9S151Eu requires 815.2089). 
[TbL5]: m/z (HRMS+) 823.2137 [M+H+]+ (C30H44N6O9STb requires 823.2144); 
ε(H2O) = 12800 M
-1cm-1; τ(H2O) = 1.14 ms (pH = 8), τ(D2O) = 1.92 ms (pD = 8.4) 
[DyL5]: m/z (HRMS+) 824.2172 [M+H+]+ (C30H44N6O9SDy requires 824.2143). 
[YL5]: m/z (HRMS+) 753.1941 [M+H+]+ (C30H44N6O9SYb requires 753.1949). 
 
       
LC-MS UV trace of [YL5] (0% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
99% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 5.0 min 
Methyl 4-(4-(dimethylamino)phenyl)picolinate, 5 
 
                                                          
 
4-Dimethylaminephenyl boronic acid (200 mg, 1.21 mmol), methyl 4-
bromopicolinate (200 mg, 0.93 mmol), caesium carbonate (350 mg, 1.07 mmol) and 
Pd(TPP)2Cl2 (25 mg, 0.036 mmol) were placed into a microwaveable vial, sealed, 
evacuated and refilled with argon. Dry 1,4-dioxane (1.3 mL) was added and two 
freeze-pump-thaw cycles were carried out to degas the solution. The reaction mixture 
was microwaved at 150 °C for 60 minutes. The crude product was purified on a silica 
column (0% to 10% of EtOAc in DCM), giving a desired product as a yellow solid 
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(72 mg, 30% yield); 1H NMR (295 K, 700 MHz, CDCl3) ẟH 8.64 (1H, d, 3JH-H = 5.0 
Hz, H1), 8.32 (1H, m, H9), 7.61 (2H, d, 3JH-H = 8.50 Hz, H5), 7.60 (1H, m, H2), 6.76 
(2H, s, d, 3JH-H = 8.50 Hz, H6), 4.00 (3H, s, H12), 3.01 (6H, s, H8); 13C NMR (295 K, 
176 MHz, CDCl3) ẟC 166.1 (C11), 151.3 (C7), 150.0 (C1), 149.3 (C10), 148.2 (C3), 
127.7 (C5), 123.7 (C4), 123.0 (C2), 121.6 (C9), 112.4 (C6), 52.9 (C12), 40.2 (C8); m/z 
(HRMS+) 257.1297 [M+H+]+ (C15H17N2O2 requires 257.1290).    
      
(4-(4-(Dimethylamino)phenyl)pyridin-2-yl)methanol, 6 
 
                                                          
 
Methyl 4-(4-(dimethylamino)phenyl)picolinate, 5 (64 mg, 0.25 mmol) was dissolved 
in ethanol (7 mL, 200 proof) and NaBH4 (122 mg, 3.21 mmol) was added. The 
reaction mixture was boiled under reflux at 78 °C for 2 h and the reaction mixture 
was quenched by adding water (35 mL). The solution was washed with DCM (3 x 40 
mL), organic fractions were combined and dried over MgSO4 and the solvent was 
removed under reduced pressure giving a desired product as an off-white solid (44 
mg, 77% yield). 1H NMR (295 K, 700 MHz, CDCl3) ẟH 8.49 (1H, m, H1), 7.57 (2H, 
d, 3JH-H = 9.0 Hz, H5), 7.43 (1H, m, H2), 7.38 (1H, m, H9), 6.77 (2H, d, 3JH-H = 9.0 
Hz, H6), 4.78 (2H, s, H11), 3.01 (6H, s, H8); 13C NMR (295 K, 176 MHz, CDCl3) ẟC 
159.3 (C10), 151.1 (C3), 148.9 (C7), 148.6 (C1), 127.7 (C5), 124.9 (C4), 119.2 (C9), 
116.9 (C2), 112.4 (C6), 64.4 (C11), 40.2 (C8); m/z (HRMS+) 229.1340 [M+H+]+ 
(C14H17N2O requires 229.1341).      
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Diethyl 2,2'-(4-((4-(4-(dimethylamino)phenyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate, 6-1     
 
                                              
 
(4-(4-(Dimethylamino)phenyl)pyridin-2-yl)methanol, 6 (44 mg, 0.19 mmol) was 
dissolved in 4 mL of dry THF, followed by addition of 0.1 mL of dry triethylamine 
(0.72 mmol) and 0.025 mL of MsCl (0.32 mmol). The reaction mixture was stirred 
for 1 h at rt and the solvent was removed under reduced pressure. The crude material 
was dissolved in DCM (25 mL), washed with water (2 x 25 mL) and dried over 
MgSO4. The solvent was removed under reduced pressure, dried and dissolved in dry 
acetonitrile (3 mL). DO2A-ethyl ester (68 mg, 0.20 mmol) was dissolved in dry 
acetonitrile (9 mL) and K2CO3 was added (96 mg, 0.70 mmol). The reaction mixture 
was cooled down using ice bath and stirred for 5 min, followed by dropwise addition 
of the 6-Ms within 5 min. The reaction mixture was allowed to reach rt and stirred 
for 18 h. The reaction mixture was filtered and purified on RP-HPLC (10% to 100% 
acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) over 10 min). The 
fractions containing the desired product were combined and neutralised with aqueous 
ammonia solution. The solvent was removed under reduced pressure, dried and 
redissolved in acetonitrile. Ammonium formate was filtered off and the solvent was 
removed under reduced pressure, giving a colourless oil (27 mg, 26% yield); 1H 
NMR (295 K, 700 MHz, CDCl3) ẟH 8.59 (1H, d, 3JH-H = 5.0 Hz, H6), 7.55 (2H, d, 3JH-
H = 9.0 Hz, H8), 7.40 (1H, dd, 3JH-H = 5.0 Hz, 4JH-H = 2.0 Hz, H5), 7.38 (1H, m, H3), 
6.77 (2H, d, 3JH-H = 9.0 Hz, H9), 4.10 (4H, q, 3JH-H = 7.0 Hz, H14), 3.75 (2H, s, H1), 
3.25 (4H, s, H12), 3.19-2.60 (16H, m, cyclen), 3.02 (6H, s, H11), 1.22 (6H, t, 3JH-H = 
7.0 Hz, H15); 13C NMR (295 K, 176 MHz, CDCl3) ẟC  171.3 (C13), 157.5 (C2), 151.2 
(C10), 149.8 (C6), 148.8 (C4), 127.6 (C8), 124.4 (C7), 120.2 (C3), 119.2 (C5), 112.4 
(C9), 60.5 (C14), 57.6 (C1), 55.6 (C12), 54.7-46.2 (cyclen), 40.2 (C11), 14.2 (C15); m/z 
(HRMS+) 555.3663 [M+H+]+ (C30H47N6O4 requires 555.3659).     
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[YbL6]         
                                                
 
Diethyl 2,2'-(4-((4-(4-(dimethylamino)phenyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate, 6-1 (27 mg, 0.049 mmol) was dissolved in 
dry acetonitrile (5mL), followed by addition of K2CO3 (11 mg, 0.14 mmol) and 2-
(methylsulfonamido)ethyl methanesulfonate (18 mg, 0.049 mmol). The reaction 
mixture was immersed into an oil bath initially heated to 80 °C and stirred at this 
temperature for 18 h. The reaction mixture was filtered and on purified on RP-HPLC 
(0% to 100% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) over 10 
min). The fractions containing the desired product and the compound with two 
sulfonamide arms were combined and neutralised with aqueous ammonia solution. 
The solvent was removed under reduced pressure, dried and redissolved in 
acetonitrile. Ammonium formate was filtered off and the solvent was removed under 
reduced pressure, giving a transparent oil. The mixture of two products was 
dissolved in 0.5M NaOH (4 mL) and stirred at 60°C for 2h. The solution was 
neutralised by addition of 1 M HCl and YbCl3 (0.060 mmol) was added. The reaction 
mixture was stirred at rt for 1 h and pH was adjusted to 6.5. The reaction mixture 
was stirred for another hour and excess of Yb3+ was precipitated in the form of 
Yb(OH)3 by adjusting the pH up to 10 with 0.5 M NaOH, followed by neutralization 
by addition of 0.5 M HCl. The mixture was purified on RP-HPLC (Chromolith® 
column, 10% to 100% acetonitrile in water). The fractions containing the desired 
product were combined and freeze-dried to give a desired complex as an off-white 
solid; m/z (HRMS+) 753.1941 [M+H+]+ (C30H44N6O9S89Yb requires 753.1949). 
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LC-MS UV trace of [YbL6] (0% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
99% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 5.0 min 
 
Di-tert-butyl 2,2'-(4-((6-(methoxycarbonyl)-4-((4-methoxyphenyl)ethynyl)pyri-
dine -2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate, 7-1 
 
                                          
 
Methyl 6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)picolinate (60 mg, 0.20 
mmol) was dissolved in dry THF (3 mL), followed by addition of dry triethylamine 
(0.1 mL, 0.72 mmol) and MsCl (30 mL, 0.38 mmol). The reaction mixture was 
stirred at rt for 1 h and the solvent was removed under reduced pressure. The crude 
material was redissolved in DCM (15 mL) and was washed with water (2 x 15 mL). 
The organic fraction was dried over MgSO4 and the solvent was removed under 
reduced pressure, dried and redissolved in dry acetonitrile (3 mL). DO2A-tBu ester 
(101 mg, 0.25 mmol) was dissolved in dry acetonitrile (10 mL) and K2CO3 (100 mg, 
0.72 mmol) was added. The reaction was cooled down using an ice bath and stirred 
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for 5 min. The mesylate solution was added dropwise within 5 min. The reaction 
mixture was allowed to reach rt and stirred for 18 h. The reaction mixture was 
filtered and purified on RP-HPLC (10% to 100% acetonitrile (+0.1% formic acid) in 
water (+0.1% formic acid) over 9 min). The fractions containing the desired product 
were combined and neutralised with aqueous ammonia solution. The solvent was 
removed under reduced pressure, dried and redissolved in acetonitrile. Ammonium 
formate was filtered off and the solvent was removed under reduced pressure, giving 
a transparent oil (63 mg, 46% yield); 1H NMR (295 K, 700 MHz, CDCl3) ẟH 8.05 
(1H, s, H5), 7.54 (1H, s, H3), 7.49 (2H, d, 3JH-H = 9.0 Hz, H12), 6.90 (2H, d, 3JH-H = 
9.0 Hz, H12), 3.99 (3H, s, H8), 3.83 (3H, s, H15), 3.79 (2H, m, H1), 3.19-2.64 (16H, 
m, cyclen), 3.13 (4H, s, H16), 1.41 (18H, s, H19); 13C NMR (295 K, 176 MHz, 
CDCl3) ẟC 170.4 (C17), 165.4 (C7), 160.7 (C14), 158.8 (C2), 147.7 (C6), 133.9 (C4), 
133.6 (C12), 128.3 (C3), 125.7 (C5), 114.4 (C13), 113.4 (C11), 96.5 (C10), 84.9 (C9), 
81.5 (C18), 57.9 (C1), 56.5 (C16), 55.4 (C15), 55.0-46.2 (cyclen), 53.2 (C8), 28.1 (C19); 
m/z (HRMS+) 680.4027 [M+H+]+ (C37H54N5O7 requires 680.4023). 
 
Di-tert-butyl 2,2'-(4-((6-((bis(pyridin-2-ylmethyl)amino)methyl)pyridin-2-
yl)methyl)-10-((6-(methoxycarbonyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate (L7) 
 
                                              
 
Di-tert-butyl 2,2'-(4-((6-(methoxycarbonyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate, 7-1 (23 mg, 0.034 
mmol) was dissolved in dry acetonitrile (5 mL), followed by addition of  Cs2CO3 (20 
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mg, 0.06 mmol),  1-(6-(chloromethyl)pyridin-2-yl)-N,N-bis(pyridin-2-
ylmethyl)methanamine (20 mg, 0.059 mmol) and KI (20 mg, 0.12 mmol) was added. 
The reaction mixture was stirred at 70 °C for 18 h. The reaction mixture was filtered 
and purified on RP-HPLC (10% to 100% acetonitrile (+0.1% formic acid) in water 
(+0.1% formic acid) over 10 min). The fractions containing the desired product were 
combined and neutralised with aqueous ammonia solution. The solvent was removed 
under reduced pressure, dried and redissolved in acetonitrile. Ammonium formate 
was filtered off and the solvent was removed under reduced pressure, giving a 
colourless oil (20 mg, 59% yield); 1H NMR (295 K, 600 MHz, CDCl3) ẟH 8.51 (2H, 
m, H32), 8.06 (1H, s, H5), 7.66 (4H, m, H3, H23, H30), 7.56-7.53 (3H, m, H22, H29), 
7.47 (2H, d, 3JH-H = 9.0 Hz, H12), 7.42 (1H, d, 3JH-H = 8.0 Hz, H24), 7.14 (2H, m, H31), 
6.88 (2H, d, 3JH-H = 9.0 Hz, H12), 4.54 (2H, s, H20), 4.20 (2H, s, H1), 3.95 (3H, s, H8), 
3.85 (6H, m, H27, H28), 3.82 (3H, s, H15), 3.36 (4H, s, H16), 3.34-2.92 (16H, m, 
cyclen), 1.39 (18H, s, H19); 13C NMR (295 K, 151 MHz, CDCl3) ẟC 169.8 (C17), 
165.1 (C7), 160.7 (C14), 159.4 (C25), 159.0 (C28), 157.6 (C2), 152.6 (C21), 149.0 (C32), 
147.4 (C6), 137.6 (C23), 136.6 (C30), 134.0 (C4), 133.6 (C12), 128.7 (C3), 125.8 (C5), 
123.8 (C24), 122.9 (C29), 122.5 (C22), 122.1 (C31), 114.2 (C13), 113.5 (C11), 96.4 
(C10), 85.0 (C9), 81.8 (C18), 60.2 (C26, C27), 59.20 (C1), 57.20 (C20), 56.8 (C16), 55.3 
(C15), 53.1-49.6 (cyclen), 53.0 (C8), 28.1 (C19); m/z (HRMS+) 982.5573 [M+H+]+ 
(C56H72N9O7 requires 982.5555).      
        
[EuL7] 
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The ligand, L7, (20 mg, 0.020 mmol) was dissolved in aqueous NaOH (0.5 M, 4 mL) 
and stirred at 60 °C for 2 h. The solution was neutralised by addition of 1 M HCl and 
EuCl3 (0.040 mmol) was added. The reaction mixture was stirred at rt for 1 h, pH 
was adjusted to 6.5 and the reaction mixture was stirred for another hour. Aqueous 
ammonia solution was added dropwise to pH 10 in order to precipitate excess 
europium in the form of Eu(OH)3, which was separated by centrifugation. The 
solution was neutralised again and was left in the fridge, causing precipitation of the 
desired complex as an off-white solid, which was separated by decanting solution (8 
mg, 40% yield); m/z (HRMS+) 1004.3085 [M+H+]+ (C47H51N9O7151Eu requires 
1004.3110); ε(H2O) = 20,000 M
-1cm-1; τ(H2O) = 0.54 ms (pH = 7.4), τ(D2O) = 0.80 
ms (pD = 7.8). 
              
LC-MS UV trace of [EuL7] (5% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
95% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 3.8 min 
 
 
N-((6-(Chloromethyl)pyridin-2-yl)methyl)-N-(pyridin-2-ylmethyl)ethanamine, 7 
 
                                                 
 
2,6-Bis(chloromethyl)pyridine (0.97 g, 5.51 mmol), N-(pyridin-2-
ylmethyl)ethanamine (0.25 g, 1.84 mmol) and K2CO3 (0.25 g, 1.84 mmol) were 
dissolved in dry acetonitrile (15 mL) and the mixture was stirred at 70 °C for 18 h. 
The solution was filtered off, the solvent was removed under reduced pressure and 
the crude was purified on a silica column (0% to 66% of EtOAc in DCM), giving a 
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desired product as a pale yellow oil (110 mg, 22% yield); 1H NMR (295 K, 600 
MHz, CDCl3) ẟH 8.50 (1H, m, H13), 7.66 (1H, t, 3JH-H = 8.0 Hz, H4), 7.62 (1H, td, 3JH-
H = 8.0 Hz, 4JH-H = 2.0 Hz, H11), 7.51 (2H, m, H10, H5), 7.30 (1H, d, 3JH-H = 7.0 Hz, 
H3), 7.11 (1H, m, H12), 4.62 (2H, s, H1), 3.81 (4H, s, H7, H8), 2.63 (2H, q, 3JH-H = 7.0 
Hz, H14), 1.09 (3H, t, 3JH-H = 7.0 Hz, H15); 13C NMR (295 K, 151 MHz, CDCl3) ẟC 
160.1 (C2), 159.9 (C9), 155.7 (C6), 149.0 (C13), 137.3 (C4), 136.3 (C11), 122.8 (C10), 
122.0 (C5), 121.8 (C3), 120.8 (C12), 59.9-59.7 (C7, C8), 48.3 (C14), 46.8 (C1), 12.0 
(C15); m/z (HRMS+) 276.1269 [M+H+]+ (C15H19N3Cl requires 276.1269). 
 
Diethyl 2,2'-(4-((6-((ethyl(pyridin-2-ylmethyl)amino)methyl)pyridin-2-
yl)methyl)-10-((6-(methoxycarbonyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate (L8)            
 
                                              
 
Diethyl 2,2'-(4-((6-(methoxycarbonyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate (38 mg, 0.061 mmol) 
was dissolved in dry acetonitrile (10 mL), followed by addition of Cs2CO3 (30 mg, 
0.09 mmol),  N-((6-(chloromethyl)pyridin-2-yl)methyl)-N-(pyridin-2-
ylmethyl)ethanamine, 7 (30 mg, 0.11 mmol)  and KI (20 mg, 0.12 mmol) was added. 
The reaction mixture was stirred at 70 °C for 18 h. The reaction mixture was filtered 
and purified on RP-HPLC (10% to 100% acetonitrile (+0.1% formic acid) in water 
(+0.1% formic acid) over 10 min). The fractions containing the desired product were 
combined and neutralised with aqueous ammonia solution. The solvent was removed 
under reduced pressure, dried and redissolved in acetonitrile. Ammonium formate 
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was filtered off and the solvent was removed under reduced pressure, giving a 
colourless oil (15 mg, 28% yield); 1H NMR (295 K, 700 MHz, CDCl3) ẟH 8.51 (1H, 
m, 3JH-H = 5.0 Hz, H32), 7.68 (2H, t, 3JH-H = 8.0 Hz, H23, H30), 7.64 (1H, br s, H3), 
7.52 (2H, d, 3JH-H = 6.0 Hz, H22, H29), 7.48 (2H, d, 3JH-H = 8.0 Hz, H12), 7.44 (1H, d, 
3JH-H = 8.0 Hz, H24), 7.17 (1H, m, H31), 6.89 (2H, d, 3JH-H = 8.0 Hz, H13), 4.66 (2H, s, 
H20), 4.29 (2H, s, H1), 4.11 (2H, q, 3JH-H = 7.0 Hz, H18), 3.97 (3H, s, H8), 3.86 (2H, s, 
H27), 3.83 (5H, m, H15, H26), 3.54 (4, s, H16), 3.45-2.97 (16H, m, cyclen), 2.66 (2H, 
q, 3JH-H = 7.0 Hz, H33), 1.21 (6H, q, 3JH-H = 7.0 Hz, H19), 1.12 (3H, q, 3JH-H = 7.0 Hz, 
H34); 13C NMR (295 K, 176 MHz, CDCl3) ẟC 170.5 (C17), 165.0 (C7), 160.7 (C14), 
159.6 (C25), 158.9 (C28), 157.2 (C2), 151.8 (C21), 148.6 (C32), 147.7 (C6), 137.6 (C23), 
136.9 (C30), 134.1 (C4),  133.7 (C12), 128.9 (C3),  125.9 (C5), 124.2 (C24), 123.1 
(C29), 122.8 (C22), 122.3 (C31), 114.2 (C13), 113.5 (C11), 96.6 (C10), 84.9 (C9), 61.0 
(C18), 59.6 (C27), 59.4 (C26), 59.1 (C1), 57.0 (C20), 56.1 (C16), 55.4 (C15), 53.0-49.3 
(cyclen), 53.0 (C8), 48.4 (C33), 14.1 (C19), 11.9 (C34); m/z (HRMS+) 863.4849 
[M+H+]+ (C48H63N8O7 requires 863.4820). 
 
[EuL8] 
 
                                        
 
 
The ligand, L8, (15 mg, 0.017 mmol) was dissolved in aqueous NaOH (0.5M, 4 mL) 
and stirred at 60 °C for 2 h. The solution was neutralised by addition of 1 M HCl and 
EuCl3 (0.040 mmol) was added. The reaction mixture was stirred at rt for 1 h, pH 
was adjusted to 6.5 and the reaction mixture was stirred for another hour. Aqueous 
ammonia solution was added dropwise to pH 10 in order to precipitate an excess of 
europium in the form of Eu(OH)3, which was separated by centrifugation. The 
solution was neutralised again, the solvent was removed under reduced pressure and 
the product was extracted several times with methanol. The methanol extracts were 
combined and the solvent was removed under reduced pressure giving a desired 
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product as an off-white solid in quantitative yield; m/z (HRMS+) 941.3011 [M+H+]+ 
(C43H50N8O7151Eu requires 941.3001), ε(H2O) = 20,000 M
-1cm-1; τ(H2O) = 0.22 ms 
(pH = 7.4), τ(D2O) = 0.29 ms (pD = 7.8). 
                
   
LC-MS UV trace of [EuL8] (5% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
95% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 3.8 min 
 
 
N-((6-(Chloromethyl)pyridin-2-yl)methyl)-N-ethylethanamine, 8 
 
                                                                 
 
2,6-Bis(chloromethyl)pyridine (1.00 g, 5.67 mmol), diethylamine (0.6 mL, 5.67 
mmol) and K2CO3 (0.80 g, 5.67 mmol) were dissolved in dry acetonitrile (20 mL) 
and the mixture was stirred at rt. After 2 h the temperature was increased up to 45 °C 
and the reaction mixture was stirred for 18 h The solution was filtered off, the 
solvent was removed under reduced pressure and the crude was purified on a silica 
column (0% to 66% of EtOAc in DCM), giving a desired product as a yellow oil (42 
mg, 4% yield); 1H NMR (295 K, 600 MHz, CDCl3) ẟH 7.66 (1H, t, 3JH-H = 8.0 Hz, 
H4), 7.45 (1H, d, 3JH-H = 8.0 Hz, H5), 7.32 (1H, d, 3JH-H = 7.0 Hz, H3), 4.64 (2H, s, 
H1), 3.72 (2H, s, H7), 2.58 (4H, q, 3JH-H = 7.0 Hz, H8), 1.04 (6H, t, 3JH-H = 7.0 Hz, H9); 
13C NMR (295 K, 176 MHz, CDCl3) ẟC 160.3 (C2), 155.7 (C6), 137.3 (C4), 122.1 
(C5), 120.7 (C3), 59.3 (C7), 47.4 (C8), 46.8 (C1), 11.8 (C9); m/z (HRMS+) 213.1165 
[M+H+]+ (C11H18N2Cl requires 213.1159). 
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Di-tert-butyl 2,2'-(4-((6-((diethylamino)methyl)pyridin-2-yl)methyl)-10-((6-
(methoxycarbonyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate (L9) 
 
                                                            
Di-tert-butyl 2,2'-(4-((6-(methoxycarbonyl)-4-((4-methoxyphenyl)ethynyl)pyridin-2-
yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate, 7-1 (30 mg, 0.04 
mmol) was dissolved in dry acetonitrile (9 mL), followed by addition of  Cs2CO3 (30 
mg, 0.09 mmol),  N-((6-(chloromethyl)pyridin-2-yl)methyl)-N-ethylethanamine, 8 
(20 mg, 0.09 mmol) and KI (20 mg, 0.12 mmol) was added. The reaction mixture 
was stirred at 70 °C for 18 h. The reaction mixture was filtered and purified on RP-
HPLC (10% to 100% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) 
over 10 min). The fractions containing the desired product were combined and 
neutralised with aqueous ammonia solution. The solvent was removed under reduced 
pressure, dried and redissolved in acetonitrile. Ammonium formate was filtered off 
and the solvent was removed under reduced pressure, giving a colourless oil (20 mg, 
52% yield); 1H NMR (295 K, 600 MHz, CDCl3) ẟH 8.08 (1H, d, 4JH-H = 1.0 Hz, H5), 
7.74 (1H, t, 3JH-H = 8.0 Hz, H23), 7.64 (1H, m, H3), 7.58 (1H, d, 3JH-H = 8.0 Hz, H22), 
7.48 (2H, d, 3JH-H = 9.0 Hz, H12), 7.46 (1H, d, 3JH-H = 8.0 Hz, H24), 6.90 (2H, d, 3JH-H 
= 9.0 Hz, H13), 4.59 (2H, s, H20), 4.26 (2H, s, H1), 4.14 (2H, H26), 3.97 (3H, s, H8), 
3.84 (3H, s, H15), 3.41 (4H, s, H16), 3.37-2.97 (20H, cyclen, H27), 1.42 (18H, s, H19), 
1.24 (6H, t, 3JH-H = 7.0 Hz, H28); 13C NMR (295 K, 151 MHz, CDCl3) ẟC 169.7 (C17), 
164.9 (C7), 160.8 (C14), 157.1 (C2), 154.4 (C25), 153.4 (C21), 147.7 (C6), 138.0 (C23), 
134.2 (C4), 133.7 (C12), 128.8 (C3), 126.1 (C5), 124.8 (C24), 124.4 (C22), 114.2 (C13), 
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113.4 (C11), 96.7 (C10), 84.9 (C9), 82.0 (C18), 57.2 (C20), 56.9 (C26), 59.8 (C16), 55.4 
(C15), 52.9 (C8), 52.9-49.6 (cyclen), 46.7 (C27), 28.1 (C19), 9.7 (C28); m/z (HRMS+) 
856.5364 [M+H+]+ (C48H70N7O7 requires 856.5337).        
                
[EuL9] 
                                                            
 
The ligand, L9, (15 mg, 0.017 mmol) was dissolved in aqueous NaOH (0.5M, 4 mL) 
and stirred at 60°C for 2 h. The solution was neutralised by addition of 1 M HCl and 
EuCl3 (0.040 mmol) was added. The reaction mixture was stirred at rt for 1 h, pH 
was adjusted to 6.5 and the reaction mixture was stirred for another hour. Aqueous 
ammonia solution was added dropwise to pH 10 in order to precipitate an excess of 
europium chloride in a form of Eu(OH)3, which was separated by centrifugation. The 
solution was neutralized again, the solvent was removed under reduced pressure and 
the product was extracted several times with methanol. Methanol extracts were 
combined and the solvent was removed under reduced pressure giving a desired 
product as an off-white solid in quantitative yield; m/z (HRMS+) 878.2879 [M+H+]+ 
(C39H49N7O7151Eu requires 878.2892), ε(H2O) = 20,000 M
-1cm-1; τ(H2O) = 0.61 ms 
(pH = 7.4), τ(D2O) = 0.80 ms (pD = 7.8). 
             
LC-MS UV trace of [EuL9] (5% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
95% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 3.8 min 
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1-(1-(2-Chloroethyl)-1H-1,2,3-triazol-4-yl)-N,N-bis(pyridin-2-ylmethyl) 
methanamine-DO2A-tBu, 10-2 
 
                                                
 
2-Azidoethanol (65 mg, 0.75 mmol) was dissolved in dry THF (3 mL), followed by 
addition of dry triethylamine (0.1 mL, 0.72 mmol) and MsCl (15 mL, 0.19 mmol). 
The reaction mixture was stirred at rt for 1h and the solvent was removed under 
reduced pressure. The crude material was redissolved in 15 mL of DCM and was 
washed with water (2 x 15 mL). The organic fraction was dried over MgSO4 and the 
solvent was removed under reduced pressure, dried and redissolved in 3 mL of dry 
acetonitrile. DO2A-tBu ester (300 mg, 0.75 mmol) was dissolved in dry acetonitrile 
(10 mL) and K2CO3 was added (300 mg, 2.17 mmol) was added. The reaction 
mixture was cooled down with an ice bath and stirred for 5 min. The mesylate 
solution was added dropwise within 5 min and the reaction mixture was allowed to 
reach rt and stirred for 18 h. The solution was filtered, concentrated down to 4 mL, 
followed by addition of N,N-bis(pyridin-2-ylmethyl)prop-2-yn-1-amine (178 mg, 
0.75 mmol), piperidine (1 mL) and CuI (10 mg, 0.05 mmol) were added. The 
reaction mixture was placed into a microwaveable vial, sealed and microwaved at 
100 °C for 30 min. The reaction mixture was filtered and purified using RP-HPLC 
(10% to 100% of acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) over 
10 min). The fractions containing the desired product were combined and neutralised 
with aqueous ammonia solution. The solvent was removed under reduced pressure, 
dried and redissolved in acetonitrile. Ammonium formate was filtered off and the 
solvent was removed under reduced pressure, giving brown oil, containing the 
desired product and tetra-alkylated side-product. The components were separated 
using alumina column (0.5%→1% of MeOH in DCM), giving the desired product as 
a yellow oil (51 mg, 10% yield over two steps); 1H NMR (295 K, 400 MHz, CDCl3) 
ẟH 8.54 (2H, d, 3JH-H = 5.0 Hz, H11), 7.89 (1H, s, H3), 7.73-7.62 (4H, m, H8, H9), 
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7.21-7.18 (2H, m, H10), 4.51 (2H, m, H1), 3.86 (2H, s, H6), 3.85 (4H, s, H6), 3.38 
(4H, s, H12), 3.11 (2H, m, H2), 3.08-2.77 (16H, m, cyclen), 1.43 (18H, s, H15); 13C 
NMR (295 K, 100 MHz, CDCl3) ẟC 170.4 (C13), 158.6 (C7), 148.5 (C11), 143.9 (C4), 
137.1 (C9), 124.0 (C3), 123.5 (C8), 122.3 (C10), 81.7 (C14), 59.1 (C6), 57.8 (C12), 
52.7-45.8 (C1, C2, C5, cyclen), 28.2 (C15); m/z (HRMS+) 707.4736 [M+H+]+ 
(C37H59N10O4 requires 707.4721).     
 
Di-tert-butyl 2,2'-(4-(2-(4-((bis(pyridin-2-ylmethyl)amino)methyl)-1H-1,2,3-
triazol-1-yl)ethyl)-10-((6-(methoxycarbonyl)-4-((4-methoxyphenyl) ethynyl) 
pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate (L10) 
 
                                                     
 
Methyl 6-(hydroxymethyl)-4-((4-methoxyphenyl)ethynyl)picolinate (30 mg, 0.10 
mmol) was dissolved in dry THF (4 mL), followed by addition of dry triethylamine 
(0.1 mL, 0.72 mmol) and MsCl (15 mL, 0.19 mmol). The reaction mixture was 
stirred at rt for 1 h and the solvent was removed under reduced pressure. The crude 
material was redissolved in 15 mL of DCM and was washed with water (2 x 15 mL). 
The organic fraction was dried over MgSO4 and the solvent was removed under 
reduced pressure, dried and redissolved in dry acetonitrile (3 mL). 1-(1-(2-
Chloroethyl)-1H-1,2,3-triazol-4-yl)-N,N-bis(pyridin-2-ylmethyl)methanamine-
DO2A-tBu ester, 10-2 (51 mg, 0.072 mmol) was dissolved in dry acetonitrile (8 mL) 
and K2CO3 (100 mg, 0.72 mmol) was added. The mesylate solution was added to the 
solution and the reaction mixture was stirred at 60 °C for 18 h. The reaction mixture 
was filtered and purified on RP-HPLC (10% to 100% acetonitrile (+0.1% formic 
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acid) in water (+0.1% formic acid) over 9 min). The fractions containing the desired 
product were combined and neutralised with aqueous ammonia solution. The solvent 
was removed under reduced pressure, dried and redissolved in acetonitrile. 
Ammonium formate was filtered off and the solvent was removed under reduced 
pressure, giving a colourless oil (53 mg, 75% yield); 1H NMR (295 K, 600 MHz, 
CDCl3) ẟH 8.50 (2H, m, H11), 8.06 (1H, 4JH-H = 1.5 Hz, H20), 7.95 (1H, s, H3), 7.69-
7.66 (2H, m, H9), 7.64 (1H, m, H18), 7.61-7.60 (2H, m, H8), 7.47 (2H, d, 3JH-H = 9.0 
Hz, H27), 7.15-7.13 (2H, m, H10), 6.89 (2H, d, 3JH-H = 9.0 Hz, H28), 4.64 (2H, t, 3JH-H 
= 7.0 Hz, H1), 4.38 (2H, m, H16), 3.95 (3H, s, H30), 3.83 (4H, s, H6), 3.82 (2H, s, H5), 
3.80 (3H, s, H23), 3.52 (2H, t, 3JH-H = 7.0 Hz, H2), 3.41 (4H, s, H12), 3.12-2.98 (16H, 
m, cyclen), 1.39 (18H, s, H15); 13C NMR (295 K, 151 MHz, CDCl3) ẟC 169.4 (C13), 
164.7 (C22), 160.7 (C17), 159.0 (C7), 148.6 (C11), 147.8 (C21), 144.6 (C4), 136.9 (C9), 
134.5 (C19), 133.7 (C27), 128.9 (C18), 126.2 (C20), 124.1 (C3), 123.2 (C8), 122.2 (C10), 
114.2 (C28), 113.3 (C26), 97.0 (C25), 84.7 (C24), 82.3 (C14), 59.3 (C23), 58.1 (C16), 
56.4 (C12), 55.4 (C6), 53.8 (C2),  53.0 (C30), 52.0-50.2 (cyclen), 48.7 (C5), 45.9 (C1),  
28.0 (C15); m/z (HRMS+) 986.5649 [M+H+]+ (C54H72N11O7 requires 986.5616).   
 
[EuL10] 
 
                                                          
The ligand, L10, (53 mg, 0.054 mmol) was dissolved in aqueous NaOH (0.5M, 4 mL) 
and stirred at 60 °C for 2 h. The solution was neutralised by addition of 1 M HCl and 
EuCl3 (0.090 mmol) was added. The reaction mixture was stirred at rt for 1 h, pH 
was adjusted to 6.5 and the reaction mixture was stirred for another hour. Aqueous 
ammonia solution was added dropwise to pH 10 in order to precipitate an excess of 
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europium chloride in a form of Eu(OH)3, which was separated by centrifugation. The 
solution was neutralised again and was left in the fridge, causing precipitation of the 
desired complex as an off-white solid, which was separated by decanting solution 
(20 mg, 37% yield); m/z (HRMS+) 1008.3200 [M+H+]+ (C45H51N11O7151Eu requires 
1008.3171), ε(H2O) = 20,000 M
-1cm-1; τ(H2O) = 0.51 ms (pH = 7.4), τ(D2O) = 1.12 
ms (pD = 7.8). 
 
LC-MS UV trace of [EuL10] (5% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
95% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 3.8 min 
 
 
Di-tert-butyl 2,2'-(4-((6-((bis(pyridin-2-ylmethyl)amino)methyl)pyridin-2-
yl)methyl)-10-((4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate (L11) 
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Di-tert-butyl 2,2'-(4-((4-((4-methoxyphenyl)ethynyl)pyridin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate, 1-1 (31 mg, 0.041 mmol) was dissolved in 
dry acetonitrile (10 mL), followed by addition of  K2CO3 (50 mg, 0.36 mmol),  1-(6-
(chloromethyl)pyridin-2-yl)-N,N-bis(pyridin-2-ylmethyl)methanamine (31 mg, 0.095 
mmol) and KI (20 mg, 0.12 mmol) was added. The reaction mixture was stirred at 70 
°C for 18 h. The reaction mixture was filtered and purified on RP-HPLC (10% to 
100% acetonitrile (+0.1% formic acid) in water (+0.1% formic acid) over 10 min). 
The fractions containing the desired product were combined and neutralised with 
aqueous ammonia solution. The solvent was removed under reduced pressure, dried 
and redissolved in acetonitrile. Ammonium formate was filtered off and the solvent 
was removed under reduced pressure, giving a colourless oil (43 mg, 70% yield); 1H 
NMR (295 K, 600 MHz, CDCl3) ẟH 8.54 (1H, d, 3JH-H = 8.0 Hz, H6), 8.50 (2H, m, 
3JH-H = 5.0 Hz, H30), 7.66 (3H, m, H21, H28), 7.56-7.53 (3H, H20, H27), 7.46 (2H, d, 
3JH-H = 9.0 Hz, H10), 7.44 (1H, s, H3), 7.39 (1H, d, 3JH-H = 8.0 Hz, H5), 7.28 (1H, d, 
3JH-H = 5.0 Hz, H22), 7.14 (2H, m, H29), 6.87 (2H, d, 3JH-H = 9.0 Hz, H11), 4.38 (2H, s, 
H18), 4.15 (2H, s, H1), 3.85 (6H, br s, H24, H25), 3.36 (4H, s, H14), 3.19-2.96 (16H, m, 
cyclen), 1.39 (18H, s, H17); 13C NMR (295K, 151 MHz, CDCl3) ẟC 169.8 (C15), 
160.4 (C12), 159.5 (C23), 159.1 (C26), 156.0 (C2), 153.2 (C19), 149.4 (C6), 149.0 (C30), 
137.5 (C21), 136.6 (C28), 133.5 (C10), 132.7 (C4), 126.1 (C3), 124.5 (C22), 123.6 (C5), 
122.8 (C29), 122.3 (C20), 122.1 (C27), 114.1 (C11), 113.9 (C9), 95.1 (C8), 85.4 (C7), 
81.8 (C16), 60.2 (C24, C25), 58.7 (C1), 57.8 (C18), 56.6 (C14), 55.3 (C13), 52.5-50.0 
(cyclen), 28.1 (C17);                      m/z (HRMS+) 924.5500 [M+H+]+ (C54H70N9O5 
requires 924.5500). 
 
[EuL11] 
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The ligand, L11, (43 mg, 0.046 mmol) was dissolved in aqueous NaOH (0.5 M, 4 
mL) and stirred at 60 °C for 2 h. The solution was purified using RP-HPLC (10% to 
100% MeOH in water (+25 mM NH4HCO3) over 10 min), fractions containing the 
desired product were combined and the solvent was removed under reduced pressure. 
EuCl3 (0.046 mmol) was added and the reaction mixture was stirred at rt for 1 h, pH 
was adjusted to 6.5 and the reaction mixture was stirred for another hour. The 
compound was found to be extremely susceptible towards irreversible chemical 
transformation basic pH and the presence of anions, and therefore it was used 
without further purification  (30 mg, 67% yield); m/z (HRMS+) 960.3215 [M+H+]+ 
(C46H51N9O5151Eu requires 960.3212), ε(H2O) = 20,000 M
-1cm-1; τ(H2O) = 0.41 ms 
(pH = 7.4), τ(D2O) = 0.99 ms (pD = 7.8).    
 
	
LC-MS UV trace of [EuL11] (5% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) to 
95% H2O (+0.1% v/v formic acid) in MeOH (+0.1% v/v formic acid) over 3.8 min		
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VI. Conclusions 
 
It has been shown in the present work that lanthanide complexes can find application 
as various luminescent probes, i.e. for pH-, protein-, metal- and anion-sensing. In 
each case a considerable spectral change can be modulated as a function of pH or 
analyte concentration, allowing unambiguous read-outs. Some of the described 
complexes have been tested in cello, demonstrating their potential for cellular 
studies. Rational design of the probes discussed herein tailored sensitivity and 
selectivity towards desired analytes, whilst macrocyclic nature of the ligands made 
corresponding chemical modifications easy to accomplish. A great potential of 
circularly polarised luminescence has been exemplified on numerous examples, 
where more conventional spectral techniques were unable to supply necessary data. 
High intensity of CPL signal even in the complexes with relatively low quantum 
yields, along with millisecond lifetimes and large Stokes shifts make lanthanide 
complexes ideal candidates for cellular imaging, whose potential will be unravelled 
even further with an advent of chiral fluorescent microscopy. 
 
However, there are still certain obstacles, which hamper their wider application, even 
though lanthanide complexes as biological assays have been available on the market 
for the last decay. Some of these limitations have been encountered in the present 
work as well. First, targeting desired organelles with high selectivity of the cell 
remains an issue and requires further studies to be carried out. Second, despite a rich 
library of lanthanide complexes has been synthesised up to now, there are still 
synthetic limitations (especially in the chemistry of pyridine derivatives), which 
restrict availability of the ligands with desired substituents. To overcome this 
problem, a closer collaboration between organic and lanthanide chemists is required. 
Third, an exceptional sensitivity of emission spectra of europium complexes to even 
subtlest changes in the coordination environment can be exploited for refining 
simulated molecular structures. The reciprocal task – predicting luminescence 
spectrum based on structural considerations - may facilitate the search for the probes 
with highest spectral change in response to the external stimuli. This requires a more 
detailed and accurate theory of f-f transitions to be conceived. 
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Appendix 1 
 
Assignment of 1H NMR spectrum of [YL5], 298 K 
 
 
 
                  
 
 
 
H1 3.25 (eq), 4.23 (ax) 
H2 7.07 
H3 7.07 
H4 8.17 
H5 3.37 
H6 6.01 
H7 3.49 
H8 2.53 (eq), 2.69 (eq), 
2.92 (ax), 3.72 (ax) 
H9  
H10  
H11 2.61 
 
For H8 equatorial protons of one arm are in exchange with an axial proton of the 
trans acetate arm and vice versa, suggesting exchange between two TSAP isomers. 
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Appendix 2 
 
1H-1H COSY of [EuL5], 298 K 
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Appendix 3 
Job plot for [EuL8] following the addition of Zn2+ ([EuL8] 2.5 µM, 
0.1 M HEPES, pH = 7.40, 298 K, λex = 335 nm). 
 
 
                  
 
